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Abstract 
Shannon Leigh Risacher 
 
MRI MEASURES OF NEURODEGENERATION AS BIOMARKERS OF 
ALZHEIMER’S DISEASE 
 
  Alzheimer’s disease (AD) is the most common age-related 
neurodegenerative disease. Many researchers believe that an effective AD 
treatment will prevent the development of disease rather than treat the disease 
after a diagnosis. Therefore, the development of tools to detect AD-related 
pathology in early stages is an important goal. In this report, MRI-based markers 
of neurodegeneration are explored as biomarkers of AD. In the first chapter, the 
sensitivity of cross-sectional MRI biomarkers to neurodegenerative changes is 
evaluated in AD patients and in patients with a diagnosis of mild cognitive 
impairment (MCI), a prodromal stage of AD. The results in Chapter 1 suggest 
that cross-sectional MRI biomarkers effectively measure neurodegeneration in 
AD and MCI patients and are sensitive to atrophic changes in patients who 
convert from MCI to AD up to 1 year before clinical conversion. Chapter 2 
investigates longitudinal MRI-based measures of neurodegeneration as 
biomarkers of AD. In Chapter 2a, measures of brain atrophy rate in a cohort of 
AD and MCI patients are evaluated; whereas in Chapter 2b, these measures are 
assessed in a pre-MCI stage, namely older adults with cognitive complaints (CC) 
but no significant deficits. The results from Chapter 2 suggest that dynamic MRI-
vii 
based measures of neurodegeneration are sensitive biomarkers for measuring 
progressive atrophy associated with the development of AD. In the final chapter, 
a novel biomarker for AD, visual contrast sensitivity, was evaluated. The results 
demonstrated contrast sensitivity impairments in AD and MCI patients, as well as 
slightly in CC participants. Impaired contrast sensitivity was also shown to be 
significantly associated with known markers of AD, including cognitive 
impairments and temporal lobe atrophy on MRI-based measures. The results of 
Chapter 3 support contrast sensitivity as a potential novel biomarker for AD and 
suggest that future studies are warranted. Overall, the results of this report 
support MRI-based measures of neurodegeneration as effective biomarkers for 
AD, even in early clinical and preclinical disease stages. Future therapeutic trials 
may consider utilizing these measures to evaluate potential treatment efficacy 
and mechanism of action, as well as for sample enrichment with patients most 
likely to rapidly progress towards AD. 
 
Li Shen, PhD, Chair  
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Introduction 
Alzheimer’s disease (AD) is the most common form of age-related 
dementia. As of 2000, nearly 25 million individuals world-wide, aged 60 or older, 
suffered from AD and that number is expected to more than double by 2030 [1]. 
Age is the primary predictor of AD, so as the proportion of the world population 
over the age of 65 years continues to grow, the rate of AD will expand rapidly. As 
of 2000, the annual cost for AD-related treatment and care in the United States 
was over $100 billion [2]. In addition to the social and economic implications of 
AD, this devastating disorder robs millions of older adults of their memories, 
ability to function independently, and ultimately their lives. Currently no 
treatments effectively target the underlying pathology associated with AD. 
Effective therapies which ameliorate or prevent the effects of AD would not only 
provide relief to millions of AD patients and their families, but would also 
potentially prevent an economic and social crisis which is likely to occur in the 
upcoming decades if this disease is allowed to grow unchecked.  
The most common form of AD is sporadic or late-onset AD (LOAD) which 
primarily affects people over the age of 65 years. Less than 5% of AD cases are 
caused by dominantly inherited mutations in three genes, including the amyloid 
precursor protein (APP) gene, and presenilin 1 and 2 (PS1, PS2) genes [3]. 
Dominantly inherited or “familial” forms of AD typically show earlier onset (<60 
years) than LOAD. Genetic factors are also likely to be important in LOAD. 
Apolipoprotein E (APOE) is the most commonly reported genetic variation 
associated with LOAD. Patients with an APOE epsilon 4 (ε4) allele are 
predisposed to developing LOAD, with a five-fold increased risk in patients with 1 
ε4 allele and an even higher risk in patients with 2 ε4 alleles relative to patients 
with 2 epsilon 3 (ε3) alleles [3-5]. On the other hand, the APOE epsilon 2 (ε2) 
allele is thought to be protective against the development of AD [6]. Numerous 
other candidate genes have also been identified for AD (see 
http://www.alzgene.org for an updated list of candidate genes). Future 
developments in the genetic basis of LOAD are likely to play an important role in 
early diagnosis.  
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Neurobiology and Neuropathology of AD  
Both the inherited and sporadic forms of AD feature two neuropathological 
hallmarks: amyloid plaques and neurofibrillary tangles (NFT). Amyloid plaques 
are extracellular aggregations of the amyloid-beta (Aβ) peptide that are found 
throughout the AD brain. Aβ is formed from processing of APP, a transmembrane 
protein thought to function as a cell surface receptor. Cleavage of APP by β-
secretase, followed by γ-secretase, results in the formation of the Aβ peptide, 
which can be 36 to 42 amino acids in length. The most common forms of Aβ are 
40 and 42 amino acids long (Aβ40 and Aβ42). As levels of Aβ increase in 
preclinical and clinical AD, the Aβ peptide aggregates into dimers and oligomers 
as a cross-linked β-sheet, with the Aβ42 form most likely to show aggregation. Aβ 
oligomers are thought to be a major neurotoxic species in the brains of patients 
with AD [7-9]. Ultimately, Aβ oligomers and soluble fragments become large 
fibrils, which further aggregate to form insoluble deposits in the extracellular 
space, including small diffuse plaques and dense core plaques, which are a 
hallmark of AD neuropathology. Insoluble Aβ plaques may also be neurotoxic, 
although the mechanisms by which this occurs are still not fully understood.  
Aβ is catabolized by a number of enzymes, including insulin-degrading 
enzyme (IDE), neprilsyn, and endothelin-converting enzyme. Aβ is also cleared 
by the brain immune cells, including astrocytes and microglia [10-12]. Recent 
studies suggest that while familial forms of AD show Aβ accumulation due to 
overproduction, accumulation of Aβ in LOAD may result primarily from 
imbalanced or ineffective Aβ clearance [13-14]. Interestingly, apolipoprotein E 
has also been implicated in Aβ metabolism and clearance [15], providing a 
potential mechanism to explain the significant impact of genetic variation in the 
APOE gene on LOAD likelihood and progression.  
NFT result from the hyperphosphorylation of a microtubule-associated 
protein known as “tau”. In the non-hyperphosphorylated state, tau is involved in 
axonal transport and promotes assembly and stabilization of microtubules. Once 
hyperphosphorylated, tau undergoes a conformational change preventing normal 
binding to microtubules. Microtubules then become destabilized and axonal 
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transport is impaired, which leads to axonal degeneration, neuron dysfunction 
and ultimately cell death. In addition, the hyperphosphorylated tau forms 
insoluble filamentous structures. These hyperphosphorylated tau filaments 
combine to create paired helical filaments, a key component of the neurofibrillary 
tangles seen in the brains of patients with AD [16]. The underlying cause of this 
abnormal hyperphosphorylation is currently unknown, but is likely due to a 
disruption in the balance between the kinases and phosphatases regulating tau 
phosphorylation. Some of the kinases known to be involved in the 
phosphorylation of tau include glycogen synthase kinase-3 (GSK3), cyclin 
dependent protein kinase-5 (cdk5), calcium and calmodulin-dependent kinase-II 
(CaMKII), and mitogen-activated protein kinases (MAPK)/extracellular signal-
related kinases (ERK) 1 and 2 [16]. 
The temporal relationship and direct link between amyloid plaques and 
NFT is not completely elucidated at this time. Current theories suggest that 
amyloid plaque formation likely precedes NFT, with amyloid accumulation 
occurring during a long preclinical period lasting years to decades [17]. However, 
formation and extent of NFT is more strongly associated than amyloid plaque 
deposition to the neurodegeneration, synaptic loss, and cognitive symptoms 
seen in AD patients [18-20]. The current framework of AD development suggests 
that amyloid accumulation initiates a pathological cascade resulting in the 
formation of NFT [17, 21]. The formation of NFT and toxic Aβ species (e.g., 
oligomers), as well as the initiation of other apoptotic cascades, leads to 
widespread neuronal injury and death and thus, the clinical symptoms associated 
with the disease. Formation of NFT may result from the oxidative stress, 
inflammatory responses, mitochondrial and metabolic dysregulation, and altered 
ionic homeostasis that occurs with Aβ accumulation [22-23]. Ultimately, the 
accumulation of amyloid and the formation of NFT results in widespread changes 
in cell signaling and neuronal loss throughout the brain. 
In addition to amyloid plaques and NFT, other biological processes are 
potentially important in the pathology of AD, including neuroinflammation, 
oxidative stress, changes in metal homeostasis, neurogenesis disruption, and 
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mitochondrial/metabolic dysfunction [10-11, 24-26]. Extensive neuroinflammation 
is observed throughout the AD brain [10-11, 25]. Activated microglial cells and 
reactive astrocytes are upregulated, especially around amyloid plaques [10, 25, 
27]. In fact, Aβ is known to directly activate microglia through secretion of pro-
inflammatory cytokines (e.g., interleukin 6 (IL-6), IL-8, tumor necrosis factor alpha 
(TNF-α)) and through p44/p42 MAP kinase signaling [25, 28-29]. Activated 
microglia are thought to be a key factor in the link between Aβ and 
neurodegeneration in AD, since activated microglia can be toxic to neurons by 
activation of the complement pathway and release of toxic free radicals [25]. Aβ 
can also directly activate the complement pathway, resulting in cell phagocytosis 
and lysis [25, 30].  
Oxidative stress is also thought to be a key process in the neuropathology 
of AD. AD brains show an increased level of oxidized proteins and significant 
DNA damage, particularly around amyloid plaques and NFT, suggesting 
extensive release of reactive oxygen species (ROS) [10, 31-33]. Aβ can directly 
cause oxidative stress by altering calcium homeostasis [10] or through activation 
of microglial cells as previously discussed. Oxidative stress caused by Aβ 
through the generation of ROS and reactive nitrogen species can result in 
widespread cell death from a variety of mechanisms, including impaired 
glutamate neurotransmission and excitotoxicity, apoptosis, lipid peroxidation, and 
DNA damage [10, 34-36].  
Altered metal homeostasis may also be important in AD pathology, as 
high levels of copper (Cu), zinc (Zn) and iron (Fe) are observed in the brains of 
patients with AD [10, 37-38]. Aβ is a metalloprotein with high affinity for Cu, Fe, 
and Zn [10, 37, 39]. The ability of amyloid plaques to promote ROS has been 
shown to be dependent on Cu and Fe, suggesting that neurodegeneration 
associated with oxidative stress in AD might be associated with metal 
accumulation [10, 40-41]. Furthermore, high levels of Zn, Cu, and Fe promote 
aggregation of Aβ [39, 42] and the formation of toxic Aβ oligomers [10, 43]. 
Impaired neurogenesis has also been observed in AD [24, 44-47], which 
may contribute to the memory deficits observed in the disease (see “Clinical 
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Symptoms and Diagnosis of AD” section). Aβ is thought to directly alter 
neurogenesis through the calpain/p35 and cdk5 pathway [24, 46, 48]. Activation 
of cdk5 may also be involved in tau hyperphosphorylation and destabilization of 
microtubules [16]. Cdk5 has also been shown to regulate other synaptic proteins, 
such as post-synaptic density 95 (PSD-95), cadherin, and synapsin [24].  
Mitochondrial and metabolic dysfunction has also been implicated in the 
pathophysiology of AD [26]. AD patients show impaired mitochondrial function, 
including reduced levels of cytochrome oxidase and Krebs cycle enzymes [26, 
49-51]. Reduced levels of cytochrome oxidase and mitochondrial dysfunction are 
thought to lead to increased release of ROS and additional oxidative stress 
responses, tau hyperphosphorylation, Aβ accumulation, and increased activation 
of apoptotic pathways [26, 52-53]. Patients with AD also show altered metabolic 
function in vivo with reduced peak levels of oxygen utilization, reduced levels of 
insulin in the central nervous system, and decreased brain metabolism at rest 
[26, 54-58].  
The biochemical processes involved in AD development ultimately 
converge upon widespread cell death and neuronal loss, likely through 
apoptosis. The direct mechanisms by which amyloid pathology and NFT lead to 
neurodegeneration are not fully understood. Aβ oligomers may be directly toxic to 
neurons, possibly through neuroinflammatory processes. Axonal degeneration 
may also result from disruption of trajectories by amyloid plaques and/or by 
intracellular breakdown due to NFT. Whatever the mechanism, the “downstream” 
result of amyloid plaques and NFT is widespread, progressive neuronal cell 
death resulting in marked brain atrophy. The stages of neurodegeneration in AD 
are described in detail by Braak and Braak (1993) [59]. The first regions of the 
brain to show neuronal loss associated with AD are in the medial temporal lobe 
(MTL), including the entorhinal cortex (EC), hippocampus, amygdala, and 
parahippocampal cortex. Additionally, extensive degeneration of the cholinergic 
innervations to the neocortex from the basal nucleus of Mynert and the medial 
septal nucleus occurs early in the disease process [60]. The next stage of 
degeneration usually involves neuronal loss in the cerebral cortex, particularly in 
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the lateral temporal and medial parietal cortices, followed by atrophy of the lateral 
parietal and frontal lobes. By the time a patient has reached a diagnosis of AD, 
neurodegeneration is usually found throughout the neocortex and subcortical 
regions, with significant atrophy of the temporal, parietal and frontal cortices, but 
relative sparing of the primary occipital cortex and primary sensory-motor regions 
[59, 61]. 
 
Clinical Symptoms and Diagnosis of AD 
The earliest clinical symptoms associated with AD are a direct result of the 
brain regions to first degenerate, namely the MTL. Memory impairments, 
particularly in the episodic and semantic domains, as well as deficits in language 
and executive functioning are common symptoms early in the disease course 
[62]. Patients with mild AD also show significant impairment in daily functioning 
with disruption or cessation of the ability to perform complex tasks associated 
with general life (e.g., balancing a checkbook, workplace performance, and social 
activities). In moderate to severe AD, patients may show an inability to function 
independently, with difficulties in even simple daily tasks, such as feeding and 
dressing. 
Clinicians and researchers have recently updated the AD diagnostic 
criteria for use in clinical practice and research [63]. To meet a clinical diagnosis 
of AD, a patient must meet the following criteria: (1) impairment in two or more 
cognitive domains (memory, executive function, language, visuospatial, 
personality/behavioral) beyond that expected for age and educational level as 
determined through patient or informant report or objective cognitive assessment 
(given either by treating physician or trained neuropsychologist); (2) cognitive 
impairment represents a gradual decline from previous levels of functioning; (3) 
cognitive impairment is severe enough to interfere with the ability to perform 
work, home and/or social activities; and, (4) cognitive impairment not explained 
by other etiologies, such as delirium, co-morbid medical conditions or medication 
usage, and/or a psychiatric disorder. Currently, the diagnosis of AD is made 
clinically, based on cognition and the relative impact of impairments on daily 
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activities. However, biomarkers (e.g., cerebrospinal fluid (CSF) protein levels, 
neuroimaging) may be used to rule out other causes of dementia (e.g., vascular) 
and to support the AD diagnosis in cases with unclear or atypical presentations. 
Attempts to diagnose AD at an earlier stage have led to the development 
of a clinical syndrome termed “mild cognitive impairment” (MCI) [64-67]. 
Recently, new criteria for diagnosis of MCI in clinical and research settings have 
been published [68]. A patient must have the following symptoms to receive a 
clinical diagnosis of MCI: (1) concern regarding a change in cognition (by the 
patient, an informant, and/or a skilled clinician); (2) impairment in one or more 
cognitive domains (memory, executive function, attention, visuospatial, language) 
greater than expected for age and education level; (3) preservation of 
independence in functional activities, meaning a patient may show mild problems 
performing complex functional tasks but they should be able to generally 
maintain their independence with minimal aid or assistance; and, (4) changes 
should be sufficiently mild so that there is no significant impairment in 
occupational or social functioning (i.e., not demented). Currently, biomarkers 
(e.g., CSF protein levels, neuroimaging) are only used in the diagnosis of MCI in 
clinical settings to rule out alternative etiologies of cognitive impairment. 
However, diagnosis of MCI in research settings may include the use of 
biomarkers to support the underlying cause of the MCI and to predict the type 
and rate of future disease progression. Patients with MCI typically show deficits 
in cognition that fall between 1 and 1.5 standard deviations below age and 
education adjusted and culturally appropriate normative levels [68-69]. The most 
common presentation of MCI features impairments in memory (amnestic MCI). 
Executive impairments are also commonly reported and can co-occur with other 
cognitive deficits (multi-domain MCI). Atypical presentations of MCI are also 
observed (e.g., visual variant with visuospatial deficits, language variant with 
speech and language deficits) [68]. Amnestic MCI is widely considered to be a 
prodromal form of AD, as nearly 10-15% of amnestic MCI patients convert to 
probable AD each year, relative to only 1-2% of the general elderly population 
[67].  
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Recently, researchers and clinicians have been attempting to detect AD-
related changes and predict progression even earlier than MCI (e.g., “pre-MCI” or 
“preclinical AD”). A recent article details a conceptual framework for identifying 
preclinical AD patients [14]. This framework was designed to categorize and 
conceptualize the presence of AD pathology in seemingly healthy older adults. In 
fact, 20-40% of older adults show extensive amyloid pathology with minimal or no 
clinical AD symptoms [14, 70-72]. In the new framework for preclinical AD 
identification, older adults with AD pathology are referred to as having “AD-
pathophysiology” (AD-P), while patients with clinical AD symptoms (i.e., patients 
diagnosed with MCI or AD) are referred to as having “AD-clinical” (AD-C). A time-
lag of 10-15 years between the initial development of AD-P and the emergence 
of AD-C is thought to be common. Thus, cognitively healthy participants with AD-
P are considered to be at increased risk for progression to AD-C. Using 
biomarkers to measure the various stages of AD pathophysiology (e.g., amyloid 
deposition, NFT formation, neurodegeneration), Sperling et al. (2011) identified 
three stages of preclinical AD, including: (1) presence of amyloidosis in the 
absence of other pathology; (2) presence of amyloidosis and neurodegeneration 
(or tau pathology) in the absence of any cognitive symptoms; and, (3) presence 
of amyloidosis, neurodegeneration, and subtle cognitive changes (i.e., cognitive 
decline and complaints which do not reach clinical criteria for MCI). Future 
studies will confirm whether these three stages of preclinical AD are ideal for 
characterizing the early stages of AD and/or progress in the indicated fashion. 
However, preclinical patients in any of these stages are likely to be at higher risk 
for future progression to MCI and AD. Other researchers define preclinical AD 
patients using other characteristics, such as subjective reports of cognitive 
changes (i.e., cognitive complaints), APOE genotype, and/or family history of 
dementia [73-77]. All of these factors have been shown to be linked with 
increased risk for future progression to AD [4, 76, 78-80]. 
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Biomarkers of AD 
Early detection of AD is an important goal because future treatments will 
likely target disease prevention or slowing of AD development, rather than 
reversal of AD related damage. Therefore, these interventions would likely be 
maximally effective in the prodromal stages of the disease. Sensitive and specific 
biological markers (“biomarkers”) of AD are desperately needed to detect 
patients in the early stages of AD, effectively monitor and predict disease 
progression, and provide differential diagnostic information for an accurate 
diagnosis of AD. Furthermore, biomarkers would be particularly helpful in clinical 
trials of new pharmaceutical interventions to enrich the sample with patients likely 
to progress to AD and monitor the outcome of new treatments. Levels of AD-
related protein (e.g., levels of Aβ40, Aβ42, total tau, phosphorylated tau) measured 
from the CSF are commonly used as biomarkers in AD research [81-83]. 
Neuroimaging is also an exceptional tool for measuring in vivo AD 
pathophysiology and brain atrophy associated with MCI and AD, as well as for 
predicting disease progression, even in patients with relatively minor cognitive 
impairments (e.g., preclinical AD patients) [17, 82, 84-99]. 
The two types of neuroimaging most commonly used as AD biomarkers 
include positron emission tomography (PET) and magnetic resonance imaging 
(MRI). PET uses radiolabeled ligands to measure metabolic and neurochemical 
processes in vivo. In AD research, two types of PET ligands are primarily utilized: 
(1) [18F] fluoro-deoxyglucose (FDG), which measures brain metabolism and (2) 
amyloid tracers (e.g., [11C] Pittsburgh Compound B (PiB), [18F] florbetapir), 
which bind to fibrillar amyloid plaques [100]. Studies with FDG-PET have 
indicated a consistent pattern of resting hypometabolism in AD patients in the 
temporoparietal cortex, precuneus and posterior cingulate, and frontal lobes 
[101-104]. Patients with MCI also show a similar pattern of hypometabolism, the 
presence and extent of which predicts future disease progression and conversion 
from MCI to probable AD [105-111]. The hypometabolism measured using FDG-
PET is thought to reflect impaired synaptic function and neuronal injury in 
patients with MCI and AD [102, 112-114].  
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The development of a PET ligand for specific and sensitive detection of 
amyloid in vivo was a significant advancement in the understanding and 
detection of AD. The most commonly used ligand to date, [11C]PiB, binds to 
fibrillar amyloid deposits but not to diffuse amyloid plaques or Aβ oligomers [115-
116]. In vivo PiB binding has been shown to correlate highly with extent and 
distribution of Aβ plaques in post-mortem tissue [115]. Researchers have 
observed that PiB often shows a somewhat bimodal distribution, with some 
participants showing significant PiB binding (“PiB-positive”) and others showing 
little or no PiB binding (“PiB-negative”). Thus, optimal cut-off values were 
reported and this delineation of participants into PiB-positive and PiB-negative is 
used in many studies [117-122]. Across PiB studies, more than 90% of AD 
patients were reported to be PiB-positive, reflecting significant amyloid deposition 
[100, 120, 122-125]. However, longitudinal studies suggest that patients with AD 
show minimal increases in PiB over 1-2 years, suggesting that patients 
diagnosed with AD may have reached a plateau of amyloid accumulation [126-
127]. Nearly 60% of MCI patients were also reported to be PiB-positive [117, 
120, 122, 125, 128-131]. PiB-positive MCI patients show a higher rate of 
progression and clinical conversion to AD than PiB-negative MCI patients [118, 
132]. At this time it is unclear whether PiB-negative MCI patients reflect AD as 
the underlying disease or whether they have a non-AD dementia. In any case, 
PiB-negative patients show much lower conversion from MCI to AD over 1-3 
years than PiB-positive MCI patients (8-15% vs. 20-50%, respectively) [118]. 
Furthermore, 20-40% of cognitively healthy older adults also show amyloid 
pathology and are PiB-positive [71, 119-122, 127, 133-136]. PiB-positive 
cognitively healthy older adults progress to MCI and AD at a much higher rate 
than those who are PiB-negative, suggesting PiB-positive healthy older adults 
are at an increased risk for the development of AD [121, 137]. 
The most widely used neuroimaging technique to investigate structural 
changes and neurodegeneration associated with AD in vivo is structural MRI. A 
number of studies have investigated differences between AD patients, MCI 
patients and healthy age-matched controls (HC) on measures of global and local 
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brain volume, tissue morphology, and rate of atrophy using both manually 
applied and automated techniques. Historically, manually applied techniques 
were used to extract volumetric and morphometric characteristics, including 
manual tracing of regions of interest (ROIs), in which an anatomically trained 
scientist traces a border around a specific brain structure on sequential MRI 
slices to extract a 3-dimensional representation [138-139], and medial temporal 
atrophy (MTA) scores, in which a trained neuroradiologist scores the amount of 
MTL atrophy [140-141]. More recently, automated techniques to extract volumes 
of interest (VOIs) and cortical thickness values for numerous neocortical regions 
[142-144], as well as semi-automated whole-brain morphometry techniques, 
such as voxel-based morphometry (VBM; [145-146]) and others [147-148], which 
determine the density of grey matter (GM), white matter (WM), and CSF on a 
voxel-by-voxel basis, have been developed and utilized in studies of brain aging 
and AD.  
MRI estimates of regional volumes, extracted using either manual or 
automated techniques, show significant brain atrophy in AD and MCI patients, 
following an anatomical distribution similar to the pattern reported in Braak and 
Braak [59] according to disease severity [149]. The most commonly reported and 
most significant differences between AD and MCI patients and HC are in the 
MTL. Numerous studies have reported that AD patients have significantly smaller 
whole brain [150], hippocampal [138-139, 151-153], EC [139, 154-157], and 
amygdalar volumes [158-160], and significantly enlarged ventricles [161-162], 
particularly in the temporal horn of the lateral ventricle [163], relative to HC. MCI 
patients tend to have intermediate volumetric estimates between AD patients and 
HC, supporting this as an intermediate stage between healthy aging and AD 
[164-170]. AD patients have also been shown to have extensive cortical atrophy 
throughout the brain, particularly in later stages of the disease. The frontal, 
parietal, and temporal lobes of AD patients show significantly reduced volume 
and thickness relative to HC [158, 171-175], while MCI patients have 
intermediate atrophy in these regions. The occipital lobe and primary sensory-
motor regions show minimal atrophy until late in the disease. A number of studies 
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have also shown that measures of hippocampal and EC volume can correctly 
classify AD patients and HC with an overall accuracy of between 85-95% [139, 
157-158, 169, 176-179] and MCI patients and HC with an overall accuracy of 
between 75-85% [157, 165, 169-170, 180-182]. 
Similar differences between AD, MCI, and HC are also seen in studies 
evaluating global and regional tissue morphometry. AD patients show reduced 
GM density and GM volume in the MTL and throughout the frontal, parietal and 
lateral temporal lobes [117, 183-190]. MCI patients tend to have a more focal GM 
density reduction in the medial and lateral temporal lobes, particularly in the EC 
and hippocampus, supporting that the degeneration of these regions occurs early 
in the disease process [184, 186, 191-193]. This technique has also been shown 
to effectively monitor progression over the course of three years, showing the 
expected expansion of atrophy as the disease progresses from MCI to probable 
AD [194]. Changes in global and local tissue morphometry have also been 
shown to correctly classify AD patients and HC with an overall accuracy of 
approximately 85-90% [188, 192] and MCI patients and HC with an overall 
accuracy of 87% [192]. 
Longitudinal structural MRI with multiple scan sessions over one or more 
years have also been collected to evaluate the rate of whole brain and regional 
atrophy in AD and MCI patients and HC. Numerous studies have shown 
accelerated whole brain atrophy rates [195-197], as well as faster rates of 
atrophy in the MTL [176, 195, 197-200], in AD and MCI patients relative to HC. 
Patients with AD show an approximate annual hippocampal decline of -4.5%, 
while MCI patients and HC show annual hippocampal declines of approximately -
3% and -1%, respectively (for meta-analysis, see [201]). The annualized rates of 
ventricular enlargement and cortical atrophy in the temporal, parietal and frontal 
lobes have also been shown to be significantly greater in patients with AD and 
MCI relative to HC [195, 197, 202-206]. 
MRI measures of volume, morphometry, and rates of brain atrophy have 
also shown sensitivity for predicting the course of AD progression. In fact, studies 
have demonstrated significantly reduced hippocampal and EC volume in patients 
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destined to convert from MCI to probable AD (MCI-Converters (MCI-C)), up to 
two years prior to clinical conversion, relative to MCI patients that remain at a 
stable MCI diagnosis (MCI-Stable (MCI-S)) [155, 166, 168, 202, 207-211]. 
Additionally, MCI-C show significantly reduced cortical thickness in regions of the 
MTL, lateral temporal cortex, and parietal cortex relative to MCI-S [212-215]. 
Techniques assessing global and local tissue morphometry have also shown 
significantly reduced GM density and GM volume in MCI-C relative to MCI-S 
[184, 191, 193, 216-217]. Rates of brain atrophy, including annualized whole 
brain, hippocampal, and EC volume decline, as well as rates of ventricular 
enlargement, are also accelerated in patients who are progressing from MCI to 
AD [197, 200, 218-221]. In addition to detecting differences between MCI-C and 
MCI-S, baseline and rate of hippocampal atrophy have been used to predict MCI 
to probable AD conversion. Using Cox proportional hazard models, reduced 
baseline hippocampal volume and increased annual hippocampal atrophy rates 
accurately predicted MCI to probable AD conversion [166, 208-209, 222-223]. 
Baseline hippocampal volume also correctly classified MCI-C and MCI-S with an 
overall accuracy of between 75-90% [156-157, 167, 207, 212, 214].  
Advanced structural and functional MRI techniques have also been 
evaluated as biomarkers of AD, although further research is needed. Diffusion 
weighted imaging (DWI) and diffusion tensor imaging (DTI) measure the integrity 
of WM pathways in the brain. Patients with AD and MCI show reduced WM 
integrity using both DWI and DTI [224-227]. DWI measures may also be sensitive 
to predicting progression from MCI to probable AD [228]. Functional MRI (fMRI) 
measures brain activity during a task or at rest by measuring blood flow and 
blood oxygen levels. fMRI techniques evaluating both task-related brain 
activation and brain activation during a resting state have been assessed for 
utility as biomarkers of AD [229]. During memory tasks, patients with AD show 
reduced brain activation in the hippocampus [230-236], as well as reduced 
deactivation of the default mode network (DMN) [237-242], a functional brain 
network that is active during rest and deactivates upon task initiation. Patients 
with MCI show different brain activation patterns depending on disease severity. 
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Early MCI patients have increased brain activation in the hippocampus and 
increased deactivation of the DMN upon initiation of a memory task [230, 237, 
241, 243-245]. However, late MCI patients show a more AD-like pattern, with 
reduced brain activation in the hippocampus during a memory task and reduced 
deactivation of the DMN [233, 237, 240, 246]. Recent longitudinal studies of 
patients with MCI demonstrated that increased or “hyperactivation” in the 
hippocampus during a memory task at baseline was predictive of future clinical 
decline [247-248]. The observed hippocampal hyperactivation during memory 
tasks in early MCI patients may reflect compensation for synaptic impairment 
and/or loss of or altered blood flow and brain oxygen utilization.  
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Current Project and Significance 
Although MRI-based techniques have shown promise as sensitive 
biomarkers of AD-related neurodegeneration, even in early stages of disease 
such as MCI and pre-MCI, the majority of previous studies have featured 
relatively small samples and selective cohorts. Therefore, a conclusive role of 
MRI-based biomarkers in the detection and prediction of AD has yet to be 
determined. Furthermore, the role of longitudinal MRI biomarkers has not been 
comprehensively examined in pre-MCI stages of disease, such as in older adults 
with cognitive complaints (CC) but no significant cognitive deficits. In Chapters 1 
and 2a, the present report aims to evaluate the role of cross-sectional and 
longitudinal MRI biomarkers in the largest sample of AD, MCI, and HC 
participants to date, the Alzheimer’s Disease Neuroimaging Initiative (ADNI). In 
Chapter 2b, alterations in cross-sectional and longitudinal MRI atrophy measures 
in CC participants will be assessed. Overall, the results of Chapters 1 and 2 will 
provide evidence regarding the sensitivity of MRI-based measures as biomarkers 
for detection and monitoring of early AD.  
In addition to exploring the use of MRI biomarkers in detection and 
monitoring of neurodegeneration in patients with MCI and AD and older adults 
with CC, the present study will assess the ability of these measures to predict 
future clinical progression. Specifically, differences in cross-sectional atrophy and 
longitudinal atrophy rate between patients who convert from MCI to probable AD 
and patients with a stable MCI diagnosis will be evaluated in Chapters 1 and 2. In 
Chapter 2b, the differences in baseline atrophy and two-year annualized atrophy 
rate between patients who convert from a diagnosis of CC at baseline to a 
diagnosis of MCI and participants with a stable CC diagnosis will also be 
assessed. Determining the sensitivity of MRI biomarkers to differences between 
stable and clinically progressing patients is important for assessing whether 
these markers could be used in early stages of AD to predict the likelihood and 
time-course of future clinical decline.  
One unique characteristic of the present report is the use of multiple MRI 
analysis techniques, which will provide a comprehensive assessment of how 
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various MRI analytic methods perform in AD detection, monitoring, and outcome 
prediction. Presently, no other reports to our knowledge have directly compared 
different MRI analysis techniques using a within-subject approach. The results 
from Chapters 1 and 2 will allow for a direct comparison of the accuracy and 
sensitivity of various MRI analytic techniques in cross-sectional and longitudinal 
analyses at various stages of AD progression. 
Finally, the determination of novel biomarkers of AD is essential for 
understanding the biological mechanisms associated with AD and to assist with 
improved detection, monitoring, and prediction of clinical progression. In order to 
properly evaluate whether a new tool is more effective than previous biomarkers 
and/or has an “added benefit” to known diagnostic assessments, analyses of the 
relative sensitivity and predictive ability of the novel biomarker alone and in 
combination with other biomarkers (e.g., MRI) is needed. Chapter 3 of the 
present study will evaluate a novel biomarker for AD, visual contrast sensitivity. 
In addition, the relationships between this novel biomarker and cognitive 
performance, as well as between contrast sensitivity and MRI-based measures of 
AD neurodegeneration, will be assessed. Results from these analyses will 
provide useful information about the role of the novel measure as an AD 
biomarker, as well as how the novel biomarker is associated with a known AD 
biomarker, neurodegeneration assessed by MRI. 
Understanding the ability of MRI measures and/or any novel biomarker of 
AD (i.e., visual contrast sensitivity) to detect and monitor neurodegeneration 
and/or other AD-related pathology in patients with MCI and AD will be important 
for determining whether these measures would be useful in therapeutic trials 
and/or clinical diagnosis. Markers that can reliably measure AD-related 
neurodegeneration could be used as outcome measures to evaluate the 
functional mechanism of a target treatment (i.e., neuronal viability/degeneration) 
and to determine the efficacy of therapeutic interventions designed to reduce AD-
related neurodegeneration. In addition, biomarkers that can identify patients with 
significant AD pathology could be used in clinical trials to enrich the patient group 
with individuals that most reflect the targeted pathological stage of disease. 
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Finally, biomarkers that are sensitive to disease pathology and show effective 
differential diagnostic utility could improve clinical diagnosis of AD by providing 
additional support to diagnoses suggested by clinical and psychometric data.  
Many researchers and clinicians currently believe that an effective 
treatment for AD will likely involve prevention of disease rather than amelioration 
of the pathology once a patient already has an AD diagnosis. In order to test 
target therapeutics for effective prevention of AD, biomarkers are needed that 
accurately predict future clinical progression to AD in patients with mild or no 
cognitive symptoms. In addition, once an effective treatment to prevent AD is 
discovered, clinicians must be able to routinely test for and accurately detect 
patients likely to progress to AD to whom this treatment should be administered. 
Therefore, biomarkers that reliably and accurately predict future progression to 
AD in patients at early clinical stages or even preclinical stages are essential.  
This report features a comprehensive assessment of the sensitivity of MRI 
measures for detecting and monitoring neurodegeneration in patients with MCI 
and AD. In addition, the ability of these measures to identify differences in early 
disease stages between patients who subsequently clinically progress and those 
who are stable will be evaluated. Finally, visual contrast sensitivity will be 
assessed as a novel biomarker of AD. The results of these studies will provide 
needed evidence to support the use of MRI biomarkers, and potentially visual 
contrast sensitivity, in therapeutic trials and clinical practice for detection and 
longitudinal monitoring of neurodegeneration and other pathology associated 
with AD, as well as prediction of future clinical decline. 
 
  
18 
 
Chapter 1: Cross-sectional MRI Biomarkers of AD 
This chapter explores the use of MRI biomarkers from a scan at a single 
visit to detect differences between patients with AD and MCI and healthy older 
adults (HC) in the extent and pattern of neurodegeneration. In addition, the 
sensitivity of baseline MRI measures to detect atrophic changes in patients 
destined to progress from MCI to probable AD is assessed. Data from 
participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is used in 
this section. Two widely-used and publically available MRI analysis techniques 
are utilized to analyze the 1.5 Tesla baseline structural MR images, including: (1) 
voxel-based morphometry (VBM), which measures the density of grey matter 
(GM), white matter (WM), and cerebrospinal fluid (CSF) across the brain on a 
voxel-wise basis; and, (2) automated parcellation (Freesurfer version 4), which 
automatically generates volumetric and cortical thickness estimates for more 
than 100 regions across the brain.  
The results of these analyses indicate that cross-sectional MRI measures, 
particularly measures of medial and lateral temporal lobe atrophy, are useful 
biomarkers for the detection of neurodegeneration in patients with MCI and AD. 
In addition, baseline MRI biomarkers are sensitive to differences between 
patients who subsequently convert from MCI to probable AD over the following 
year and patients with a stable MCI diagnosis. In fact, patients who progressed 
from MCI to probable AD show nearly equivalent hippocampal and medial 
temporal lobe (MTL) atrophy to AD patients, up to one year before clinical 
conversion. This result suggests that MRI measures of neurodegeneration may 
precede the clinical AD diagnosis by up to one year. In summary, this article, 
which was published in Current Alzheimer Research in 2009 [213], supports 
cross-sectional MRI measures as sensitive biomarkers for detecting AD-related 
neurodegeneration and predicting progression from MCI to probable AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common neurodegenerative illness 
associated with aging, accounting for 60-70% of age-related dementia cases. In 
2000, approximately 25 million people over the age of 60 were diagnosed with 
dementia worldwide, and the number afflicted is expected to reach over 80 
million by 2040 [1, 249]. Earlier diagnosis of AD is widely considered to be an 
important goal for researchers. Characterization of the earliest known clinical 
signs has led to the development of the classification of mild cognitive 
impairment (MCI), which is thought to be a transitional stage between normal 
aging and the development of AD [64]. Patients with MCI, specifically those with 
primary memory deficits or “amnestic MCI”, have a significantly higher likelihood 
to progress to probable AD, with a conversion rate of 10-15% per year [67]. 
Therefore, MCI represents an important clinical group in which to study 
longitudinal changes associated with the development of AD. The detection of 
subtle changes in brain structure associated with disease progression and the 
development of tools to detect those who are most likely to convert from MCI to 
probable AD is an important goal. 
The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a five-year 
public-private partnership to test whether serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), other biological markers, and clinical 
and neuropsychological assessment can be combined to measure the 
progression of amnestic MCI and early probable AD [250-252]. One of the major 
goals of ADNI is to assess selected neuroimaging and analysis techniques for 
sensitivity and specificity for both cross-sectional diagnostic group classification 
and longitudinal progression of MCI and AD. A powerful technique for analyzing 
high resolution structural MRI data is voxel-based morphometry (VBM), which 
allows specific tissue classes (i.e., grey matter (GM), white matter (WM), or CSF) 
to be analyzed in an automated and unbiased manner [145-146, 253]. VBM 
analyses, particularly comparisons of GM density between groups, have been 
used to examine diagnostic group differences in both cross-sectional and 
longitudinal studies of brain aging and AD [77, 117, 183-185, 187-194, 216-217, 
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254-258]. In fact, VBM has been shown to accurately classify controls and AD 
patients and to predict conversion from MCI to AD and rate of progression in 
studies of brain aging [184, 191, 193, 216-217, 257]. However, the small sample 
sizes in these studies and minimal longitudinal monitoring has prevented VBM 
from being established as a conclusive biomarker for MCI to probable AD 
conversion.  
Regions of interest (ROIs) and volumes of interest (VOIs) have also been 
effective in measuring local atrophy associated with AD and MCI and longitudinal 
monitoring of neurodegeneration in studies of brain aging. Numerous studies 
using manually defined ROIs have found that local hippocampal and total brain 
volume are significantly reduced in AD and MCI patients relative to healthy older 
adults [77, 81-82, 92, 117, 139, 156, 162, 167, 192, 197, 202, 208-210, 219-220, 
254, 259-260]. Rates and amount of hippocampal, medial temporal lobe (MTL), 
and total brain atrophy have also been shown to correlate with MCI to AD 
conversion [81-82, 92, 140, 166, 197, 208-209, 211, 219, 223, 259-262]. 
Recently, automated methods for extraction of specific regional volumes have 
been developed and found to provide similar reliability as manually traced ROIs 
in AD [143, 263-265]. Automated parcellation methods have also demonstrated 
reliable cortical thickness value estimations and decreased cortical thickness in 
AD [143, 266].  
The goal of the present study was to perform group comparisons using the 
1.5T T1-weighted structural scans obtained from ADNI participants at baseline. 
Using VBM as implemented in SPM5 (http://www.fil.ion.ucl.ac.uk/spm/), we 
examined cross-sectional GM differences between groups stratified by baseline 
diagnosis and one-year conversion from MCI to probable AD. Study groups 
included participants diagnosed with AD at the screening, baseline, 6-, and one-
year follow-up visits (AD), participants designated as healthy age-matched 
controls at all four visits (HC), participants who were diagnosed with MCI at all 
four visits (MCI-Stable (MCI-S)), and participants who were diagnosed with MCI 
at baseline and converted from MCI to probable AD within the first year (MCI-
Converters (MCI-C)). We extracted bilateral hippocampal GM density values, 
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hippocampal and amygdalar volumes, and entorhinal cortex, temporal lobe, and 
parietal lobe cortical thickness values for between-group comparisons. We 
hypothesized that patients with AD would show extensive GM reduction in medial 
and lateral temporal lobes and other neocortical regions, and that both of the MCI 
groups would demonstrate focal reduction in MTL structures compared to HC. 
We also hypothesized that MCI participants who converted to AD within one year 
would show a more extensive pattern of global GM reduction relative to HC, 
particularly in regions of the MTL, than participants with a stable diagnosis of 
MCI, but a less extensive pattern than AD participants. We also predicted that 
MCI-C would show greater MTL and neocortical GM density reductions relative 
to MCI-S participants. Finally, we investigated whether local hippocampal GM 
density and volume, amygdalar volume, and entorhinal, temporal, and parietal 
cortical thickness values would reflect the same pattern of group differences, and 
the relative ability of these MRI metrics to detect differences between MCI-C and 
MCI-S groups.  
 
Methods 
 
ADNI  
ADNI was launched in 2004 by the National Institute on Aging (NIA), the 
National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food 
and Drug Administration (FDA), private pharmaceutical companies, and nonprofit 
organizations. More than 800 participants, ages 55-90, have been recruited from 
59 sites across the U.S. and Canada to be followed for 2-3 years. The primary 
goal of ADNI is to determine whether serial magnetic resonance imaging (MRI), 
positron emission tomography (PET), other biological markers, and clinical and 
neuropsychological assessment can accurately measure the progression of MCI 
and early AD. The identification of specific biomarkers of early AD and disease 
progression will provide useful tools for researchers and clinicians in both the 
diagnosis of early AD and in the development, assessment and monitoring of 
new treatments. For additional information about ADNI, see www.adni-info.org.  
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MRI Scans  
Baseline 1.5T MRI scans from 820 participants were downloaded from the 
ADNI public website (http://www.loni. ucla.edu/ADNI/
250
) onto local servers at 
Indiana University School of Medicine between January and April 2008. The 
downloaded data initially included baseline scans from 229 HC, 403 patients with 
MCI, and 188 patients with AD. Complete details regarding participant exclusion 
and categorization are provided in Figure 1. Scan data were acquired on 1.5T 
GE, Philips, and Siemens MRI scanners using a magnetization prepared rapid 
acquisition gradient echo (MP-RAGE) sequence that was selected and tested by 
the MRI Core of the ADNI consortium [ ]. Briefly, two high-resolution T1-
weighted MRI scans were collected for each participant using a sagittal 3D MP-
RAGE sequence with an approximate TR = 2400ms, minimum full TE, 
approximate TI = 1000ms, and approximate flip angle of 8 degrees (scan 
parameters vary between sites, scanner platforms, and software versions). 
Scans were collected with a 24cm field of view and an acquisition matrix of 192 x 
192 x 166 (x, y, z dimensions), to yield a standard voxel size of 1.25 x 1.25 x 1.2 
mm. Images were then reconstructed to give a 256 x 256 x 166 matrix and voxel 
size of approximately 1 x 1 x 1.2 mm. Additional scans included prescan and 
scout sequences as indicated by scanner manufacturer, axial proton density T2 
dual contrast FSE/TSE, and sagittal B1-calibration scans as needed. Further 
details regarding the scan protocol can be found in Jack et al. (2008) [250] and at 
www.adni-info.org. 
Scans were collected at either screening (n=845) or baseline visits 
(n=184) between August 2005 and October 2007. If scans existed from both 
sessions for a single participant, the scan from the screening visit was used. 
Details of the ADNI design, participant recruitment, clinical testing, and imaging 
methods, have been published previously [250-252] and at www.adni-info.org.  
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Figure 1. Flowchart of Participant Pool Selection with Group Exclusion and 
Inclusion Criteria 
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Image Processing  
VBM: Analysis was performed using previously described methods [145-
146, 253], as implemented in SPM5 (http://www.fil.ion.ucl.ac.uk/spm/
Region of Interest: A hippocampal ROI template was created by averaging 
manual tracings of the left and right hippocampi from an independent sample of 
40 HC participants enrolled in a study of brain aging and MCI at Dartmouth 
Medical School [
). Briefly, 
scans were converted from DICOM to NIfTI format, co-registered to a standard 
T1-weighted template image, bias corrected, and segmented into GM, WM, and 
CSF compartments using standard SPM5 templates. GM maps were then 
normalized to Montreal Neurologic Institute (MNI) atlas space as 1 x 1 x 1 mm 
voxels and smoothed using a 10 mm FWHM Gaussian kernel. In cases where 
the first MP-RAGE scan could not be successfully segmented we attempted to 
use the second MP-RAGE. This was successful for only 1 of 8 cases.  
77, 267]. These hippocampal ROIs were used to extract GM 
density values from smoothed, unmodulated normalized and modulated 
normalized GM maps for the ADNI cohort.  
Automated Parcellation: VOIs, including bilateral hippocampi and 
amygdalar nuclei, were extracted using Freesurfer version 4 [142-144, 268-270]. 
Freesurfer was also used to extract cortical thickness values from the left and 
right entorhinal cortex, inferior, middle, and superior temporal gyri, inferior 
parietal gyrus, and precuneus.  
The final sample reported here passed site, ADNI MRI Core, and our 
internal quality control, and did not fail any step of the processing pipeline  
(Figure 1).  
 
Demographic Data  
Demographic information, apolipoprotein E (APOE) ε4 genotype, 
neuropsychological test scores, and diagnosis were downloaded from the ADNI 
clinical data repository 
(https://www.loni.ucla.edu/ADNI/Data/ADCS_Download.jsp). The “10-27-08” 
version of the ADNI clinical database was used for all analyses. Participants 
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were classified into groups based on screening, baseline, 6-month, and one-year 
diagnoses as reported in the diagnosis and conversion/reversion database.  
 
VBM Statistical Analyses  
Statistical analyses were performed on a voxel-by-voxel basis using a 
general linear model (GLM) approach implemented in SPM5. A false discovery 
rate (FDR) adjustment was used to control for multiple comparisons, and a 
minimum cluster size (k) of 27 voxels was required for significance. Age, gender, 
years of education, handedness, and total intracranial volume (ICV) were 
included as covariates, and an explicit GM mask was used to restrict analyses to 
GM regions. A one-way ANOVA was performed to compare the smoothed, 
unmodulated normalized GM maps between groups to determine the effects of 
diagnosis and one-year conversion from MCI to probable AD on GM density. The 
initial comparison was done using the entire available sample of 693 participants. 
A second comparison was completed using the same methods but with sub-
groups of matched participants to correct for unequal group sizes (n=248; 62 in 
each group). Matching was done on a case by case basis using the best 
available match on age, gender, education, and handedness, while preserving 
the relative proportion of APOE ε4 positive participants within each sub-group. 
After matching there were no significant group differences in age, gender, 
education, or handedness. Finally, a third set of analyses were performed with 
the full available sample of 693 participants, adding a volume preserving 
modulation step to the VBM method, yielding an assessment of local GM volume 
differences instead of GM density.  
 
Other Statistical Analyses  
Mean left and right hippocampal GM density, hippocampal and amygdalar 
volumes, and cortical thickness values for all 693 participants were compared 
between groups using a one-way multivariate ANCOVA in SPSS (version 
16.0.1). Age, gender, education, handedness, and total ICV were included as 
covariates in all ROI, VOI, and cortical thickness comparisons. One-way 
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ANCOVA and chi-square tests were used to determine between-group 
differences in age, gender distribution, APOE ε4 genotype, education, 
handedness distribution, primary language distribution, and baseline global, 
functional, behavioral, neurological, neuropsychiatric, and neuropsychological 
test scores. Post-hoc pairwise comparisons were performed for all ANCOVA 
analyses using a Bonferroni correction for multiple comparisons. All graphs were 
created using SigmaPlot (version 10.0).  
Effect sizes for the comparison between MCI-C and MCI-S participants 
were also calculated for selected imaging biomarkers, including bilateral mean 
hippocampal GM density and GM volume from the VBM images, bilateral mean 
hippocampal, amygdalar, accumbens, ventral dorsal column, inferior lateral 
ventricle, lateral ventricle, cerebral cortex, and cerebral white matter volumes 
extracted using Freesurfer, and bilateral mean cortical thickness values from the 
entorhinal cortex, inferior, middle, and superior temporal gyri, inferior parietal 
gyrus, and precuneus, which were also extracted using Freesurfer. These values 
were assessed due to significant differences between MCI-C and MCI-S groups 
upon post-hoc pairwise comparisons (p<0.05). Left and right adjusted means for 
each imaging measure, adjusted for age, gender, education, handedness, and 
ICV, were averaged to give a bilateral estimate, and used to calculate effect 
sizes (Cohen’s d) in SPSS and Microsoft Excel (version 2007).  
 
Results 
 
Sample Characteristics  
Demographic information and mean baseline test scores for all groups are 
presented in Table 1. Mean participant age and handedness distribution did not 
differ across groups. Years of education and percent of participants with either 
one or two APOE ε4 alleles (APOE4+) were significantly different among 
diagnosis groups (both p<0.001). AD participants showed significantly fewer 
years of education than either HC (p<0.001) or MCI-S (p=0.003) participants. 
Years of education did not differ significantly between any other groups in post-
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hoc pairwise comparisons. As expected, the HC group had a lower percentage of 
APOE4+ participants than any of the clinical groups, while the AD group had the 
highest percentage of APOE4+ participants. The MCI-S and MCI-C groups had 
different proportions of APOE4+ participants, with the MCI-C group showing a 
higher percentage of APOE4+ participants than the MCI-S group.  
Neuropsychiatric test results, including scores from the Geriatric 
Depression Scale (GDS) [271] and Neuropsychiatric Inventory Questionnaire 
(NPI-Q) [272], were significantly different among groups (both p<0.001). HC 
participants showed significantly fewer depressive symptoms than either AD or 
MCI-S participants (both p<0.001), and had a lower mean score on the NPI-Q 
than the AD, MCI-S, and MCI-C groups (all p<0.001). AD participants also had a 
significantly higher mean NPI-Q score than the MCI-S (p<0.001) and MCI-C 
(p=0.008) groups. No significant differences in mean GDS scores were found 
between the MCI-S, MCI-C, and AD groups. No group showed clinically 
meaningful levels of depressive symptoms. Ischemic events and/or risk were not 
significantly different between groups as assessed by the Modified Hachinski 
scale [273].  
As expected, clinical test scores (Mini-Mental Status Exam (MMSE) total 
score [274-275], Clinical Dementia Rating Scale (CDR) Global score (CDR-GL) 
and Sum of Boxes score (CDR-SB) [276], and the Functional Assessment 
Questionnaire (FAQ) total score [277]) varied significantly among groups (all 
p<0.001). Post-hoc pairwise comparisons showed a similar pattern for the 
MMSE, CDR-GL, and CDR-SB. HC participants had significantly higher MMSE 
and lower CDR scores relative to all other groups (all p<0.001). Additionally, 
MCI-S and MCI-C participants showed significantly higher MMSE and lower CDR 
scores compared to AD participants (all p<0.001), but did not differ from one 
another on these assessments. Mean FAQ total scores were significantly 
different across groups and in all post-hoc pairwise comparisons (all p<0.001).  
Neuropsychological scores from the Rey Auditory Verbal Learning Test 
(RAVLT) [278], Boston Naming Test (BNT) [279], and category verbal fluency 
tests (Fluency-Animals, Fluency-Vegetables) [280] also showed significant 
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differences among groups (all p<0.001). However, these assessments showed a 
different pattern in pairwise comparisons than the MMSE, CDR-GL, and FAQ. 
MCI-C and AD participants showed similar scores on the learning and verbal 
neuropsychological tests, with no significant differences in post-hoc comparisons 
on RAVLT measures, BNT, or verbal fluency tests. As expected, all of the clinical 
groups performed below HC participants for RAVLT, BNT, and verbal fluency 
measures (all p<0.001). MCI-S participants also had significantly higher scores 
on all RAVLT measures and Fluency-Vegetables than both the AD and MCI-C 
groups (all p<0.001). Finally, MCI-S participants had significantly higher scores 
than AD participants but not MCI-C on Fluency-Animals and BNT (both p<0.001).  
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AD MCI-C MCI-S HC ANOVA 
p-value 
Post-hoc Comparisons 
(at p<0.01) (n=148) (n=62) (n=277) (n=206) 
Age (years) 75.4 (0.6) 74.3 (0.9) 75.1 (0.4) 76.0 (0.5) NS No pairs significant 
Gender (M, F) 77, 71 36, 26 178, 99 107, 99 0.02 MCI-S>HC 
Education (years) 14.8 (0.2) 15.2 (0.4) 15.8 (0.2) 16.1 (0.2) <0.001 HC, MCI-S>AD 
Handedness (R, L) 141, 7 57, 5 253, 24 189, 17 NS No pairs significant 
% English Speaking 98.7% 98.4% 97.5% 99.0% NS No pairs significant 
% APOE ε4 Positive 
(1 or 2 alleles) 
65.5% 59.7% 53.1% 27.2% <0.001 AD, MCI-C, MCI-S>HC 
 
MMSEe 23.5 (0.1) 26.7 (0.2) 27.1 (0.1) 29.1 (0.1) <0.001 HC>allf; MCI-S, MCI-C>AD 
CDR-GLe 0.75 (0.01) 0.50 (0.02) 0.50 (0.01) 0.00 (0.01) <0.001 AD>allg; MCI-S, MCI-C>HC 
CDR-SBe 4.3 (0.1) 1.9 (0.1) 1.5 (0.1) 0.3 (0.7) <0.001 AD>allg; MCI-S, MCI-C>HC 
FAQa,e 13.0 (0.4) 6.4 (0.5) 3.2 (0.3) 0.1 (0.3) <0.001 All pairs significant 
 
Geriatric Depression 
Scalee 
1.6 (0.1) 1.3 (0.2) 1.6 (0.1) 0.8 (0.1) <0.001 AD, MCI-S>HC 
NPI-Qe 3.5 (0.2) 2.2 (0.3) 1.7 (0.2) 0.4 (0.2) <0.001 AD>allg; MCI-S, MCI-C>HC 
Modified Hachinskie 0.64 (0.06) 0.63 (0.09) 0.65 (0.04) 0.57 (0.05) NS No pairs significant 
 
RAVLT (1-5)b,e 23.5 (0.7) 26.2 (1.1) 31.9 (0.5) 42.5 (0.6) <0.001 HC>allf; MCI-S>MCI-C, AD 
RAVLT 30min Recallc,e 0.8 (0.3) 1.2 (0.4) 3.1 (0.2) 7.5 (0.2) <0.001 HC>allf; MCI-S>MCI-C, AD 
RAVLT 30min 
Recognitionc,e 
7.4 (0.3) 8.1 (0.4) 10.0 (0.2) 13.0 (0.2) <0.001 HC>allf; MCI-S>MCI-C, AD 
Boston Naming Testd,e 22.8 (0.3) 24.4 (0.5) 25.5 (0.2) 27.9 (0.3) <0.001 HC>allf; MCI-S>AD 
Fluency - Animalse 12.7 (0.4) 14.3 (0.6) 16.2 (0.3) 20.1 (0.3) <0.001 HC>allf; MCI-S>AD 
Fluency - Vegetablese 7.8 (0.3) 9.3 (0.4) 11.2 (0.2) 14.7 (0.2) <0.001 HC>allf; MCI-S>MCI-C, AD 
 
Total Intracranial 
Volume (ICV)e 
1607159.5 
(14004.6) 
1598192.9 
(21470.1) 
1597844.8 
(10181.0) 
1576429.8 
(11855.6) 
<0.001 No pairs significant 
 a 3 MCI-S participants removed due to incomplete scores 
 b 7 participants removed due to incomplete scores (3 AD, 4 HC) 
 c 1 HC participant removed due to an incomplete score 
 d 3 participants removed due to incomplete scores (1 AD, 1 MCI-S, 1 HC) 
 e Covaried for age, education, gender, and handedness 
 f HC>all is HC>MCI-S, MCI-C, AD 
 g AD>all is AD>MCI-S, MCI-C, HC  
(Note: greater scores on these measures (CDR, FAQ, GDS, NPI-Q, and Modified Hachinski) signify more impairment) 
 
Table 1. ADNI Participants at Baseline (Adjusted Mean (SE)) 
  
30 
 
VBM Group Comparisons by Baseline Diagnosis and One-Year Conversion 
Status  
All 693 participants were included in the initial VBM analyses. A one-way 
ANCOVA indicated striking between-group differences in smoothed, 
unmodulated normalized GM maps (Figures 2 and 3; unless noted, all 
differences are p<0.005 (FDR)). AD participants showed reduced density in 
nearly all GM regions compared to the HC group, with the maximum global 
difference in the left hippocampus (Figure 2A, HC>AD). Surface renderings of the 
comparison between the HC and AD groups showed that the GM density of 
nearly the entire cortical surface is significantly lower in AD (Figure 2B, HC>AD), 
including significant differences in the temporal, frontal and parietal lobes. MCI-C 
also showed reduced GM density compared to HC, with a global maximum in the 
left hippocampus (Figure 2C, HC>MCI-Converters). The pattern of significant 
voxels in the comparison between HC and MCI-C was very similar to that seen in 
the HC>AD comparison, both in subcortical regions and on the cortical surface 
(Figure 2D, HC>MCI-Converters). Selected sections (Figure 2E, HC>MCI-Stable) 
show a more focal distribution of differences in the comparison of GM maps from 
MCI-S and HC participants. MCI-S participants showed reduced GM density in 
focal bilateral MTL regions relative to HC, with a global maximum in the right 
parahippocampal gyrus and additional local maxima in bilateral amygdalar and 
hippocampal regions. Surface renderings reflect the focal distribution of 
significant voxels in the HC>MCI-S contrast (Figure 2F, HC>MCI-Stable), with 
differences localized primarily in the temporal and frontal lobes.  
A widespread pattern of significant voxels was also detected in the 
comparison between the MCI-S and AD groups. MCI-S participants showed 
significantly higher GM density than AD in the MTL, including a global maximum 
difference in the left hippocampus (Figure 3A, MCI-Stable>AD) and additional 
local maxima in bilateral amygdalar and hippocampal regions. The extensive 
pattern of GM differences between MCI-S and AD participants is further reflected 
in the surface renderings, with AD participants having significant GM reductions 
on nearly the entire cortical surface relative to MCI-S participants (Figure 3B, 
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MCI-Stable>AD). A more focal pattern was observed when comparing MCI 
groups. MCI-C had significantly reduced GM density relative to MCI-S 
participants in bilateral MTL regions, with a global maximum in the right insula 
and additional local maxima in bilateral amygdalar and hippocampal regions 
(Figure 3C, MCI-Stable>MCI-Converters). Surface renderings of the comparison 
between the MCI-S and MCI-C groups also show a focal pattern of GM 
differences in the frontal and temporal lobes (Figure 3D, MCI-Stable>MCI-
Converters). No significant voxels were found in the comparison between GM 
density maps from MCI-C and AD participants (Figure 3, MCI-Converters>AD). 
At a lower statistical threshold (p<0.001 (uncorrected)), AD participants showed 
reduced GM density in focal regions of the posterior parietal and occipital lobes 
relative to MCI-C (data not shown).  
Similar contrasts were performed using matched participants in equal 
sized groups to control for power as a function of group size. This comparison 
resulted in a similar pattern of between-group differences as seen using the full 
sample but at a lower statistical threshold (data not shown). Results from 
comparisons between groups using modulated normalized GM maps from the full 
sample were also similar to those using unmodulated images (data not shown). 
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Figure 2. Comparisons of GM Density Maps between Healthy Control 
Participants and Patient Groups using a One-way ANCOVA 
Selected slices (A) and surface renderings (B) of regions where HC>AD. 
Selected slices (C) and surface renderings (D) of regions where HC>MCI-C. Selected 
slices (E) and surface renderings (F) of regions where HC>MCI-S. All comparisons are 
displayed at a threshold of p<0.005 (FDR), minimum cluster size (k) = 27. Age, gender, 
years of education, handedness and ICV were included as covariates in all comparisons. 
Reverse comparisons showed no significant voxels at the established threshold. 
Selected sections for (A), (C), and (E) include left to right MNI coordinates: (0, -9, 0, 
coronal), (0, -23, -16, axial), (-26, -10, -15, sagittal), and (26, -10, -15, sagittal). 
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Figure 3. Comparisons of GM Density Maps between Patient Groups by 
Baseline Diagnosis and One-Year Conversion Status using a One-way 
ANCOVA  
Selected slices (A) and surface renderings (B) of regions where MCI-S> AD. 
Selected slices (C) and surface renderings (D) of regions where MCI-S> MCI-C. No 
significant voxels were found in the comparison between MCI-C and AD participants. 
Using a more lenient statistical threshold, differences were apparent in the posterior 
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parietal and occipital lobes for MCI-C>AD (data not shown). All comparisons are 
displayed at a threshold of p<0.005 (FDR), minimum cluster size (k) = 27 voxels. Age, 
gender, years of education, handedness and ICV were included as covariates in all 
comparisons. Reverse comparisons showed no significant voxels at the established 
threshold. Selected sections for (A) and (C) include left to right MNI coordinates: (0, -9, 
0, coronal), (0, -23, -16, axial), (-26, -10, -15, sagittal), and (26, -10, -15, sagittal).  
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ROI Grey Matter Density Comparisons  
Mean left and right hippocampal GM density values from the smoothed, 
unmodulated normalized GM maps of all 693 participants were extracted as 
described above. GM density was significantly different among all groups for both 
the left and right hippocampi (Figure 4A, both p<0.001). In post-hoc pairwise 
comparisons, HC participants showed significantly greater hippocampal GM 
density bilaterally relative to all other groups (all p<0.001). MCI-C had 
significantly reduced local GM density relative to MCI-S participants in both the 
left (p=0.001) and right (p=0.034) hippocampi, as did AD participants (p<0.001, 
bilaterally). Hippocampal GM density did not differ significantly between AD 
participants and MCI-C. Analyses using smoothed, modulated normalized GM 
maps showed a similar pattern of results to those using unmodulated images 
(data not shown).  
 
Freesurfer-Derived VOI and Cortical Thickness Comparisons  
Bilateral hippocampal and amygdalar volumes and cortical thickness 
values from the entorhinal cortex, inferior, middle, and superior temporal gyri, 
inferior parietal gyrus and precuneus were extracted from all 693 participants as 
described above. Comparisons of mean bilateral hippocampal (Figure 4B) and 
amygdalar (Figure 4C) volumes and entorhinal cortex thickness (Figure 4D) were 
significant across all groups (all p<0.001), and show similar results to 
hippocampal GM density in pairwise comparisons. All of the clinical groups (AD, 
MCI-C, MCI-S) had decreased bilateral hippocampal and amygdalar volumes 
and entorhinal cortex thickness compared to HC (all p<0.001). MCI-C also 
showed significant reductions relative to MCI-S participants, including reduced 
bilateral hippocampal volumes (both p<0.001), bilateral amygdalar volumes 
(p<0.001 left, p=0.01 right), and thinner bilateral entorhinal cortex (p=0.006 left, 
p<0.001 right). AD participants also had significant reductions in bilateral 
hippocampal and amygdalar volumes and entorhinal cortex thickness relative to 
MCI-S participants (all p<0.001). However, MCI-C and AD participants showed  
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no significant differences in any of the MTL measures (hippocampal and 
amygdalar volume or entorhinal cortex thickness).  
Mean cortical thickness values from lateral temporal cortices were also 
significantly different across groups (Figure 5, p<0.001). Similar to other ROI and 
VOI comparisons, HC participants had significantly greater bilateral inferior 
(Figure 5A), middle (Figure 5B) and superior (Figure 5C) temporal gyrus cortical 
thickness relative to all other groups in post-hoc pairwise comparisons (all 
p<0.001). MCI-C had significant cortical thinning bilaterally relative to MCI-S 
participants in the inferior (both p<0.001), middle (p<0.001 left, p=0.001 right), 
and superior (p=0.003 left, p=0.002 right) temporal gyri. AD participants also had 
significantly thinner bilateral inferior, middle, and superior temporal gyri relative to 
MCI-S participants (all p<0.001). MCI-C and AD participants showed no 
difference in temporal gyri cortical thicknesses.  
Parietal lobe cortical thickness values also showed significant differences 
across all groups, specifically in the inferior parietal gyrus (Figure 6A, p<0.001) 
and precuneus (Figure 6B, p<0.001). Post-hoc pairwise comparisons showed 
similar patterns as those of other imaging biomarkers. HC participants had 
significantly greater cortical thickness in bilateral inferior parietal gyrus and 
precuneus relative to all other groups (all p<0.001). AD participants had 
significantly reduced cortical thickness in bilateral inferior parietal and precuneus 
regions relative to MCI-S participants (both p<0.001), as did MCI-C (inferior 
parietal gyrus p=0.006 left, p=0.009 right; precuneus p=0.012 left, p=0.013 right). 
MCI-C and AD participants showed no significant differences in either inferior 
parietal gyrus or precuneus cortical thickness values. 
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Figure 4. Comparison of Medial Temporal Lobe GM Density, Volume, and 
Cortical Thickness Values among Groups 
Hippocampal GM density values (A) were extracted from the unmodulated VBM 
GM maps using standard left and right hippocampal ROIs traced on an independent 
sample of 40 HC participants [77, 267]. Bilateral hippocampal (B) and amygdalar (C) 
volume estimates and entorhinal cortex thickness values (D) were extracted using 
automated parcellation. The comparisons of all four measures show a significant 
difference (all p<0.001) across all groups. In post-hoc pairwise comparisons, 
hippocampal GM density, hippocampal and amygdalar volumes, and entorhinal cortex 
thickness show significant differences between HC and all clinical groups (all p<0.001) 
bilaterally and MCI-S and AD groups (all p<0.001) bilaterally. Furthermore, MCI-S and 
MCI-C groups show significant differences in GM density and volume in the left (GM 
density (A), p=0.001; volume (B), p<0.001) and right (GM density (A), p=0.034; volume 
(B), p<0.001) hippocampi, as well as significant differences in left (p<0.001) and right 
amygdalar volumes (p=0.01). MCI-C also showed significantly thinner entorhinal cortices 
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than MCI-S participants on both the left (p=0.006) and right (p<0.001). No significant 
differences were found in hippocampal GM density, hippocampal or amygdalar volumes, 
or entorhinal cortex thickness values between MCI-C and AD groups. Group mean 
values (+/- SE) adjusted for age, gender, years of education, handedness, and total ICV 
are displayed. 
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Figure 5. Differences in Temporal Lobe Cortical Thickness Values 
Extracted using Automated Parcellation by Group 
Comparisons between cortical thickness values from three regions of the 
temporal lobe, including the left and right inferior (A), middle (B), and superior (C) 
temporal gyri, demonstrated significant differences (all p<0.001) across all groups. Post-
hoc pairwise comparisons demonstrated significantly greater cortical thickness values 
for all temporal gyri bilaterally in HC relative to all other groups (all p<0.001), as well as 
in MCI-S participants relative to AD patients (all p<0.001). MCI-C showed significantly 
thinner cortices in the bilateral inferior temporal gyri (both p<0.001), left (p<0.001) and 
right (p=0.001) middle temporal gyri, and left (p=0.003) and right (p=0.002) superior 
temporal gyri relative to MCI-S participants. Cortical thickness values from bilateral 
inferior, middle, and superior temporal gyri were not significantly different between the 
MCI-C and AD groups. Group mean values (+/- SE) adjusted for age, gender, years of 
education, handedness, and total ICV are displayed. 
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Figure 6. Differences by Group in Parietal Lobe Cortical Thickness Values 
Extracted using Automated Parcellation 
Cortical thickness values from the inferior parietal gyrus (A) and precuneus (B) 
showed significant differences among groups (p<0.001). Post-hoc pairwise comparisons 
showed significantly greater cortical thickness values in the bilateral inferior parietal gyri 
and precuneus in HC relative to all clinical groups (all p<0.001), as well as in MCI-S 
participants relative to AD patients (both p<0.001). In addition, MCI-S participants 
showed significantly greater thickness values in the left (p=0.006) and right (p=0.009) 
inferior parietal gyri and left (p=0.012) and right (p=0.013) precuneus than MCI-C. No 
significant differences were found between MCI-C and AD groups in any region. Group 
mean values (+/- SE) adjusted for age, gender, years of education, handedness, and 
total ICV are displayed. 
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Effect Sizes of Imaging Biomarkers 
Imaging metrics with the 20 largest effect sizes are shown in Figure 7. 
Effect sizes of selected imaging biomarkers extracted using both unmodulated 
and modulated VBM GM maps and automated parcellation for the comparison of 
MCI-C versus MCI-S participants were calculated. Large effect sizes were 
observed for in medial and lateral temporal lobe and parietal lobe ROIs (Figure 
7). Bilateral mean hippocampal volume had the highest effect size, with a 
Cohen’s d of 0.603. Cortical thickness values from the inferior and middle 
temporal gyri, as well as the entorhinal cortex, also showed strong effect sizes, 
with Cohen’s d values of 0.535, 0.529, and 0.493, respectively. Amygdalar 
volume (Cohen’s d=0.478), superior temporal cortical thickness (Cohen’s 
d=0.448), inferior parietal cortical thickness (Cohen’s d=0.417), precuneus 
cortical thickness (Cohen’s d=0.408), and hippocampal GM density (Cohen’s 
d=0.408) also showed high effect sizes.  
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Figure 7. Effect Sizes of Selected Imaging Biomarkers for the Comparison 
between MCI-Stable and MCI-Converter Groups  
GM density, volume, and cortical thickness estimates were extracted using VBM 
and automated parcellation and compared between MCI sub-groups based on one-year 
MCI to probable AD conversion status. Effect sizes (Cohen’s d) for the comparison 
between MCI-S and MCI-C groups showed that measures of temporal lobe atrophy, 
including hippocampal and amygdalar volume and cortical thickness values from the 
entorhinal cortex and inferior, middle, and superior temporal gyri, provided the greatest 
difference. Bilateral mean values from target ROIs adjusted for age, gender, education, 
handedness, and total ICV were used to calculate effect size. 
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Discussion 
We examined baseline 1.5T T1-weighted MRI scans from 693 participants 
in the ADNI cohort to (1) characterize initial differences between the AD, MCI, 
and HC groups and (2) detect anatomic features associated with imminent 
conversion from MCI to probable AD within one year (MCI-C). We hypothesized 
that cross-sectional baseline differences would be consistent with the well-
established progression of neurodegeneration from MTL structures to neocortical 
involvement, and that those individuals with MCI who are about to convert to AD 
will appear more similar to AD prior to conversion than those MCI patients who 
remain stable for at least one additional year. Publically available and widely 
used semi-automated image analysis methodologies (VBM in SPM5, automated 
parcellation in Freesurfer) were employed to assess these hypotheses. 
Several key conclusions can be drawn from the obtained results. First, the 
overall pattern of structural MRI changes in MCI and AD patients observed at 
baseline in the ADNI cohort is similar to prior findings in other, typically smaller 
and less intensively characterized samples [77, 81-82, 92, 117, 139, 156, 162, 
167, 171, 183-185, 187-191, 202, 208-209, 216, 219, 223, 254-256, 258, 260, 
263, 266]. Second, MCI-C are distinguishable at baseline from individuals with 
MCI who will not show significant clinical progression over the next year (MCI-S). 
Third, MCI-C show significantly greater global and MTL atrophy than MCI-S 
participants, a pattern previously reported in earlier studies with smaller samples 
[81-82, 92, 156, 167, 184, 191, 193-194, 197, 207-210, 216-217, 219-220, 222, 
257, 260]. Fourth, MCI-C show a neurodegenerative profile more similar to that 
seen in AD patients than that seen in stable MCI patients. In fact, the MCI-C 
group demonstrated a pattern of atrophic changes nearly equivalent to those of 
the AD group up to a year before meeting clinical criteria for probable AD. Finally, 
a comparison of effect sizes of MRI metrics for the contrast between the MCI-C 
and MCI-S groups indicated that degree of neurodegeneration of MTL structures 
is the best antecedent MRI marker of imminent conversion, with decreased 
hippocampal volume (left more than right) being the most robust structural MRI 
feature. 
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There are several aspects to these results and analyses that warrant 
comment. This report is among the first, in the fully enrolled ADNI cohort, to 
assess group differences between AD, MCI, and controls at baseline, as well as 
to examine antecedent imaging predictors of future change in clinical status (i.e., 
conversion to probable AD by patients with amnestic MCI). Our comparisons of 
the three baseline diagnostic groups using VBM are similar to previous reports 
using alternative methods to compare global atrophy between AD, MCI, and HC 
participants in the ADNI cohort [148, 281-282]. One recent study from Hua et al. 
[148] found significant MTL atrophy in both AD and MCI participants in the ADNI 
cohort using tensor-based morphometry (TBM), similar to our results using VBM. 
Furthermore, our results using the one-year MCI to AD converter population from 
the ADNI cohort provided congruent results with those of Hua et al. (2008), in 
which temporal lobe atrophy as assessed using TBM correlated with MCI to AD 
conversion in a subset of the ADNI MCI to probable AD converters (n=40) [148]. 
A recent study using another imaging analysis technique (RAVENS) also found a 
similar pattern of distinctive atrophy in MCI-C relative to MCI-S participants in a 
sub-sample (27 MCI-C, 76 MCI-S) of the ADNI cohort, which could be used to 
predict MCI to probable AD conversion using a pattern classification technique 
[282]. In the present study, we were able to substantially extend the results of 
earlier partial cohort analyses by including the largest possible set of ADNI 
participants with usable data, since one-year outcomes were only recently 
completed. Further, our multi-method approach included VBM-based analyses of 
GM density and GM volume and Freesurfer-derived ROI analyses of volume and 
cortical thickness, which together provide a more detailed picture of anatomical 
differences among groups. 
Studies employing VBM methods differ with regard to including a volume 
conserving step referred to as “modulation” [145-146, 253]. Briefly, unmodulated 
GM maps are typically interpreted as indicating differences in GM density or 
concentration. By contrast, VBM performed with modulated GM maps are 
interpreted as local GM volume estimates. At present there is no strong 
consensus in the literature regarding which approach is more appropriate for a 
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given application. Furthermore, the pathophysiological significance of differences 
detected by one method versus the other has not been conclusively determined. 
Our primary VBM analyses were performed without modulation. We then 
repeated the analyses with the modulation step for comparison, and found highly 
similar patterns of GM differences between groups (Figures 2 and 3, modulated 
data not shown). Specifically, the overall pattern of GM reduction for all patient 
groups (AD, MCI-C, MCI-S) compared to HC participants remained significant 
using both VBM methods, with the greatest differences remaining in bilateral 
MTL. Similarly, the pattern for MCI-C relative to the MCI-S participants was 
largely unaffected by analytic methodology. Analysis of GM values extracted 
from left, right and combined hippocampal ROIs defined in an independent 
cohort of healthy older adult controls [77, 267] showed similar group differences, 
and the effect size for MCI-C versus MCI-S participants was nearly identical 
(Figure 7). Overall, inclusion of a volume conserving modulation step in the VBM 
analyses had little influence on the pattern or magnitude of group differences. 
This may in part be related to our inclusion of intracranial volume as a covariate 
in all analyses. To eliminate the possibility of bias due to markedly unequal group 
sizes when comparing MCI-C and MCI-S participants, we repeated the main 
VBM analyses on four matched groups of equal size. Despite slightly attenuated 
power to detect group differences, the additional matched group analyses did not 
alter the overall pattern of results (data not shown). 
The second major approach to assess morphological changes in AD and 
MCI patients relative to HC entailed examining Freesurfer parcellation derived 
ROIs, selected on the basis of their status as important regions for AD pathology. 
Group differences were evaluated for left, right and combined hippocampal 
volume and GM density, additional MTL ROIs, and regional cortical thickness 
estimates. Significant differences between groups were found in hippocampal, a-
mygdalar, and other MTL regions, as well as widespread neocortical regions. 
These results are consistent with prior ROI and VOI studies in AD and MCI, in 
which hippocampal volumes [77, 81-82, 92, 117, 139, 156, 166, 202, 208-210, 
219, 223, 263, 283], hippocampal GM density [77, 190, 192], and other regions 
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[81-82, 92, 139-140, 156, 162, 167, 189-190, 202, 207-209, 211, 222, 260-261], 
were found to be significantly decreased relative to HC. As in our VBM results, 
ROI measures indicated that participants who convert from MCI to AD within one 
year show significant baseline atrophy relative to MCI participants who remain 
clinically stable, and also have a generally equivalent degree of atrophy at 
baseline to AD participants. Decreased hippocampal GM density and volume, 
amygdalar volume, and cortical thickness in the entorhinal cortex, inferior, 
middle, and superior temporal gyri, inferior parietal gyrus, and precuneus reflect 
the antecedent structural characteristics of neurodegeneration in MCI-C 
compared to individuals with MCI who remained clinically stable for at least a 
year. Similar to the global atrophy detected using VBM, local measures of 
volume and cortical thickness detected significant degeneration in MCI-C up to 
one year prior to the point at which they meet clinical criteria for an AD diagnosis, 
suggesting an accelerated amount and rate of neuropathological changes in 
these individuals which is not well captured by the MCI diagnosis alone. 
Furthermore, these results, obtained from assessment of the largest group of 
one-year conversion from MCI to probable AD to date, extend the findings of 
previous smaller studies which have reported local atrophy in MCI to AD 
converters using measures of hippocampal, amygdalar, entorhinal cortex, and 
other MTL volume estimates [81-82, 92, 140, 167, 184, 191, 193, 207-210, 216-
217, 219, 222, 257, 259-260, 284]. 
Taken together, the present findings support the use of structural MRI as a 
biomarker for assessing prodromal and early AD-related neurodegenerative 
changes. An important implication of the analyses performed in this report is that 
although many regions and measurements are sensitive to early AD pathology, 
MRI markers have differential sensitivities for detection of those individuals who 
are at greatest risk for short-term progression to probable AD. The MRI 
measures with the largest effect sizes (far left, Figure 7) for MCI-C versus MCI-S 
contrasts appear to be important biomarker candidates for prediction of MCI to 
AD conversion. Previous studies have investigated the use of MTL density and 
volume in the prediction of MCI to AD conversion, with some reports finding 
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significantly greater sensitivity and specificity achieved by adding imaging 
biomarkers to clinical test prediction algorithms, while others suggested minimal 
utility of including additional imaging variables [81-82, 92, 166-167, 207-209, 211, 
214, 220, 222, 259-261, 283]. However, the majority of these studies included 
modest participant pools and manually drawn ROIs. The time-consuming nature 
of manual ROI tracing limits the utility of these endpoints as biomarkers in 
studies with large numbers of participants, as well as in routine clinical settings. 
Automated or semi-automated extraction of volume and cortical thickness values 
from ROIs in the MTL requires minimal manual intervention. The largely 
automated nature and wide availability and use of this and other methods (e.g., 
[263, 285]) in assessing local and global atrophy will facilitate incorporation of 
these measures as key variables in pharmacological efficacy and 
neuroprotection trials. 
A limitation of the present report is the inclusion of only baseline scans in 
characterizing anatomic changes. Additional information, including changes in 
imaging measures over time and rate of atrophy, has been shown to be useful in 
assessing and accurately predicting rapid conversion [197, 220]. As a cross-
sectional assessment of structural neuroimaging measures, the present study 
does not capture the dynamic atrophic processes associated with MCI to AD 
conversion. Future studies assessing multiple timepoints, including two and three 
year MCI to AD conversion patterns, will be needed to determine the diagnostic 
and predictive value of dynamic measures of global and local atrophy. 
Furthermore, the current participant pool includes 182 participants diagnosed 
with MCI at baseline who were on AD-indicated medications during the first year 
of the study. Pharmacological treatments, such as AChE inhibitors and 
memantine, have been shown to reduce or delay MCI to AD conversion [286-
290]. The impact of medications was not assessed in the current study. Future 
studies should focus on including this variable in predicting and assessing 
conversion from MCI to AD. Another limitation of this report is the inclusion of 
only structural imaging. It is possible that FDG PET, obtained on approximately 
half of the ADNI cohort, could enhance the detection and characterization of 
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antecedent AD-related changes alone or in combination with MRI and other 
measures. Targeted molecular PET imaging for amyloid deposition with [11C]PiB 
is also being investigated in a smaller add-on study in the ADNI cohort [136]. 
Future studies will undoubtedly clarify the contribution of FDG and PiB PET to 
understanding early changes and predicting clinical trajectory of patients 
progressing towards AD. Finally, the role of genetic factors was only considered 
to a limited degree in the present study by evaluating the distribution of APOE ε4 
genotype in the sample. A genome-wide association study employing a high 
density microarray with over 620,000 single nucleotide polymorphisms is 
underway by the ADNI Genetics Working Group and these forthcoming results 
will permit inclusion of data on individual differences in important biological 
pathways in predictive models. 
In summary, a major goal of ADNI is to identify imaging biomarkers that 
could be used for early detection and prediction of longitudinal changes in MCI 
and AD. Two semi-automated, widely used and publically available image 
analysis methods (VBM, automated parcellation) revealed significant global and 
local atrophy in AD and MCI patients in a large sample from the ADNI cohort at 
baseline relative to HC. These techniques were also successful at detecting 
differences at baseline between participants who would convert from MCI to AD 
within one year and those who would remain stable with a diagnosis of MCI for at 
least one year. The results of these analyses suggest that VBM and automated 
parcellation are useful tools for characterization of atrophy in MCI and AD and 
prediction of disease course. Employed with repeated scans for longitudinal 
monitoring of brain degeneration, these methods may be useful for clinical trials 
in MCI and AD. With further refinement, MRI coupled with advanced image 
analysis approaches appears to have potential for individualized prediction of risk 
of progression and enhancement of clinical trials by including those at greatest 
risk of conversion. 
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Chapter 2a: Longitudinal MRI Biomarkers in Patients with AD, MCI, and HC 
This chapter explores the use of MRI biomarkers from two scans collected 
at repeated visits which were approximately one year apart. The goal was to 
detect differences in the rate of brain atrophy between patients with AD and MCI 
and healthy older adults (HC). In addition, we explored whether rates of atrophy 
in selected MRI biomarkers can sensitively monitor progression from MCI to 
probable AD. 1.5 Tesla MRI scans from the baseline and one-year follow-up 
visits for participants from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) were used in this analysis. Multiple MRI analytic techniques, including 
VBM, automated parcellation (Freesurfer version 4), and an additional region of 
interest (ROI) extraction technique (MarsBaR), were used to evaluate dynamic 
changes in brain structure and atrophy rates in target regions.  
The results of this study indicate that longitudinal MRI measures of brain 
atrophy rate are useful biomarkers for measuring the progression of 
neurodegeneration in patients with MCI and AD, as well as distinguishing MCI 
patients who progress to probable AD (MCI-Converters (MCI-C)) from those who 
have a stable diagnosis of MCI (MCI-Stable (MCI-S)) over one year. In addition, 
rates of hippocampal volume and grey matter loss are sensitive measures for 
differentiating AD and MCI patients from HC, as well as MCI-C from MCI-S. The 
sensitivity of these measures as endpoints for drug trials is assessed by 
calculating the needed sample sizes for each measure to detect a 25% reduction 
in atrophy rate. Using the most sensitive brain atrophy measures, only 100-150 
participants would be needed to detect significant 1-year changes in patients with 
MCI and AD. The impact of apolipoprotein E (APOE) genotype on brain atrophy 
rate is assessed, as the presence of an APOE ε4 allele is the most significant 
genetic risk factor for late-onset AD. Patients with an APOE ε4 allele show higher 
rates of brain atrophy in the medial temporal lobe than patients without an APOE 
ε4 allele in all diagnostic groups. In summary, this article, which was published in 
Neurobiology of Aging in 2010 [291], supports the use of MRI measures of brain 
atrophy rate as biomarkers for AD. 
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Introduction 
Alzheimer’s disease (AD) is the most common age-related 
neurodegenerative disease, affecting nearly 25 million people worldwide, a 
number expected to triple in the next 50 years [1, 249]. Patients with AD show 
significant impairment in multiple cognitive domains, including deficits in memory 
and executive functioning. Progress in the early clinical diagnosis of AD has led 
to the characterization of a prodromal syndrome featuring relatively isolated 
memory deficits termed “amnestic mild cognitive impairment” (MCI) [292-293]. 
Amnestic MCI is conceptualized as a preliminary stage of AD-associated 
pathology with the majority of patients eventually progressing to AD at a rate of 
approximately 10-15% per year [67, 294]. 
The increasing recognition that early diagnosis and therapeutic 
intervention will be necessary to prevent the development of AD underscores the 
need to develop sensitive and specific biomarkers for detecting and monitoring 
MCI and AD. Structural magnetic resonance imaging (MRI) has shown significant 
promise as a biomarker to detect early MCI and AD-associated 
neurodegenerative changes, as well as to predict the rate of disease progression 
[82, 93, 166]. Cross-sectional studies evaluating the utility of structural MRI in 
detecting neurodegeneration have identified significant brain atrophy in patients 
with MCI and AD, particularly in regions of the medial temporal lobe (MTL), using 
regional volumetric extraction tools such as manual tracing of regions of interest 
(ROIs) [77, 82, 138, 155-157, 165, 168-169], and more recently automated 
segmentation and parcellation of target regions [143, 173, 213, 263, 266]. Other 
semi-automated tools which provide three-dimensional mapping of brain 
morphology, including voxel-based morphometry (VBM), tensor-based 
morphometry (TBM) and related techniques have also identified significant global 
and local tissue changes in patients with MCI and AD, including decreased whole 
brain, hippocampal, and temporal lobar grey matter (GM) density [77, 117, 185-
187, 189, 192, 258]. Structural MRI techniques have also been shown to provide 
sensitive prediction of disease progression. Hippocampal volume and GM 
density, as well as measures of MTL volume and cortical thickness, have been 
53 
 
identified as sensitive biomarkers for predicting conversion from MCI to probable 
AD [166, 184, 193, 209, 211, 213, 216, 257, 284].  
Longitudinal monitoring of atrophy rate using MRI measures has also 
proven sensitive to AD-related changes. Increased rates of whole brain and MTL 
atrophy in patients with MCI and AD relative to healthy elderly controls (HC) are 
routinely reported in studies of brain aging and dementia ([for recent review, see 
87]). Manual tracing or automated ROI techniques and analysis of deformation 
fields reflecting brain shrinkage are the most commonly employed methods for 
evaluating longitudinal changes in global and regional volume, particularly in the 
MTL. Previous studies have reported rates of hippocampal annual decline of                
-4.5% in patients with AD and -3% in patients with MCI in contrast to -1% in HC 
([for meta-analysis see 201]). Furthermore, increased atrophy rates can predict 
future clinical decline, including MCI to probable AD conversion [197, 200, 218-
220, 295]. Patients who convert from MCI to probable AD show higher rates of 
hippocampal atrophy compared to patients with a stable diagnosis of MCI, 
reported as -3.5% and -2.2%, respectively [197, 219].  
Genetic factors play a significant role in the development and progression 
of MCI and AD. Genetic variation in the apolipoprotein E gene (APOE) is the 
most commonly reported genetic risk factor associated with late-onset AD, with 
the presence of a single ε4 allele conferring a 2-fold or 3-fold increased risk of 
developing AD and two ε4 alleles associated with nearly an 11-fold increased risk 
[3, 296-297]. In addition to an increased risk of AD, the presence of an ε4 allele 
has been associated with imaging markers of neurodegeneration. Significantly 
greater cross-sectional hippocampal atrophy and an increased rate of 
hippocampal and whole brain atrophy in ε4 carriers has been reported in non-
demented individuals, as well as in MCI and AD patients in some studies [223, 
256, 298-305], but not in others [306-307]. 
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a five-year 
consortium study designed to assess the utility of various biomarkers for 
detecting early changes associated with MCI and AD and predicting disease 
course over time. Target biomarkers collected as part of ADNI include 
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longitudinal structural MRI and positron emission tomography (PET) scans, 
genetic factors, psychometric scores, CSF markers, and other variables. A 
number of studies utilizing MRI data from this cohort have been published 
recently. Using both ROI and three-dimensional mapping techniques the 
expected differences in structural MRI markers have been found between 
diagnostic (AD, MCI, HC) groups at baseline assessment, including atrophy in 
hippocampal and other MTL regions and enlarged ventricles in patients with AD 
and MCI [213, 281, 308-314]. Hippocampal volume has also been found to be 
sensitive and specific for predicting one-year conversion from MCI to probable 
AD [213, 282, 309, 311-312, 315-316]. MRI studies of the ADNI cohort have also 
examined longitudinal change in brain volumes using ROI and whole-brain 
structural change techniques (e.g., Jacobian determinants, boundary shift 
integral), and have detected differences in annual change in whole brain volume, 
hippocampal volume, and ventricular volume as a function of baseline diagnostic 
group (AD, MCI, HC) [127, 282, 304-305, 311, 316-323] and of APOE ε4 
genotype [303-305, 311]. Several studies have reported larger declines in whole 
brain and regional volumes as well as larger ventricular volume increases in MCI 
to AD converters than MCI non-converters [282, 311, 317, 322].  
In order to better evaluate the effectiveness of future disease modifying 
therapeutics, biomarkers of disease state and progression are likely to be more 
sensitive and reliable than clinical measures, which may be highly variable within 
and between participants. When designing clinical trials, an important 
consideration is the sample size needed to detect a therapeutic effect that is both 
statistically significant and clinically meaningful in a target biomarker with 80% or 
90% power. Several previous studies in the ADNI cohort have calculated the 
relative sample size needed to detect a hypothetical treatment-induced 25% 
reduction in brain atrophy for various regional MRI markers and have suggested 
that to achieve 80% power approximately 35-100 AD and 100-200 MCI 
participants are required [311, 318, 320-321].  
Despite the extensive MRI analyses in AD and MCI, prior studies have not 
directly compared the relative sensitivity of longitudinal changes in GM density 
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and volume, cortical thickness and ROI volumes in relation to changes in clinical 
status. In ADNI, longitudinal studies have primarily focused on baseline 
diagnostic groups rather than one-year clinical conversion status. The present 
study was designed to compare the annual percent change (APC) of different 
types of structural MRI markers among groups defined by baseline diagnosis and 
one-year MCI to probable AD conversion status using the final one-year sample. 
We hypothesized that patients with more advanced clinical indicators of disease 
progression, particularly AD and MCI to probable AD converter participants, 
would show significantly greater APC in major structural MRI markers. We also 
evaluated the relative sensitivity of these markers to progression of atrophy over 
time. Because of the important implications for design of future therapeutic trials 
of disease modifying agents, we also calculated the sample size needed to 
detect a 25% reduction in atrophy rate for selected markers. We hypothesized 
that the MTL atrophy rates would constitute the most sensitive regional markers 
of progression and therefore require the smallest potential sample sizes. Prior 
ADNI reports have not evaluated the sample size needed for trials in rapidly 
progressing MCI participants compared to stable MCI participants, an important 
distinction for trial design. Additionally, previous reports have focused primarily 
on sample sizes needed for MRI markers that were extracted using a single 
technique. In the present study, we compared GM density and volume, cortical 
thickness and ROI volumetric markers. Finally, we assessed the impact of APOE 
genotype on the APC in several key target regions, which to date has not been 
examined in patients who converted from MCI to probable AD the ADNI cohort to 
our knowledge. We hypothesized that the presence of an ε4 allele would 
increase the annual rate of decline in selected MRI markers of MTL integrity. 
 
Methods 
 
ADNI 
ADNI is a consortium study initiated in 2004 by the National Institute on 
Aging (NIA), the National Institute of Biomedical Imaging and Bioengineering 
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(NIBIB), the Food and Drug Administration (FDA), private pharmaceutical 
companies, and non-profit organizations. More than 800 participants age 55-90 
have been recruited from 59 sites across the U.S. and Canada to be followed for 
2-3 years, with repeated structural MRI and PET scans and functional, 
psychological, and psychometric test data collected every 6 or 12 months. For 
additional information about ADNI, see www.adni-info.org and Mueller et al. 
(2005a, 2005b) [251-252]. 
 
MRI Scans 
Raw baseline 1.5T MRI scans from 820 participants were downloaded 
from the ADNI public website (http://www.loni.ucla.edu/ADNI/) onto local servers 
at Indiana University School of Medicine between January and April 2008 and 
processed using Freesurfer and VBM implemented in SPM5 as previously 
described [213]. All available 1.5T MP-RAGE scans collected at the one-year 
follow-up visit were also downloaded for all participants (n=693) as of June 2009. 
A minimum of two MP-RAGE images were acquired at each timepoint for each 
participant, using a standard MP-RAGE protocol that was selected and tested by 
ADNI [250].  
Participants were only included in the present analysis if their baseline and 
one-year MRI scans were successfully preprocessed. Four participants failed 
Freesurfer processing and were not included in any analyses. 30 additional 
participants were excluded from only the VBM analyses due to failed processing 
of scans from either the baseline or one-year visit. Participants who did not have 
either baseline (n=2) or one-year (n=124) scans were also excluded. Included 
participants (n=673 for Freesurfer analyses, n=643 for VBM analyses) were 
divided into groups by baseline and one-year clinical diagnosis and one-year MCI 
to probable AD conversion status, resulting in 4 groups: (1) participants with a 
stable AD diagnosis for the first year of the study (AD; n=152 for Freesurfer 
analyses, n=143 for VBM analyses); (2) participants with an MCI diagnosis at 
baseline who converted to a diagnosis of probable AD at either the 6-month or 
one-year visit (MCI-Converters (MCI-C); n=60 for Freesurfer analyses, n=57 for 
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VBM analyses); (3) participants with a stable diagnosis of MCI over the first year 
of the study (MCI-Stable (MCI-S); n=261 for Freesurfer analyses, n=253 for VBM 
analyses); (4) participants with a stable designation of healthy control for the first 
year of the study (HC; n=200 for Freesurfer analyses, n=190 for VBM analyses). 
Participants who showed other forms of conversion, reversion, or otherwise 
unstable diagnostic designation were excluded (e.g., conversion from HC to MCI 
at the 6-month visit, followed by a reversion from MCI to HC at the one-year visit, 
etc.; n=16). Details of the ADNI design, participant recruitment, clinical testing, 
and additional methods have been published previously [251-252, 259, 324] and 
at www.adni-info.org.  
 
Demographic and Clinical Data 
Demographic information, APOE genotype, neuropsychological test 
scores, and diagnosis information for all analyzed visits were downloaded from 
the ADNI clinical data repository 
(https://www.loni.ucla.edu/ADNI/Data/ADCS_Download.jsp). The “8-09-09” 
version of the ADNI clinical database was used for all analyses. By this time all 
one-year clinical and scan data were complete. Participants were classified into 
groups based on baseline and one-year diagnoses as reported in the 
conversion/reversion database. 
In order to evaluate the impact of APOE genotype on annual rate of 
atrophy, we also classified participants by the presence or absence of an APOE 
ε4 allele. Given the unknown impact of having an ε2ε4 genotype (i.e., possessing 
a potential protective allele (ε2) and a risk allele (ε4) for AD), we chose to run 
analyses both including and excluding the ε2ε4 participants (n=13; 3 AD, 7 MCI-
S, 3 HC). We found similar results from the two comparisons (data not shown), 
and thus, chose to use the largest available sample in the results presented in 
this report. For the evaluation of hippocampal volume and EC thickness, 673 
participants were included: 99 AD, 35 MCI-C, 143 MCI-S, and 56 HC who were 
APOE ε4 positive (ε2ε4, ε3ε4 or ε4ε4 genotypes) and 53 AD, 25 MCI-C, 118 
MCI-S, and 144 HC who were APOE ε4 negative (ε2ε2, ε2ε3, or ε3ε3 
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genotypes). 30 participants were excluded due to failed VBM processing, as 
previously described. Thus, the analysis of the effect of APOE ε4 genotype on 
bilateral mean hippocampal GM density and volume included the following 
participants (n=643): 95 AD, 34 MCI-C, 142 MCI-S, and 53 HC who were APOE 
ε4 positive and 48 AD, 23 MCI-C, 111 MCI-S, and 137 HC who were APOE ε4 
negative.  
 
Image Processing  
VBM: Scans were processed with VBM in SPM5 
(http://www.fil.ion.ucl.ac.uk/spm/), using previously described methods [145-146, 
253]. Briefly, after conversion from DICOM to NIfTI, both baseline MP-RAGE 
scans were aligned to the T1-weighted template and both one-year scans were 
co-registered to the first T1-template aligned baseline scan. After alignment, all 
scans were bias corrected and segmented into GM, WM, and CSF 
compartments using standard SPM5 templates. GM maps were normalized to 
MNI atlas space as 1 x 1 x 1 mm voxels and smoothed using a 10 mm FWHM 
Gaussian kernel. Both modulated and unmodulated GM maps were generated. 
In order to maximize signal and minimize variability in the imaging markers, we 
chose to create a mean GM image of the two independent MP-RAGE-derived 
GM maps using SPM5. These mean GM maps were then employed in all 
subsequent VBM analyses. This process was completed for both unmodulated 
and modulated normalized GM maps at each timepoint (baseline and one-year), 
yielding a mean GM density image and a mean GM volume image, respectively.  
Regions of Interest (ROIs): A hippocampal ROI template was created by 
manual tracing of the left and right hippocampi in an independent sample of 40 
HC participants enrolled in a study of brain aging and MCI [77, 267, 270]. 
Hippocampal GM density and GM volume values were extracted from baseline 
and one-year mean GM maps from VBM, as previously described [213]. 
Additionally, mean GM density and mean GM volume were extracted from 90 
cortical and 26 cerebellar regions using MarsBaR ROI templates [325]. Mean 
lobar measures from MarsBaR regions were calculated from target ROIs as 
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follows: mean frontal lobe is the mean of GM density values from inferior frontal 
operculum and triangularis, inferior, medial, middle and superior orbital frontal, 
middle and superior frontal, and medial superior frontal regions; mean parietal 
lobe is the mean of inferior and superior parietal, angular gyrus, supramarginal 
gyrus, and precuneus GM density values; and mean temporal lobe value is the 
mean of GM density values from the amygdala and hippocampus, middle and 
superior temporal pole, inferior, middle and superior temporal gyri, and fusiform, 
Heschl’s, lingual, olfactory, and parahippocampal gyri.  
Automated Parcellation: Bilateral volumetric and cortical thickness 
estimates from the baseline and one-year scans were extracted using Freesurfer 
version 4 [142-144, 268, 270], as previously described [213]. Each baseline and 
one-year scan was processed independently. The final extracted values were 
then used to calculate a mean volume or cortical thickness for each region for 
both the baseline and one-year visits. Mean lobar cortical thickness measures 
were calculated from selected ROI mean cortical thicknesses from Freesurfer as 
follows: mean frontal lobe was the mean of caudal midfrontal, rostral midfrontal, 
lateral orbitofrontal, medial orbitofrontal, and superior frontal gyri, pars 
opercularis, oribitalis, and triangularis, and frontal pole thicknesses; mean 
parietal lobe was the mean of inferior parietal, superior parietal and 
supramarginal gyri, and precuneus thicknesses; and mean temporal lobe was the 
mean of the fusiform, lingual, parahippocampal, inferior temporal, middle 
temporal, and lateral temporal gyri, as well as temporal and transverse temporal 
pole thicknesses. Baseline total intracranial volume (ICV), which was used in 
most subsequent analyses as a covariate, was also generated using Freesurfer. 
 
VBM Statistical Analysis 
A two-way ANCOVA assessing time and group membership (AD, MCI-C, 
MCI-S, HC) was performed to compare the change in GM density over one year 
between groups using the smoothed, unmodulated normalized mean GM maps. 
Statistical analyses were performed on a voxel-by-voxel basis using a general 
linear model (GLM) approach implemented in SPM5. A threshold of p<0.0001 
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(uncorrected for multiple comparisons) and minimum cluster size (k) of 27 voxels 
was considered significant. We chose to show the VBM comparison images at 
this threshold (p<0.0001 unc.) for display purposes although all comparisons 
survive p<0.05 with a false discovery rate (FDR) correction for multiple 
comparisons and have at least 1 cluster which survives p<0.01 with a family-wise 
error (FWE) multiple comparison correction. Baseline age, gender, years of 
education, handedness, and baseline mean total intracranial volume (ICV) were 
included as covariates, and an explicit GM mask was used to restrict analyses to 
GM regions.   
 
Other Statistical Analyses 
Annual percent change (APC) estimates were calculated using mean 
values from left and right ROIs from baseline and one-year scans for each 
participant using the following equation: 
 
               (one-year ROI estimate – baseline ROI estimate)  
Annual percent change (APC) =      baseline ROI estimate    
           (Time (in years) between baseline and one-year visits) 
 
A one-way multivariate ANCOVA was used to assess differences in APC 
between groups. Baseline age, gender, education, handedness, and baseline 
mean ICV were included as covariates. Post-hoc pairwise comparisons with a 
Bonferroni adjustment for multiple comparisons were used to assess differences 
between individual group pairs. One-way ANCOVA and chi-square tests were 
used to determine group differences in demographic variables, as well as 
baseline values and annual change of psychometric test scores. Baseline age, 
gender, years of education, and handedness were included as covariates where 
appropriate. SPSS (version 17.0.2) was used for all statistical analyses. 
The sample size needed to detect a 25% reduction in atrophy rate (two-
sided t-test; α=0.05) with 80% or 90% power was also calculated using Microsoft 
Excel 2007 for the absolute change over one year of all target variables in all four 
groups. Only participants with values for all analyzed regions were included in 
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these calculations (n=643; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC). Sample size 
was calculated using the following equation: 
 
    n = 2σ2 (z1-α/2 + zpower)2  
    (0.25 β)2 
 
where n is the target sample size, α = 0.05, β is the mean absolute change in a 
target ROI adjusted for baseline age, gender, education, handedness and 
baseline ICV, σ is the standard deviation of the measure, and za is the value from 
the standard distribution for 80% or 90% power [318, 321, 326]. 
Effect sizes for the comparisons between pairs of diagnostic groups were 
also calculated for bilateral mean APC and baseline values of selected imaging 
markers. Left and right adjusted means, covaried for baseline age, gender, 
education, handedness, and baseline mean ICV, were averaged to yield a 
bilateral estimate. These bilateral mean values were then used to calculate the 
effect size (Cohen’s d) between group pairs for all imaging measures in Microsoft 
Excel 2007 using the following equation: 
 
    d =     (M1 – M2)  
             √[(σ1
2 + σ2
2) / 2] 
 
where, for the target biomarker, M1 = mean value for group 1, M2 = mean value 
for group 2, σ1 = standard deviation for group 1, and σ2 = standard deviation for 
group 2 [327]. In order to accurately compare the resulting effect sizes, only 
participants with values for all analyzed regions were included in this comparison 
(n=643; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC).  
Finally, a two-way ANCOVA was used to assess the impact of diagnostic 
group and APOE ε4 genotype on the most sensitive imaging phenotypes as 
determined by effect size in the comparison of MCI-C and MCI-S participants, 
namely the APC in bilateral mean hippocampal GM density and GM volume, 
hippocampal total volume, and EC thickness. Additionally, two-sample t-tests 
were used to evaluate the influence of APOE ε4 genotype within each of the 4 
diagnostic groups on MTL change measures. Age, gender, education, 
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handedness, and baseline ICV were included as covariates in all analyses. All 
graphs were created using SigmaPlot (version 10.0). 
 
Results 
 
Group Characteristics and Change in Psychometric Scores 
Demographic information and the baseline values and change over the 
first year in selected psychometric scores are found in Table 2. Significant 
differences were demonstrated in education level (F=6.53, p<0.001) and APOE 
genotype (percentage positive for 1or 2 ε4 alleles; χ2=56.64, p<0.001). Post-hoc 
tests indicated significant differences between HC and all patient groups (all 
p<0.05). Expected differences between groups in psychometric test scores were 
found to be significant for both baseline scores and annual change in scores on 
the Clinical Dementia Rating Scale Sum of Boxes score (CDR-SB; baseline, 
F=532.91, p<0.001; annual change, F=21.42, p<0.001), Mini-Mental Status 
Exam (MMSE; baseline, F=342.97, p<0.001; annual change, F=23.14, p<0.001), 
and Rey Auditory Verbal Learning Test (RAVLT; baseline, F=193.85, p<0.001; 
annual change, F=8.02, p<0.001). Post-hoc paired comparisons between groups 
also indicated significant differences in both baseline values and annual change 
as shown in Table 2. No significant difference among groups was detected in 
baseline or one-year age, gender distribution, handedness distribution, or 
baseline mean total intracranial volume (ICV). 
 
  
63 
 
 
AD 
(n=152) 
MCI-C 
(n=60) 
MCI-S 
(n=261) 
HC 
(n=200) 
ANOVA 
p-value 
Significant Post-hoc 
Comparisons (p<0.05) 
Baseline Age 75.33 (0.5) 74.04 (0.9) 75.07 (0.4) 75.95 (0.5) NS none 
One-Year Visit Age 76.41 (0.5) 75.11 (0.9) 76.15 (0.4) 77.04 (0.5) NS none 
Education 14.82 (0.2) 15.15 (0.4) 15.89 (0.2) 16.08 (0.2) <0.001 HC, MCI-S>AD 
Gender (M, F) 80, 72 35, 25 166, 95 105, 95 0.06 MCI-S vs. AD, HC 
Handedness (R, L) 144, 8 55, 5 239, 22 185, 15 NS none 
APOE Genotype 
(% APOE4+) 
65.13% 58.33% 54.79% 28.00% <0.001 AD, MCI-C, MCI-S>HC 
Baseline CDR-SBe 4.18 (0.1) 2.00 (0.1) 1.52 (0.1) 0.02 (0.1) <0.001 AD>MCI-C>MCI-S>HC 
One-Year Change 
in CDR-SBa,e 
+2.13 (0.1) +2.64 (0.2) +1.26 (0.1) +1.1 (0.1) <0.001 AD, MCI-C>MCI-S, HC 
Baseline MMSEe 23.53 (0.1) 26.58 (0.2) 27.11 (0.1) 29.11 (0.1) <0.001 HC>MCI-S, MCI-C >AD 
One-Year Change 
in MMSEb,e 
-1.88 (0.7) -2.56 (0.4) -0.35 (0.2) 0.00 (0.2) <0.001 HC, MCI-S>MCI-C, AD 
Baseline RAVLTc,e 23.25 (0.7) 26.20 (1.1) 32.00 (0.5) 43.65 (0.6) <0.001 HC>MCI-S>MCI-C, AD 
One-Year Change 
in RAVLTd,e 
-2.91 (0.5) -2.68 (0.8) -0.81 (0.4) +0.3 (0.5) <0.001 
HC>MCI-C, AD; MCI-
S>AD 
Baseline ICV 
1552677.32 
(13807.5) 
1566297.8
3 (21976.7) 
1570616.0
6 (10537.0) 
1534944.9
0 (12037.1) 
NS none 
Data are given as mean (standard error of the mean) or n. 
Key: AD = Alzheimer’s disease; CDR-SB = Clinical Dementia Rating Scale Sum of Boxes score; F = female; 
HC = healthy control; ICV = total intracranial volume; L = left; M = male; MCI-C = converters from mild 
cognitive impairment to probable AD; MCI-S = mild cognitive impairment-stable; MMSE = Mini-Mental Status 
Exam; NS = nonsignificant; R = right, RAVLT = Rey Auditory Verbal Learning Test. 
a 7 participants missing data (2 AD, 1 MCI-S, 4 HC) 
b 2 participants missing data (1 MCI-S, 1 HC) 
c 3 participants missing data (1 AD, 2 HC) 
d 14 participants missing data (8 AD, 3 MCI-S, 3 HC) 
e Baseline age, gender, education, and handedness 
 
Table 2. Demographic Information and Baseline and One-Year Change in 
Neuropsychological Test Scores for ADNI Participants (Adjusted Mean 
(SE)) 
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VBM Comparisons 
AD participants showed greater one-year decline in global GM density 
than HC (Figure 8A) and MCI-S participants (Figure 8D) in widespread regions of 
the brain, including bilateral medial and lateral temporal lobes, frontal lobes, and 
parietal lobes, with maximal the differences of both comparisons found in the left 
MTL for both comparisons (global peaks). MCI-C participants also showed 
greater decline in global GM density relative to HC (Figure 8B) in bilateral medial 
and lateral temporal lobes. This difference between MCI-C and HC was maximal 
in the left MTL (global peak). Differences in one-year decline in bilateral 
hippocampal GM density were also detected between HC and MCI-S 
participants, with MCI-S showing greater decline in focal clusters of the bilateral 
medial and lateral temporal lobes than HC (Figure 8C). MCI-C also showed 
greater 1-year decline in bilateral medial and lateral temporal lobes GM density 
than MCI-S (Figure 8E). Finally, greater one-year decline in global GM density 
was detected for AD participants relative to MCI-C in a small cluster of voxels in 
the anterior parietal lobe/posterior frontal lobe (Figure 8F). All comparisons were 
significant above a threshold of p<0.0001 (uncorrected for multiple comparisons) 
and a minimum cluster size (k) of 27 voxels. 
 
Target Region Comparisons 
Results from regional assessments of GM density and GM volume, as well 
as cortical thickness and volumetric measures, show a similar magnitude and 
anatomical pattern of decline over one year by group as seen in the results from 
the VBM comparisons. The APC values for all selected ROIs, including 
hippocampal GM density and GM volume extracted using two ROI methods [77, 
267, 270, 325], hippocampal volume, entorhinal cortex (EC) thickness and mean 
lobar thickness values extracted using Freesurfer [142-144, 268], and mean 
lobar GM density and GM volume extracted using MarsBaR ROIs [325] are found 
in Table 3 and Figures 9-11. All APC values were significantly different across 
groups (p<0.001). Significant post-hoc paired comparisons using a Bonferroni 
correction are indicated in Table 3. 
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Figure 8. Group Differences in Global Reductions in Grey Matter (GM) 
Density over One Year in the ADNI Cohort 
Comparisons between groups in the reduction in GM density from baseline to 
one-year in the ADNI cohort demonstrate significantly greater annual atrophy in patients 
relative to HC (n=643*; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC). All comparisons of the 
interaction of time x diagnosis group are displayed at a threshold of p<0.0001 
(uncorrected for multiple comparisons) with a minimum cluster size (k) = 27 voxels. 
Reverse comparisons showed no significant clusters at the established threshold. Cross-
sections in (A-E) are (0, -9, 0, coronal) and (0, -23, -16, axial), left to right. Cross-section 
in (F) is (34, -29, 64, coronal). (*30 participants removed from comparisons due to failed 
image processing) 
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AD 
(n=152) 
MCI-C 
(n=60) 
MCI-S 
(n=261) 
HC 
(n=200) 
ANOVA 
p-value 
Significant Post-hoc 
Comparisons (p<0.05) 
Hippocampal GM Density  
(Independent ROI)a,b 
L -4.50 (0.2) -3.94 (0.4) -2.09 (0.2) -0.86 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -4.50 (0.2) -3.82 (0.4) -2.23 (0.2) -0.84 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
Hippocampal GM Density 
(MarsBaR)a,b 
L -4.57 (0.2) -4.02 (0.4) -2.16 (0.2) -0.97 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -4.62 (0.2) -4.05 (0.4) -2.33 (0.2) -0.85 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
Hippocampal GM Volume  
(Independent ROI)a,b 
L -4.69 (0.2) -4.58 (0.4) -2.12 (0.2) -1.17 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -4.71 (0.2) -4.33 (0.4) -2.31 (0.2) -1.09 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
Hippocampal GM Volume 
(MarsBaR)a,b 
L -4.66 (0.2) -4.55 (0.4) -2.14 (0.2) -2.24 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -4.85 (0.3) -4.55 (0.4) -2.39 (0.2) -1.07 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
Hippocampal Volume  
(FreeSurfer)b 
L -4.12 (0.3) -4.20 (0.5) -2.55 (0.2) -0.92 (0.3) <0.001 HC>MCI-S>MCI-C, AD 
R -3.76 (0.3) -3.99 (0.5) -2.74 (0.2) -1.31 (0.3) <0.001 HC>MCI-S, MCI-C, AD 
 
EC Thickness (Freesurfer)b 
L -4.84 (0.5) -6.08 (0.8) -2.49 (0.4) -0.76 (0.4) <0.001 HC>MCI-S>MCI-C, AD 
R -4.49 (0.5) -3.86 (0.8) -2.16 (0.4) -0.69 (0.4) <0.001 HC>MCI-C, AD; MCI-S>AD 
Mean Frontal Cortical 
Thickness (Freesurfer)b 
L -1.57 (0.3) -2.29 (0.4) -0.94 (0.2) -0.40 (0.2) <0.001 HC, MCI-S>MCI-C; HC>AD 
R -1.36 (0.2) -1.91 (0.4) -0.78 (0.2) -0.56 (0.2) <0.001 HC>MCI-C 
Mean Parietal Cortical 
Thickness (Freesurfer)b 
L -2.14 (0.3) -2.22 (0.4) -1.17 (0.2) -0.58 (0.2) <0.001 HC>MCI-C, AD; MCI-S>AD 
R -2.18 (0.3) -2.28 (0.4) -0.98 (0.2) -0.60 (0.2) <0.001 HC, MCI-S>MCI-C, AD 
Mean Temporal Cortical 
Thickness (Freesurfer)b 
L -2.45 (0.2) -3.11 (0.4) -0.96 (0.2) -0.62 (0.2) <0.001 HC, MCI-S>MCI-C, AD 
R -2.46 (0.2) -2.81 (0.4) -1.05 (0.2) -0.49 (0.2) <0.001 HC, MCI-S>MCI-C, AD 
 
Mean Frontal GM Density 
(MarsBaR)a,b 
L -3.02 (0.2) -2.47 (0.4) -1.48 (0.2) -0.65 (0.2) <0.001 HC>MCI-S>AD; HC>MCI-C 
R -2.91 (0.2) -2.25 (0.4) -1.37 (0.2) -0.59 (0.2) <0.001 HC>MCI-S>AD; HC>MCI-C 
Mean Frontal GM Volume 
(MarsBaR)a,b 
L -2.92 (0.2) -2.59 (0.6) -1.46 (0.2) -0.86 (0.2) <0.001 HC, MCI-S>MCI-C, AD 
R -2.84 (0.2) -2.37 (0.4) -1.36 (0.2) -0.86 (0.2) <0.001 HC>MCI-S>AD; HC>MCI-C 
Mean Parietal GM Density 
(MarsBaR)a,b 
L -3.21 (0.3) -2.40 (0.5) -1.53 (0.2) -0.51 (0.3) <0.001 HC>MCI-S>AD; HC>MCI-C 
R -3.02 (0.3) -1.95 (0.5) -1.41 (0.2) -0.55 (0.3) <0.001 HC, MCI-S>AD 
Mean Parietal GM Volume 
(MarsBaR)a,b 
L -3.60 (0.3) -2.71 (0.4) -1.76 (0.2) -0.90 (0.2) <0.001 HC>MCI-S>AD; HC>MCI-C 
R -3.64 (0.3) -2.45 (0.5) -1.51 (0.2) -0.76 (0.3) <0.001 HC>MCI-S>AD; HC>MCI-C 
Mean Temporal GM Density 
(MarsBaR)a,b 
L -3.33 (0.2) -2.81 (0.3) -1.63 (0.1) -0.76 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -3.04 (0.2) -2.66 (0.3) -1.59 (0.1) -0.65 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
Mean Temporal GM Volume 
(MarsBaR)a,b 
L -3.32 (0.2) -3.30 (0.3) -1.52 (0.2) -0.89 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
R -3.14 (0.2) -3.00 (0.3) -1.52 (0.2) -0.73 (0.2) <0.001 HC>MCI-S>MCI-C, AD 
a 30 participants excluded because of failed processing (9 AD, 3 MCI-C, 9 MCI-S, 9 HC) 
b Covaried for baseline age, gender, education, handedness, and baseline ICV 
 
Table 3. APC of Selected Imaging Biomarkers in the ADNI Cohort (Adjusted 
Mean (SE)) 
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Figure 9. APC in Selected MTL Imaging Biomarkers 
Plots of the mean APC in (A, B) hippocampal GM density and (C, D) GM volume 
extracted using left and right hippocampal ROIs extracted using a template derived on 
an independent sample of 40 healthy elderly controls [77, 267, 270] (A and C) and from 
MarsBaR (B and D) (n=643*; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC). APC in 
hippocampal GM density and GM volume was significantly different among groups with 
AD and MCI-C participants showing greater faster atrophy rates than MCI-S and HC. 
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The APC in (E) hippocampal volume (n=673; 152 AD, 60 MCI-C, 261 MCI-S, 200 HC) 
extracted using Freesurfer showed a similar trend. See Table 3 for post-hoc comparison 
results. (*30 participants removed from comparisons due to failed image processing; 
group mean APC values (+/-SE) adjusted for baseline age, gender, education, 
handedness, and baseline total ICV are displayed) 
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Figure 10. APC in Entorhinal Cortex and Mean Frontal, Parietal, and 
Temporal Lobe Cortical Thickness 
APC in (A) entorhinal cortex thickness, and mean (B) frontal, (C) parietal, and (D) 
temporal lobar cortical thickness are significantly different across groups. See Table 3 
for the results of post-hoc comparisons. (n=673; 152 AD, 60 MCI-C, 261 MCI-S, 200 HC; 
group mean APC values (+/-SE) adjusted for baseline age, gender, education, 
handedness, and baseline total ICV are displayed)  
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Figure 11. APC in Mean Frontal, Parietal, and Temporal Lobe GM Density 
and GM Volume 
The APC in mean frontal lobe (A) GM density and (B) GM volume, mean parietal 
lobe (C) GM density and (D) GM volume, and mean temporal lobe (E) GM density and 
(F) GM volume are significantly different across groups. See Table 3 for results from 
post-hoc comparisons. (n=643*; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC; *30 
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participants removed due to failed image processing; group mean APC values (+/-SE) 
adjusted for baseline age, gender, education, handedness, and baseline total ICV are 
displayed) 
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Sample Sizes 
The sample size needed to detect a 25% reduction in 1-year change in 
MRI biomarkers was calculated for 80% or 90% power and a type I error (α) of 
p<0.05 for significant regions from the ANCOVA analysis (Table 4). Mean 
bilateral hippocampal GM density and GM volume estimates measured using 
either the independent sample or MarsBaR ROIs would require the smallest 
sample size to detect the desired reduction for all of the target groups. Other 
relatively sensitive ROIs for detecting a reduction in regional brain atrophy 
include hippocampal volume extracted using Freesurfer, mean temporal lobar 
GM density and GM volume, mean temporal lobe cortical thickness (MCI-C only), 
and mean frontal lobar GM density and GM volume. A full list of sample sizes 
needed to detect a 25% decline in brain atrophy at either 80% or 90% power for 
selected ROIs is found in Table 4. 
 
  AD MCI-C MCI-S HC 
Power: 0.8 0.9 0.8 0.9 0.8 0.9 0.8 0.9 
Hippocampal GM Density (Independent ROI) 134 180 95 128 307 411 1243 1665 
Hippocampal GM Density (MarsBaR ROI) 129 173 96 129 290 388 1204 1612 
Hippocampal GM Volume (Independent ROI) 133 178 77 103 400 535 745 998 
Hippocampal GM Volume (MarsBaR ROI) 135 181 74 100 378 507 767 1028 
Hippocampal Volume (Freesurfer) 242 324 129 173 452 606 1136 1521 
  
EC Thickness (Freesurfer) 328 439 214 286 1156 1548 7948 10648 
Mean Frontal Lobe Cortical Thickness (Freesurfer) 1037 1389 369 494 2488 3333 4727 6333 
Mean Parietal Lobe Cortical Thickness (Freesurfer) 629 842 515 689 1848 2475 3142 4209 
Mean Temp. Lobe Cortical Thickness (Freesurfer) 403 539 121 162 1405 1882 3031 4061 
 
Mean Frontal Lobe GM Density (MarsBaR ROIs) 284 381 222 297 788 1056 3682 4932 
Mean Frontal Lobe GM Volume (MarsBaR ROIs) 280 376 263 353 856 1147 1475 1976 
Mean Parietal Lobe GM Density (MarsBaR ROIs) 384 514 373 499 1437 1925 7260 9726 
Mean Parietal Lobe GM Volume (MarsBaR ROIs) 238 319 315 422 976 1308 1977 2649 
Mean Temp. Lobe GM Density (MarsBaR ROIs) 157 210 129 173 456 610 1850 2479 
Mean Temp. Lobe GM Volume (MarsBaR ROIs) 158 212 100 134 646 866 1427 1911 
 
Table 4. Sample Sizes Needed to Detect 25% Reduction in One-Year 
Change in Selected MRI Biomarkers 
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Effect Sizes 
In order to effectively compare the relative sensitivity of MRI markers to 
distinguish between groups, we calculated the effect size for all available 
baseline and APC ROIs from VBM and Freesurfer for each group pair. Effect 
sizes for the comparison of AD and HC participants and MCI-C and MCI-S 
participants are found in Figure 12, while those for other pairs (MCI-C vs. HC; 
MCI-S vs. HC; AD vs. MCI-S; AD vs. MCI-C) are found in Figure 13. Baseline 
medial temporal lobe biomarkers, including EC thickness, hippocampal volume, 
and middle temporal gyri cortical thickness measures, had the highest effect 
sizes for the comparison of AD vs. HC (Figure 12A), with Cohen’s d values of 
1.846, 1.628, and 1.579, respectively. The APC in hippocampal GM density 
extracted using the MarsBaR ROIs had the highest effect size of the APC 
measures for AD vs. HC with a Cohen’s d of 1.308.  
Measures with maximal effect sizes for the comparison of MCI-C and MCI-
S participants included APC in hippocampal GM volume (Figure 12B; 
independent sample ROI, Cohen’s d=0.853; MarsBaR ROI, Cohen’s d=0.852), 
APC in inferior temporal gyri GM volume (Cohen’s d=0.842), and APC in mean 
temporal lobe GM volume (Cohen’s d=0.830). Medial temporal lobe ROIs also 
had high effect sizes for some of the other comparisons with baseline 
hippocampal volume showing the highest effect sizes for MCI-C vs. HC (Figure 
13A, Cohen’s d=1.652) and MCI-S vs. HC (Figure 13B, Cohen’s d=0.958), and 
baseline middle temporal gyri thickness having the highest effect size for AD vs. 
MCI-S (Figure 13C, Cohen’s d=0.890). APC in superior parietal gyri GM volume 
demonstrated the highest effect size for AD vs. MCI-C with a Cohen’s d of 0.456 
(Figure 13D).  
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Figure 12. Effect Sizes of Selected Imaging Biomarkers for Comparisons 
between AD and HC and MCI-C and MCI-S 
The effect sizes for baseline and APC values for the comparison of (A) AD and 
HC participants and (B) MCI-C and MCI-S participants are shown. Baseline MTL regions 
had the greatest effect sizes when comparing AD and HC, while APC in MTL regions 
demonstrated the greatest effect sizes in the MCI-C vs. MCI-S comparison. (n=643*; 143 
AD, 57 MCI-C, 253 MCI-S, 190 HC; *30 participants removed due to failed image 
processing; effect sizes are calculated from bilateral mean values of target ROIs 
adjusted for baseline age, gender, education, handedness, and baseline total ICV) 
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Figure 13. Effect Sizes of Selected Imaging Biomarkers for Comparisons of 
MCI-C vs. HC, MCI-S vs. HC, AD vs. MCI-S, and AD vs. MCI-C 
The effect sizes for baseline and APC values for the comparison of (A) MCI-C vs. 
HC participants, (B) MCI-S vs. HC participants, (C) AD vs. MCI-S participants, and (D) 
AD vs. MCI-C participants are shown. (n=643*; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC; 
*30 participants removed due to failed image processing; effect sizes are calculated from 
bilateral mean values of target ROIs adjusted for baseline age, gender, education, 
handedness, and baseline total ICV) 
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Influence of APOE ε4 Genotype 
Participants with one or more APOE ε4 alleles showed increased atrophy 
rates in all evaluated measures, including hippocampal GM density (p=0.001, 
Figure 14A), hippocampal GM volume (p<0.001; Figure 14B), hippocampal 
volume (p=0.001; Figure 14C), and EC thickness (p=0.003; Figure 14D). 
Additionally, a significant interaction between diagnosis group and APOE ε4 
genotype was observed for the APC in EC thickness (p=0.029). Subsequent 
analyses within diagnostic group demonstrated that for AD patients APOE ε4 
carriers showed greater decline in hippocampal GM volume (p=0.031) and EC 
thickness (p=0.002). For MCI-C, APOE ε4 positive participants also showed 
greater rate of atrophy in hippocampal GM density (p=0.031) and GM volume 
(p=0.001). For the MCI-S group, the atrophy rate in all evaluated regions was 
greater in APOE ε4 positive than negative participants, including APCs for 
hippocampal GM density (p=0.004), hippocampal GM volume (p<0.001), 
hippocampal volume (p=0.006), and EC thickness (p=0.004). Finally, APOE ε4 
positive HC participants showed a significantly greater APC in hippocampal 
volume than those who were APOE ε4 negative (p=0.004). 
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Figure 14. Impact of APOE ε4 Genotype on APC in Selected MTL Measures 
The APC in bilateral mean hippocampal (A) GM density and (B) GM volume 
(n=643*; 143 AD, 57 MCI-C, 253 MCI-S, 190 HC), extracted using an independent 
sample of 40 healthy elderly controls [77, 267, 270], as well as (C) hippocampal volume, 
and (D) EC thickness extracted using automated parcellation (n=673; 152 AD, 60 MCI-
C, 261 MCI-S, 200 HC) show a significant effect of both diagnostic group and APOE ε4 
genotype. (*30 participants removed due to failed image processing; group mean (+/- 
SE) APC values adjusted for baseline age, gender, education, handedness, and 
baseline total ICV are displayed) 
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Discussion 
Our main goal was to assess a detailed panel of longitudinal MRI atrophy 
markers in the ADNI cohort, including in patients with probable AD, MCI to 
probable AD converters (within one year), stable MCI (over one year) and 
healthy control participants. Our main findings were that AD and MCI-C groups 
had a significantly higher rate of annual decline than MCI-S and HC participants 
in global and hippocampal GM density and GM volume, hippocampal total 
volume, EC thickness, and mean frontal, parietal and temporal lobar GM density, 
GM volume and cortical thickness measures. Sample size calculations indicated 
that hippocampal GM density and GM volume required the smallest samples to 
detect a 25% reduction in rate of regional brain atrophy. Finally, effect size 
estimates indicated that dynamic measures, including APC in MTL volumes and 
cortical thickness, showed the greatest difference between MCI-C and MCI-S 
participants. However, baseline hippocampal volume and GM density, as well as 
baseline temporal lobe cortical thickness measures, demonstrated the greatest 
effect size when comparing AD and HC participants. This pattern suggests that 
different structural MRI markers may have differential utility as a function of stage 
of disease and/or role within a clinical trial. Where hippocampal volume and GM 
density are powerful tools for assessing baseline neurodegeneration, annual 
change rate in MTL volumes and cortical thickness may be most useful for 
comparing stable vs. rapidly progressing individuals, and may be the best choice 
for surrogate markers in trials of disease modifying agents. 
Our estimates of APC in hippocampal volume, including -3.95% for AD 
patients, -4.10% for MCI-C participants, -2.65% for MCI-S participants, and -
1.12% for HC, were similar to estimates from previous reports in the ADNI 
cohort, as well as other samples (Table 3; [201]). These results demonstrate a 
significantly accelerated rate of brain atrophy in participants diagnosed with AD, 
as well as those who show rapid clinical decline from MCI to probable AD. 
Participants who show stable clinical diagnoses (both MCI and HC) also show 
relatively stable brain volume and cortical thickness measures, as well as 
minimal change in psychometric variables (Table 2).  
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We examined the influence of APOE ε4 genotype on annual atrophy rate 
in selected MTL MRI markers given the mixed prior findings, including significant 
effects of APOE on brain atrophy in some reports [300-301], whereas others 
found no effect [306-307]. In the present study, we observed a modest but 
significant effect of APOE ε4 genotype on annualized hippocampal and EC 
atrophy rates. This effect was maximal in MCI-S participants, with ε4 positive 
participants demonstrating significantly greater APC in all measures evaluated. 
However, the effect of APOE genotype in AD and MCI-C groups was only 
observed on some measures, suggesting a more moderate yet still detectable 
effect of genotype. Finally, APOE ε4 positive HC participants showed a faster 
rate of atrophy relative to ε4 negative participants only on hippocampal volume. 
Our results support the complicated nature of the relationship between APOE 
genotype and MRI markers of neurodegeneration and suggest that the 
magnitude of the effect may differ by diagnostic stage, as has been previously 
reported in the ADNI cohort [305, 311]. Future studies will further characterize 
the impact of APOE, as well as that of variation in other candidate genes, on MRI 
and other ADNI biomarkers, which may assist in elucidating the role of genetic 
factors in the neuropathology of AD [328]. 
This report adds to the body of research demonstrating the utility of MRI 
metrics in detecting and monitoring atrophy associated with AD and MCI, and 
extends prior research by focusing on identifying differences between rapidly 
declining MCI to probable AD converters and individuals with a relatively stable 
MCI diagnosis. Reports in other smaller samples have led to similar conclusions 
regarding the utility of MRI measures of global and local brain volume, cortical 
thickness, and morphometry in detecting and monitoring brain atrophy 
associated with AD and MCI [195-197, 199-200, 204, 206, 218-220, 295, 329]. 
As previously reported in the ADNI sample, baseline values of hippocampal GM 
density and volume, amygdalar volume, EC thickness, and temporal and parietal 
lobe cortical thickness measures are significantly different between MCI-C and 
MCI-S participants [213]. In fact, MCI-C and AD participants show nearly 
equivalent atrophy at baseline, up to one year prior to equivalent clinical 
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diagnoses, indicating that MRI can serve as an antecedent biomarker. Measures 
of annual decline provide further evidence that MCI to AD converters have 
characteristic cross-sectional and longitudinal brain atrophy more similar to AD 
patients than to stable MCI patients. The different longitudinal phenotypes 
warrant investigation and may be useful in examining genetic variation 
associated with rate of decline [300, 330]. 
Our results are generally consistent with previous reports using subsets of 
the ADNI cohort and alternative methods. Four studies employed Freesurfer 
based ROI techniques to estimate APC in selected cortical and subcortical 
regions and reported similar APC values and differences between diagnostic 
groups as those observed in the present analysis [316, 319-320, 323]. 
Furthermore, two of these studies divided the MCI group by baseline CDR-SB 
[323] and by atrophy pattern (AD-like vs. HC-like, [316]) and showed variability of 
APC values within the MCI group similar to that seen in the present report 
between MCI-C and MCI-S participants. Two studies used various hippocampal 
ROIs and reported significantly greater APC in hippocampal volume in AD 
participants relative to MCI and HC participants [304-305]. Two studies examined 
changes in ventricular volume, demonstrating greater rates of ventricular 
enlargement in AD and MCI participants relative to HC, as well as greater 
ventricular enlargement in participants who converted from MCI to probable AD 
within the first 6 months of the study relative to stable MCI patients [127, 311]. 
Three additional studies employed tensor-based morphometry (TBM) and 
Jacobian maps to investigate whole brain and temporal lobe atrophy rates and 
found a similar pattern of differences between participants as seen in the present 
study [318, 321-322]. One of these studies also reported a higher rate of atrophy 
in MCI-C relative to MCI-S participants, albeit in a significantly smaller sample (7 
MCI-C and 32 MCI-S) than used in the present analysis [322]. Misra et al. (2009) 
also reported significant differences in atrophy rate between MCI-C and MCI-S 
participants using a VBM-like technique (RAVENS), although differences were 
limited to periventricular WM and the temporal horn [282]. Finally, another study 
used a boundary shift integral (BSI) technique to evaluate annual rates of whole 
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brain atrophy and ventricular enlargement [317]. This study reported greater 
annual rates of whole brain atrophy and ventricular enlargement in AD 
participants relative to MCI and HC participants, as well as in MCI-C relative to 
MCI-S participants. In fact, Evans et al. (2009) noted that MCI-C demonstrated 
nearly equivalent rates of atrophy as seen in the AD participants, similar to the 
pattern reported in the present study. Overall, the results of the present study 
extend this line of research by providing one of the first direct comparisons of 
annual atrophy rates for an ensemble of state-of-the-art MRI morphometric, 
volumetric, and cortical thickness variables in the ADNI cohort, particularly 
focusing on participants who converted from MCI to AD within the first year of the 
study.  
There are several limitations of the present study. First, we were unable to 
account for some other variables which may have impacted the results. Since 
ADNI is an observational study, many participants were taking a number of 
medications prescribed for AD or other conditions that could have affected the 
results. Additionally, differences in disease severity beyond clinical diagnostic 
classification (i.e., AD, MCI, or HC) were not considered in the present analyses. 
Although diagnostic classification and conversion status incorporate information 
from psychometric performance, the present report does not explicitly examine 
the relationship between changes in MRI variables and changes in psychometric 
performance. Secondly, the inclusion of only two timepoints separated by 
approximately one year in the present study limited the specificity and accuracy 
of the APC estimations. One of the major advantages of the ADNI project is the 
extensive longitudinal data collection. Therefore, as full datasets from the two-
year and three-year timepoints become available, we plan to expand our analysis 
of annual atrophy rates in patients with AD, MCI-C, MCI-S, and healthy older 
adults. Furthermore, we will employ more advanced statistical modeling to 
compare the atrophy rates between MCI-C from several timepoints. With 3 or 
more timepoints any potential non-linearities in longitudinal decline can be 
detected. Finally, this study was limited by the nature of the methods employed 
to measure atrophy. Specifically, some variability in segmentation and extraction 
83 
 
of ROIs is likely, based on the interaction between scan quality or other 
properties and specific image processing algorithms, which may have resulted in 
variation in the accuracy of the annual change estimates. However, the largely 
automated methodology employed in these analyses provides for little or none of 
the rater bias which is inherent in manually directed tools of volume extraction. 
Furthermore, other analysis techniques (e.g., TBM, BSI) may provide additional 
and complementary information to that extracted in the present study using VBM 
and automated parcellation. Although a comprehensive and direct comparison of 
the relative sensitivity and specificity of target MRI-based atrophy measures 
extracted using different methods has not been completed to our knowledge, 
ADNI provides an ideal cohort for investigating this issue.  
In summary, these results used a combination of analysis methods to 
confirm that MRI based morphometric markers detect higher rates of brain 
atrophy in patients with AD and MCI compared to controls and are highly 
sensitive to clinical progression with one year. Measures of GM density change 
within medial and lateral temporal regions have been employed less than 
volumetric measures to date but appear particularly promising and 
complementary to more standard measures such as hippocampal volumetry. The 
sensitivity of automated and unbiased methods for detecting differences in rate of 
neurodegenerative changes encourages their use in clinical trials of disease 
modifying agents and in prevention trials. 
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Chapter 2b: Longitudinal MRI Biomarkers in a pre-MCI Stage 
 The next chapter evaluates the use of cross-sectional and longitudinal 
MRI measures of neurodegeneration in a pre-MCI stage, namely older adults 
with cognitive complaints (CC) but without significant cognitive impairment. For 
this report, data from a cohort of older adults in a longitudinal study on 
neuroimaging and brain aging at Dartmouth Medical School (PI: Dr. Andrew 
Saykin) were analyzed. Longitudinal MRI, clinical, and neuropsychological test 
data from two visits, with the follow-up visit approximately two years after the 
initial visit, were assessed. Participants included patients with a stable diagnosis 
of probable AD, patients with a diagnosis of MCI at baseline who converted to 
probable AD (MCI-Converters (MCI-C)), patients with a stable diagnosis of MCI 
(MCI-Stable (MCI-S)), older adults with cognitive complaints but no significant 
cognitive deficits at baseline who converted to a diagnosis of MCI (CC-
Converters (CC-C)), older adults with cognitive complaints who were stable (CC-
Stable (CC-S)), and stable healthy older controls without significant cognitive 
complaints (HC). MRI scans were analyzed using the methods discussed in 
Chapters 1 and 2a, including regional grey matter (GM) density and volume data 
from voxel-based morphometry (VBM) and MarsBaR regions of interest (ROIs) 
and regional volumetric and cortical thickness data from automated parcellation 
(Freesurfer version 4). We assessed both baseline and two-year annualized 
percent change (APC) for selected temporal lobe ROIs. In addition, we 
calculated the effect sizes of baseline and APC measures for the differences 
between converters and stable participants (MCI-C vs. MCI-S, CC-C vs. CC-S). 
Finally, we evaluated the relationship between hippocampal atrophy rate and 
two-year change in clinical and psychometric performance variables. 
 We observed significant differences among groups in temporal lobe ROIs 
both at baseline and in two-year annualized atrophy rate. Similar to the previous 
reports (Chapters 1 and 2a), patients with MCI and AD show greater cross-
sectional atrophy and faster atrophy rates in the temporal lobe than HC. MCI-C 
show more baseline atrophy and faster annualized atrophy rates than MCI-S, 
although these differences were not significant (likely due to a small sample 
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size). The novel findings of the present report concern the CC group. Patients 
who convert from CC to MCI show slightly more atrophy at baseline and faster 
rates of atrophy in the temporal lobe relative to those who have a stable CC 
diagnosis. This is the first report to date to evaluate differences in neuroimaging 
biomarkers between CC-C and CC-S. We also observed that atrophy rate 
estimates of medial temporal lobe regions are the most sensitive to differences 
between converter and stable participants. Finally, there was a significant 
relationship between two-year change in clinical dementia severity and 
hippocampal atrophy rate in the full cohort, but not in the sub-group of 
participants with a CC diagnosis at baseline. However, two-year change in 
memory performance was significantly associated with hippocampal atrophy rate 
in both the full cohort and the CC at baseline sub-group. 
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Introduction 
Alzheimer’s disease (AD) is the most common age-related 
neurodegenerative disease, affecting more than 25 million people over the age of 
60 [1, 249, 331]. AD is characterized pathologically by the accumulation of 
extracellular amyloid plaques, intracellular neurofibrillary tangles of 
hyperphosphorylated tau protein, and progressive and widespread neuronal 
death and brain atrophy [10-11]. Clinically, patients with AD show significantly 
impaired cognition in memory and other cognitive domains, resulting in dementia 
and an inability to perform normal daily activities [63].  
 AD is thought to develop over years or decades, beginning with the 
accumulation of amyloid and hyperphosphorylated tau, followed by the 
widespread neurodegeneration and finally the emergence of the clinical 
syndrome [17]. The most commonly recognized early clinical stage of AD is mild 
cognitive impairment (MCI) [68, 293]. Patients with MCI show significantly 
impaired cognition without significant disruption of activities of daily living [64, 
68]. MCI patients with a primary deficit in memory are termed “amnestic MCI” 
and have a much greater risk of progressing to AD than normal older adults (10-
15% annual conversion to probable AD in amnestic MCI vs. 1-2% in healthy 
older adults) [67].  
Recently earlier stages of AD than MCI have been explored, although their 
definitions differ by research group. Some researchers have focused on 
cognitively healthy older adults with significant AD neuropathology (i.e., amyloid 
deposition) and have shown these patients to be a higher risk for progression to 
MCI and AD [14, 71]. Other researchers define early AD stages and at-risk 
patients by genetic background (i.e., apolipoprotein E (APOE) ε4 status) and/or 
family history of AD [74, 298, 332-336]. Finally, patients who have significant 
complaints about their cognition, even in the absence of cognitive deficits, may 
also represent an early stage of AD. In fact, cognitive complaints have repeatedly 
been shown to be associated with future cognitive decline in memory and 
progression to dementia [76, 78-79, 337-341], even in the absence of depression 
or measurable cognitive impairment at baseline. In addition, older adults with 
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cognitive complaints (particularly memory complaints) show AD-like 
neuropathology using neuroimaging, including significant neurodegeneration 
measured using structural magnetic resonance imaging (MRI) [76-77, 342-345], 
altered white matter integrity measured using diffusion tensor imaging (DTI) 
[345], and changes in brain function both at rest and during cognitive tasks using 
positron emission tomography (PET) [337, 346]. These reports highlight 
preliminary evidence that preclinical stages of AD exist and are identifiable using 
biomarkers before the diagnosis of MCI can be made. Additional investigation 
into the preclinical stages of AD is still needed to further characterize the clinical 
course of these patients. The identification and understanding of preclinical AD 
stages is important because effective therapeutic interventions are likely to be 
maximally effective in the earliest stages of disease.  
In the present study, we sought to characterize longitudinal outcomes and 
associated brain atrophy over two years of euthymic older adults with cognitive 
complaints (CC), patients with MCI and AD, and healthy older adults without 
cognitive complaints (HC). We divided our sample by baseline and two-year 
follow-up diagnoses resulting in six groups, including patients with a stable 
diagnosis of AD, patients who converted from MCI to probable AD (MCI-
Converters (MCI-C)), patients with a stable diagnosis of MCI (MCI-Stable (MCI-
S)), participants with a CC diagnosis at baseline who converted to MCI (CC-
Converters (CC-C)), participants with a stable diagnosis of CC (CC-Stable (CC-
S)), and stable healthy older adults without complaints (HC). In this report, we 
evaluated: (1) baseline differences among groups in brain atrophy of selected 
MRI measures of volume and grey matter (GM) density; (2) differences among 
groups annualized rate of atrophy (annualized percent change (APC)) over two 
years in selected MRI volumetric and GM density measures; (3) the relative 
sensitivity measured by effect size (Cohen’s d) of baseline and APC measures to 
differences between converter and stable groups (MCI-C vs. MCI-S, CC-C vs. 
CC-S); and, (4) the relationship between selected MRI measures of APC and 
two-year change in clinical dementia severity and memory performance in the 
entire sample and within all participants with a CC diagnosis at baseline. The 
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goal of these analyses is to characterize MRI measures of neurodegeneration as 
biomarkers for AD in participants with cognitive complaints but no cognitive 
impairment. 
 
Methods 
 
Participants 
 Participants with baseline and a minimum of two-year follow-up data, 
including successfully processed structural MRI scans and clinical and 
neuropsychological test scores, were selected from a cohort of patients with 
probable AD and MCI, older adults with subjective and informant-verified 
cognitive complaints (CC), and older adults without cognitive complaints (HC) 
that has been described previously [77, 344-345, 347-348]. Briefly, participants 
were recruited for a study on neuroimaging and brain aging from Dartmouth 
Hitchcock Medical Center and the surrounding community. Participants were 
initially screened by phone and those meeting criteria underwent a 
comprehensive protocol of structural and functional MRI scans, diffusion tensor 
imaging (DTI), clinical interview and extensive neuropsychological testing, and 
other measures (e.g., blood panel, targeted genetic assessment). Inclusion and 
exclusion criteria, as well as complete details of clinical and psychometric tests 
used to characterize cognitive deficits and complaints, have been previously 
described [77]. All participants included in this report underwent our protocol of 
neuroimaging and clinical and psychometric testing at least annually, and were 
therefore seen a minimum of three times over the two-year follow-up period. 
For the present analysis, 82 participants were divided into six groups by 
baseline and two-year follow-up clinical diagnosis, including patients with stable 
AD over the two-year follow-up period (n=4; AD), patients who converted from 
MCI to probable AD over the two-year follow-up period (n=5, MCI-Converters 
(MCI-C)), patients with a stable MCI diagnosis during the two-year follow-up 
window (n=21, MCI-Stable (MCI-S)), older adults with significant cognitive 
complaints at the baseline visit who converted to MCI during the two-year follow-
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up period (n=4,CC-Converters (CC-C)), older adults with a stable CC diagnosis 
for the two-year follow-up period (n=19, CC-Stable (CC-S)), and healthy older 
adults without any significant cognitive complaints at the baseline visit or at any 
time during the two-year follow-up period (n=29, HC). Any participants who did 
not fall into these groups (e.g., participants who converted from HC to CC, 
participants who reverted from AD to MCI, MCI to CC, or CC to HC) were 
excluded from the present analyses. In addition, any participants with incomplete 
clinical and/or neuroimaging data were excluded. 
 
Structural Magnetic Resonance Imaging (MRI) Scans 
 Structural SPGR MRI scans were collected annually for a minimum of two 
years at Dartmouth-Hitchcock Medical Center using a GE Signa 1.5 Tesla 
Horizon magnet, as previously described [77]. Scans were processed using 
voxel-based morphometry (VBM) in SPM5 [145-146, 253] and Freesurfer version 
4 [142-144, 268] as described below and in previous reports [213, 270, 291]. 
VBM: Baseline MRI scans were converted from DICOM to NIfTI format 
and aligned to a standard T1-weighted template image. All follow-up scans were 
aligned to the T1-aligned baseline image for each participant. All scans were 
then segmented with bias correction into grey matter (GM), white matter (WM) 
and cerebrospinal fluid (CSF) compartments using standard VBM templates in 
SPM5. Finally, all scans were normalized with and without modulation as 1 x 1 x 
1 mm voxels to Montreal Neurologic Institute (MNI) standard space and 
smoothed with a 10mm FWHM Gaussian kernel. Quality control (QC) of VBM 
processing was done at each step of the processing and scans which failed 
segmentation were excluded from all analyses. Unmodulated and modulated 
normalized GM maps were then used to extract GM density (unmodulated) and 
GM volume (modulated) estimates for regions of interest (ROIs) using MarsBaR 
[325]. 
Automated parcellation: All scans were independently processed using 
Freesurfer version 4. More than 100 ROIs, including more than 50 volumetric and 
50 cortical surface thickness measures, were extracted. In addition, total 
91 
 
intracranial volume (ICV), which was used as a covariate in many subsequent 
statistical analyses, was generated using Freesurfer. 
 
Annualized Percent Change (APC) Calculations 
 Atrophy rate in target ROIs was assessed using annualized percent 
change (APC) calculated using the baseline and two-year follow-up scans as 
follows. First, estimates for target ROIs from the baseline and two-year follow-up 
scans generated using Freesurfer and VBM/MarsBaR were extracted. Then, the 
annualized percent change (APC) was calculated for each measure using the 
following formula: 
 
                     (two-year ROI estimate – baseline ROI estimate)  
Annualized percent change (APC) =           baseline ROI estimate    
              (Time (in years) between baseline and two-year visits) 
 
For all participants, if either the baseline or two-year follow-up scan failed QC 
then that individual was excluded from all APC analyses (n=4). 
 
Statistical Analyses 
 Baseline and APC estimates for selected ROIs were compared among 
groups defined by baseline diagnosis and two-year clinical conversion using an 
analysis of covariance (ANCOVA). Age at baseline scan, gender, years of 
education, and baseline total ICV were included as covariates in all analyses. 
Due to the known relationship of depressive symptoms with cognitive complaints, 
the analyses were also evaluated with the Geriatric Depression Scale (GDS) total 
score as a covariate. However, no significant effects of GDS on either baseline or 
APC in target ROIs were observed (data not shown). Therefore, the results 
presented here do not include GDS total as a covariate. For all ROI analyses, 
post-hoc comparisons with a Bonferroni correction for multiple comparisons, as 
implemented in SPSS as an adjusted p-value, were utilized to compare specific 
group differences. 
92 
 
ROIs known to be sensitive to neurodegeneration associated with AD 
were evaluated, including hippocampal volume, mean temporal lobe cortical 
thickness, mean medial temporal lobe cortical thickness, mean lateral temporal 
lobe cortical thickness, hippocampal GM density and GM volume, mean temporal 
lobe GM density and GM volume, mean medial temporal lobe GM density and 
GM volume, and mean lateral temporal lobe GM density and GM volume. 
Baseline and APC estimates of the mean occipital lobe GM density and GM 
volume were evaluated as control regions. Participants were excluded from all 
analyses if the baseline MRI processing did not meet QC standards. Four 
participants (1 MCI-S, 2 CC-S, 1 HC) were included in the baseline analyses but 
excluded from APC analyses due to failed QC of two-year follow-up MRI 
processing. Thus, 82 participants were included in the baseline analyses (4 AD, 
5 MCI-C, 21 MCI-S, 4 CC-C, 19 CC-S, 29 HC) and 78 participants were included 
in the analyses of APC measures (4 AD, 5 MCI-C, 20 MCI-S, 4 CC-C, 16 CC-S, 
29 HC). 
For the cortical thickness analyses, mean lobar regions included the 
following Freesurfer-generated ROIs: mean temporal lobe cortical thickness 
included estimates from the banks of the superior temporal sulcus, entorhinal 
cortex, fusiform gyrus, lingual gyrus, parahippocampal gyrus, and inferior, middle 
and superior temporal gyri, as well as the temporal pole and transverse temporal 
pole; mean medial temporal lobe cortical thickness included estimates from the 
entorhinal cortex, fusiform gyrus, lingual gyrus, parahippocampal gyrus, temporal 
pole, and transverse temporal pole; and mean lateral temporal lobe cortical 
thickness included estimates from the banks of the superior temporal sulcus, and 
the inferior, middle and superior temporal gyri. For the GM density and GM 
volume mean lobar estimates, the following VBM/MarsBaR ROIs were included: 
mean temporal lobe GM density and GM volume included estimates from the 
amygdala, fusiform gyrus, Heschl’s gyrus, hippocampus, lingual gyrus, olfactory 
gyrus, parahippocampal gyrus, and inferior, middle and superior temporal gyri, as 
well as the inferior and superior temporal poles; the mean medial temporal lobe 
GM density and GM volume estimates included the amygdala, fusiform gyrus, 
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Heschl’s gyrus, hippocampus, lingual gyrus, olfactory gyrus, parahippocampal 
gyrus, and the inferior and superior temporal poles; the mean lateral temporal 
lobe GM density and GM volume estimates included the inferior, middle and 
superior temporal gyri; and the mean occipital lobar GM density and GM volume 
measures included estimates from the calcarine gyrus, cuneus, and the inferior, 
middle, and superior occipital gyri. No significant lateralized differences were 
observed so bilateral mean estimates of the selected ROIs were used in all 
statistical analyses.  
An ANCOVA model was also used to assess continuous demographic 
variables, as well as baseline and two-year change in psychometric performance. 
Age at baseline visit, gender, and years of education were included as covariates 
in all statistical models assessing psychometric performance. Post-hoc 
comparisons with a Bonferroni correction for multiple comparisons were also 
evaluated for all variables of interest. A chi-square test was used to evaluate 
differences among groups in dichotomous demographic variables. Clinical and 
psychometric tests evaluated included: the Clinical Dementia Rating (CDR) Scale 
Global score (CDR-GL) and Sum of Boxes score (CDR-SB) [276]; the Mini-
Mental Status Exam (MMSE) total score [274-275]; the Dementia Rating Scale-2 
(DRS) total score [349]; the California Verbal Learning Test-II (CVLT) total score, 
short delay recall score (CVLT-SD) , and long delay recall score (CVLT-LD) [350-
351]; Wechsler Memory Scale-III (WMS-III) Logical Memory (LM) total score and 
delayed recall score [352-353]; and the Geriatric Depression Scale (GDS) total 
score [271]. 
The effect size of all baseline and APC variables for differences between 
converters and stable participants (MCI-C vs. MCI-S and CC-C vs. CC-S) was 
calculated using the following formula: 
 
    d =     (M1 – M2)  
             √[(σ1
2 + σ2
2) / 2] 
 
where, for the target ROI, M1 = mean value for group 1, M2 = mean value for 
group 2, σ1 = standard deviation for group 1, and σ2 = standard deviation for 
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group 2 [327]. In order to accurately compare the resulting effect sizes, only 
participants with values for all analyzed regions were included in this comparison 
(5 MCI-C and 20 MCI-S; 4 CC-C and 16 CC-S).  
The relationships between APC in selected MRI variables and two-year 
change in psychometric performance on selected tests was assessed for the full 
available sample (n=78) and for only participants with a CC diagnosis at baseline 
(n=20) using a bivariate Pearson correlation. APC in hippocampal volume and 
APC in hippocampal GM volume were selected for the correlation analyses since 
these variables showed the greatest effect size for the comparison of CC-C and 
CC-S (Figure 19B). Selected psychometric tests included a measure of clinical 
dementia severity, CDR-SB, and a measure of memory performance, LM total 
score. Prior to the correlation analysis, selected MRI and psychometric variables 
were tested for significant association with confounding variables, including age 
at baseline visit, gender, years of education, and total ICV (MRI variables only). 
No associations were found (data not shown), thus, raw values for APC and two-
year change in psychometric performance were entered into the correlation 
analyses. SPSS (version 19.0) was used for all statistical analyses. All graphs 
were made in SigmaPlot version 10. 
 
Results 
 
Demographics and Psychometric Performance 
 Demographic information and baseline and two-year change in clinical 
dementia severity and selected psychometric test performance are presented in 
Table 5. No significant differences were observed among groups in age, gender, 
years of education or APOE genotype. Expected significant differences among 
groups in clinical dementia severity (Global CDR and CDR-SB), global cognition 
(MMSE total score, DRS total score) and memory performance (CVLT total 
score, CVLT-SD score, CVLT-LD score, LM total score, LM delayed recall score) 
were observed (all p<0.001). The results of post-hoc comparisons between 
groups are displayed in Table 5. Generally, post-hoc comparisons show 
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significantly higher dementia severity and reduced global cognition and memory 
performance in patients with AD and MCI at baseline relative to CC and HC 
participants (p<0.05). By definition, CC participants do not show significant 
impairments in psychometric performance relative to HC at baseline. Significant 
differences among groups in two-year change in clinical dementia severity 
(Global CDR, CDR-SB), global cognition (MMSE total score, DRS total score) 
and memory performance (CVLT total score, CVLT-LD score, LM total score, LM 
delayed recall score) were also observed (p<0.05). Result of post-hoc 
comparisons are shown in Table 5. No significant difference among groups in the 
two-year change in GDS total score was observed. 
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AD 
(n=4) 
MCI-C 
(n=5) 
MCI-S 
(n=21) 
CC-C 
(n=4) 
CC-S 
(n=18) 
HC 
(n=30) 
ANOVA 
p-value 
Significant Post-hoc 
Comparisons (p<0.05) 
BL Age (years) 70.3 (2.9) 71.1 (2.6) 74.6 (1.3) 76.7 (2.9) 72.8 (1.4) 70.8 (1.1) 0.158 n/a 
Gender (male, female) 3, 1 1, 4 12, 9 3, 1 6, 12 11, 19 0.203 n/a 
Education (years) 14.5 (1.5) 16.0 (1.3) 16.5 (0.6) 17.8 (1.5) 17.2 (0.7) 17.1 (0.5) 0.525 n/a 
APOE Genotype 
(% APOE ε4 positive)1 
100.0% 60.0% 47.4% 50.0% 27.8% 43.3% 0.184 n/a 
BL Global CDR2 0.8 (0.09) 0.6 (0.08) 0.5 (0.04) 0.5 (0.09) 0.5 (0.04) 0.2 (0.03) <0.001 AD, MCI-C, MCI-S, CC-C,  CC-S>HC; CC-S>AD 
BL CDR-SB2 3.5 (0.3) 2.1 (0.3) 1.2 (0.1) 1.1 (0.3) 0.8 (0.1) 0.2 (0.1) <0.001 
AD>MCI-C, MCI-S, CC-S>HC;  
AD>CC-C;  
MCI-C>MCI-S, CC-S 
BL MMSE Total Score2 25.0 (0.8) 24.5 (0.7) 27.1 (0.4) 28.8 (0.8) 29.2 (0.4) 28.9 (0.3) <0.001 
HC, CC-S>MCI-S, MCI-C, AD;  
CC-C>MCI-C, AD;  
MCI-S>MCI-C 
BL DRS Total Score2 123.8 (1.7) 133.9 (1.5) 137.5 (0.7) 138.1 (1.7) 141.3 (0.8) 141.0 (0.6) <0.001 HC, CC-S>MCI-S, MCI-C, AD;  CC-C, MCI-S, MCI-C>AD 
BL CVLT Total Score2 22.1 (3.6) 30.7 (3.0) 31.5 (1.5) 44.0 (3.5) 46.7 (1.6) 47.7 (1.3) <0.001 HC, CC-S>MCI-S, MCI-C, AD; CC-C>MCI-S, AD 
BL CVLT-SD2  2.7 (1.1) 3.0 (1.0) 5.3 (0.5) 9.2 (1.1) 10.1 (0.5) 11.3 (0.4) <0.001 HC, CC-S, CC-C> MCI-S, MCI-C, AD 
BL CVLT-LD2 0.4 (1.2) 3.8 (1.0) 5.8 (0.5) 8.9 (1.2) 10.7 (0.5) 12.1 (0.4) <0.001 HC, CC-S>MCI-S, MCI-C, AD;  CC-C>MCI-C, AD; MCI-S>AD 
BL LM Total Score2 26.0 (4.3) 27.8 (3.7) 35.7 (1.9) 45.8 (4.2) 43.6 (2.0) 48.7 (1.5) <0.001 HC>MCI-S, MCI-C, AD;  CC-S, CC-C>MCI-C, AD 
BL LM Delayed Recall2 10.0 (3.6) 10.5 (3.1) 20.6 (1.6) 24.7 (3.5) 26.5 (1.6) 32.3 (1.3) <0.001 HC>MCI-S, MCI-C, AD;  CC-S>MCI-C, AD 
BL GDS Total2 9.3 (2.0) 7.9 (1.7) 5.1 (0.9) 8.7 (2.0) 5.8 (0.9) 1.7 (0.7) <0.001 HC>CC-S, CC-C, MCI-C, AD 
2yr Chg in  
Global CDR2 
0.4 (0.12) 0.1 (0.11) 0.0 (0.05) 0.0 (0.1) 0.0 (0.05) 0.0 (0.04) 0.02 AD>MCI-S, HC 
2yr Chg in CDR-SB2 4.0 (0.4) 1.2 (0.3) 0.3 (0.2) 0.6 (0.4) 0.1 (0.2) -0.1 (0.1) <0.001 AD>CC-S, CC-C, MCI-S;  AD>MCI-C>HC 
2yr Chg in  
MMSE Total Score2 
-5.1 (1.0) -0.7 (0.9) -0.1 (0.2) -1.4 (1.0) -0.9 (0.5) 0.0 (0.4) <0.001 HC, CC-S, MCI-S, MCI-C>AD 
2yr Chg in  
DRS Total Score2 
-7.1 (2.3) -2.3 (2.0) 1.5 (1.0) 0.5 (2.3) -0.4 (1.1) 0.9 (0.8) 0.021 HC, MCI-S>AD 
2yr Chg in  
CVLT Total Score2 
-6.3 (3.5) -5.7 (3.0) 5.8 (1.5) -4.3 (3.4) 2.5 (1.6) 1.8 (1.2) 0.001 MCI-S>MCI-C, AD 
2yr Chg in CVLT-SD2 -2.0 (1.2) -0.04 (1.1) 1.0 (0.5) -1.2 (1.2) 1.3 (0.6) -0.05 (0.4) 0.061 n/a 
2yr Chg in CVLT-LD2 -0.01 (1.3) -2.7 (1.1) 0.4 (0.5) 0.1 (1.2) 1.5 (0.6) -0.86 (0.4) 0.008 HC>CC-S; CC-S>MCI-C 
2yr Chg in  
LM Total Score2 
-14.5 (3.9) -0.8 (3.3) 2.6 (1.7) -10.6 (3.8) 1.3 (1.8) 1.2 (1.4) <0.001 CC-C>MCI-S;  
HC, CC-S, MCI-S>AD 
2yr Chg in  
LM Delayed Recall2 
-6.9 (3.0) -2.9 (2.6) 2.8 (1.3) -2.9 (2.9) 3.5 (1.4) 2.1 (1.1) 0.01 CC-S>AD 
2yr Chg in GDS Total2 -0.3 (1.3) -0.3 (1.1) -1.0 (0.6) -1.9 (1.3) -1.6 (0.6) -0.61 (0.5) 0.696 n/a 
1 2 participants missing APOE genotype data 
2 Baseline age, gender, and years of education included as covariates. 
BL = Baseline; 2yr Chg = Two-year Change; APOE = apolipoprotein E; CDR = Clinical Dementia Rating Scale; CDR-SB = 
CDR Sum of Boxes score; MMSE = Mini-Mental Status Exam; DRS = Dementia Rating Scale; BNT = Boston Naming Test; 
CVLT = California Verbal Learning Test II; CVLT-SD = CVLT Short Delay Recall Score; CVLT-LD = CVLT Long Delay Recall 
Score; LM = Wechsler Logical Memory Scale; GDS = Geriatric Depression Scale 
 
Table 5. Demographic Information and Baseline and Two-Year Change in 
Psychometric Performance (Adjusted Mean (SE)) 
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Baseline Differences in Temporal Lobe ROIs 
 Significant differences among groups were observed in baseline 
hippocampal volume (Figure 15A, p<0.001), mean temporal lobe cortical 
thickness (Figure 15B, p=0.01), hippocampal GM density and GM volume 
(Figures 15C and 15E, both p<0.0001), and mean temporal lobe GM density and 
GM volume (Figures 15D and 15F, both p<0.001). Post-hoc comparisons show 
greater hippocampal volume, hippocampal GM density and GM volume, as well 
as mean temporal lobe cortical thickness and GM density in HC, CC-S, and MCI-
S relative to AD patients (all p<0.05). In addition, MCI-C participants show 
smaller hippocampal volume and GM volume than HC and CC-S participants, as 
well as smaller hippocampal GM density relative to HC only (all p<0.05). Finally, 
differences in mean temporal lobe GM volume were observed, with CC-S 
participants showing greater GM volumes than MCI-C and AD patients and CC-C 
participants showing greater GM volumes than AD patients only (all p<0.05). 
Although the comparisons did not reach statistical significance, MCI-C 
participants had reduced hippocampal volume, GM density and GM volume 
relative to MCI-S participants at baseline. In addition, CC-C participants showed 
slight but notable reductions in hippocampal volume and GM volume at baseline 
relative to CC-S participants, although these differences did not reach statistical 
significance. 
 
Annualized Percent Change in Target ROIs 
 Significant differences among groups were observed in the APC over two 
years in hippocampal total volume (Figure 16A, p=0.002), GM density (Figure 
16B, p<0.0001), and GM volume (Figure 16C, p<0.0001). Post-hoc comparisons 
showed a faster atrophy rate in hippocampal GM density and GM volume in AD 
patients relative to all other groups (all p<0.05). In addition, MCI-C showed a 
greater atrophy rate in hippocampal total volume than CC-S participants, as well 
as a faster annualized decline in hippocampal GM density and GM volume than 
HC and CC-S participants (all p<0.05). MCI-C participants showed a slightly 
faster hippocampal atrophy rate than MCI-S participants, although the results did 
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not reach statistical significance. CC-C participants showed a trend for a greater 
atrophy rate in total hippocampal volume than CC-S participants (Figure 16A, 
p=0.084) and a notable but non-significant increased decline relative to CC-S in 
hippocampal GM density and GM volume.  
Significant differences across groups were also observed for the APC in 
mean temporal lobe GM density (Figure 17A, p=0.005) and GM volume (Figure 
17B, p<0.001), mean medial temporal lobe GM density (Figure 17C, p=0.002) 
and GM volume (Figure 17D, p<0.001), and mean lateral temporal lobe GM 
density (Figure 17E, p=0.04) and GM volume (Figure 17F, p<0.001). Post-hoc 
comparisons indicated that patients with AD showed faster atrophy rates than 
HC, CC-S, and MCI-S in mean temporal lobe GM volume and mean lateral 
temporal lobe GM volume, as well as faster rates of atrophy in mean temporal 
lobe GM density and mean medial temporal lobe GM density and GM volume 
relative to HC and CC-S (all p<0.05). Additionally, MCI-C showed a more 
negative APC in mean lateral temporal lobe GM volume relative to CC-S and HC 
(both p<0.05). MCI-C also showed a moderately greater atrophy rate in all 
evaluated regions relative to MCI-S, although these differences did not reach 
statistical significance. CC-C showed a slightly faster atrophy rate than CC-S 
participants in all evaluated regions except for mean lateral temporal lobe GM 
density, although again these comparisons did not reach statistical significance. 
In comparison to the temporal lobe regions, APC in mean occipital lobe 
GM density (Figure 18A) and GM volume (Figure 18B) was not significantly 
different between groups (p>0.05). However, AD and MCI-C participants showed 
slightly but not significantly elevated mean occipital lobe GM volume atrophy 
rates relative to the other groups. 
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Figure 15. Baseline Differences among Groups in Temporal Lobe Atrophy 
 Significant differences among groups were observed for baseline (A) 
hippocampal volume (p<0.001), (B) mean temporal lobe cortical thickness (p=0.01), (C) 
hippocampal GM density (p<0.0001), (D) mean temporal lobe GM density (p<0.001), (E) 
hippocampal GM volume (p<0.0001), and (F) mean temporal lobe GM volume 
(p<0.001). For significant post-hoc comparisons, see the results section. (Group mean 
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values (+/- SE) adjusted for baseline age, gender, education, and baseline total ICV are 
displayed) 
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Figure 16. APC in Selected Medial Temporal Lobe ROIs 
Significant differences among groups in annualized percent change (APC) over 
two years in (A) hippocampal volume (p=0.002), (B) hippocampal GM density 
(p<0.0001), and (C) hippocampal GM volume (p<0.0001). For a complete listing of 
significant post-hoc comparisons, see the results section. (Note: n=78, 4 participants (1 
MCI-S, 2 CC-S, 1 HC) from baseline analysis (Table 5, Figure 15) were excluded 
because of failed two-year follow-up MRI processing; group mean APC values (+/- SE) 
adjusted for baseline age, gender, education, and baseline total ICV are displayed) 
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Figure 17. APC in Temporal Lobe GM Density and GM Volume 
Significant differences among groups were observed in annualized percent 
change (APC) in mean temporal lobe (A) GM density (p=0.005) and (B) GM volume 
(p<0.001), mean medial temporal (C) GM density (p=0.002) and (D) GM volume 
(p<0.001), and mean lateral temporal (E) GM density (p=0.04) and (F) GM volume 
(p<0.001). For a complete listing of significant post-hoc comparisons, see the results 
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section. (Note: n=78, 4 participants (1 MCI-S, 2 CC-S, 1 HC) from baseline analysis 
(Table 5, Figure 15) were excluded because of failed two-year follow-up MRI processing; 
group mean APC values (+/- SE) adjusted for baseline age, gender, education, and 
baseline total ICV are displayed) 
 
 
 
 
Figure 18. APC in Mean Occipital Lobe GM Density and GM Volume 
 No significant differences among groups were observed in mean occipital lobe 
(A) GM density and (B) GM volume. (Note: n=78, 4 participants (1 MCI-S, 2 CC-S, 1 HC) 
from baseline analysis (Table 5, Figure 15) excluded because of failed two-year follow-
up MRI processing; group mean APC values (+/- SE) adjusted for baseline age, gender, 
education, and baseline total ICV are displayed) 
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Effect Sizes of MRI ROIs for the Comparison between Converters and Stable 
Participants 
 Effect sizes for target biomarkers were calculated for the comparisons of 
MCI-C versus MCI-S and CC-C versus CC-S. The top biomarkers ranked by 
effect size (Cohen’s d) are displayed in Figure 19. APC in mean medial temporal 
lobe, mean temporal lobe and mean lateral temporal lobe cortical thickness 
showed the highest effect size for the comparison of MCI-C vs. MCI-S, with 
Cohen’s d values of 1.42, 1.37, and 1.19, respectively (Figure 19A). Longitudinal 
measures of brain atrophy rate were more sensitive than baseline measures to 
differences between MCI-C and MCI-S participants, as 12 of the top 15 
biomarkers with the highest effect sizes were APC measures. For the 
comparison of CC-C vs. CC-S, APC in hippocampal volume, hippocampal GM 
density, and mean temporal lobe GM volume had the greatest effect size, with 
Cohen’s d values of 1.56, 0.81, and 0.79, respectively (Figure 19B). Similar to 
the comparison between MCI-C and MCI-S, APC measures were slightly more 
sensitive than baseline measures to the differences between CC-C and CC-S, 
representing 8 of the top 15 measures with the highest effect sizes.  
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Figure 19. Effect Sizes of Selected Imaging Biomarkers for the Comparison 
of Converters and Stable Participants 
 Significant effect sizes (Cohen’s d) for selected baseline and APC in temporal 
lobe ROIs for the comparison of (A) MCI-C vs. MCI-S and (B) CC-C vs. CC-S were 
observed. APC measures are shown in solid colors and baseline measures are shown in 
light colors with diagonal lines. (n=25 (5 MCI-C, 20 MCI-S) for (A) MCI-C vs. MCI-S and 
n=20 (4 CC-C, 16 CC-S) for (B) CC-C vs. CC-S for baseline and APC measures due to 
inclusion of only the participants with successfully processed baseline and two-year 
follow-up MRI scans; TL=temporal lobe, LTL=lateral temporal lobe, MTL=medial 
temporal lobe, GM=grey matter; effect sizes are calculated using bilateral mean values 
of target ROIs adjusted for baseline age, gender, education, and baseline total ICV) 
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Relationship between Brain Atrophy Rates and Two-Year Change in Dementia 
Severity and Memory Performance 
 The relationships between annualized hippocampal atrophy rate (APC in 
hippocampal volume and hippocampal GM volume) and two-year change in 
dementia severity and memory performance were evaluated in both the full 
cohort of available participants (n=78) and in participants with a CC diagnosis at 
baseline only (n=20; CC-C and CC-S only). A significant association between 
APC in hippocampal GM volume and two-year change in the CDR-SB was 
observed in the full cohort (Figure 20A; r=-0.573, p<0.001), but not in the CC at 
baseline only sub-sample (Figure 20B; r=-0.170, p>0.05). A significant 
association was also observed between APC in hippocampal volume and two-
year change in LM total score in both the full sample (Figure 20C; r=0.276, 
p=0.014) and the CC at baseline only sub-sample (Figure 20D; r=0.661, 
p=0.004).  
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Figure 20. Relationship between Hippocampal Atrophy Rate and Two-Year 
Change in Psychometric Performance 
 A significant association between (A) APC in hippocampal GM volume and two-
year change in clinical dementia severity (CDR-SB) was observed in the full cohort (r=-
0.573, p<0.001), but not in (B) the sub-group of participants with a CC diagnosis at 
baseline (CC-C and CC-S; r=-0.171, p>0.05). However, significant associations were 
observed between APC in hippocampal volume and two-year change in memory 
performance (LM total score) in both the (C) full cohort (r=0.276, p=0.014) and (D) the 
sub-group of participants with a CC diagnosis at baseline (r=0.611, p=0.004). (n=78 for 
(A) and (C) and n=20 for (B) and (D) due to inclusion of participants with successfully 
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processed baseline and two-year follow-up MRI scans only; CDR-SB=CDR Sum of 
Boxes, LM=WMS-III Logical Memory; GM=grey matter)  
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Discussion 
 The present report evaluated MRI biomarkers of AD-related 
neurodegeneration in a longitudinal study of patients with AD and MCI, older 
adults with cognitive complaints but no significant cognitive impairment, and 
healthy older adults with no cognitive complaints. We specifically focused on the 
sensitivity of MRI measures to detecting differences between patients who 
clinically declined over the two-year study follow-up period and those who were 
clinically stable. MRI biomarkers of temporal lobe neurodegeneration showed 
significant differences among groups both at baseline and in two-year 
longitudinal annualized atrophy rate. Patients with MCI and AD generally had 
greater atrophy at baseline and a faster rate of atrophy than CC and HC 
participants. In addition, patients who demonstrated clinical progression (MCI to 
AD converters and CC to MCI converters) over the two-year follow-up period 
showed more baseline atrophy and faster atrophy rates than stable MCI and CC 
participants. Measures of atrophy rate were more sensitive, as reflected in higher 
effect sizes, than baseline measures to the differences between MCI-C and MCI-
S and between CC-C and CC-S. Finally, the relationship between hippocampal 
atrophy rate and two-year change in clinical dementia severity was significant 
across the full sample, but not in the CC at baseline only sub-group. However, 
the relationship between hippocampal atrophy rate and two-year change in 
memory performance was significant across the whole cohort and within the CC 
at baseline only sub-sample.  
The significant baseline atrophy and faster atrophy rate observed in 
patients who convert from MCI to probable AD is similar to findings that have 
been reported in previous studies [92, 166-167, 207, 213, 219-220, 291]. In 
addition, the rate of hippocampal atrophy in patients with AD, MCI-C, MCI-S and 
HC in our sample is similar to previous estimates of annualized decline [201, 
219, 291]. However, this is the first report to date to evaluate longitudinal change 
in patients who convert from CC to MCI relative to stable CC participants. The 
results suggest that patients with CC show AD-like neurodegenerative patterns at 
baseline up to two years before clinical symptoms, similar to previous reports 
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[76-77, 342-345]. Furthermore, a subset of CC participants will progress to MCI 
each year, with a progression rate in our sample of 5-10% annually. A previous 
report demonstrated a progression rate of CC participants to MCI and AD of 
approximately 7-8% annually [78], similar to the rate observed in the present 
report. In addition, previous reports have indicated that CC participants are more 
likely than healthy older adults with no cognitive complaints to show cognitive 
decline, including progression to MCI and AD [79, 337-340, 343, 354], a finding 
we also observed. The presence of notable differences in MRI measures of 
neurodegeneration between patients who convert from CC to MCI up to two 
years before clinical progression and those who have a stable CC diagnosis 
suggests the AD-like neurodegeneration in these participants may precede the 
clinical symptoms. In addition, the conversion of patients with CC to a diagnosis 
of MCI is coupled with a faster rate of brain atrophy in the temporal lobe, 
including a hippocampal volume loss of more than 3.5% annually.  
 Similar to previous reports, dynamic measures of atrophy rate appear to 
be more sensitive than cross-sectional baseline estimates of atrophy to the 
differences between patients who are clinically progressing and those who are 
stable [291]. These results suggest that patients who are declining clinically show 
associated brain degeneration in regions known to degenerate in AD even in 
early stages of disease (i.e., CC). Furthermore, these results support the utility of 
MRI biomarkers of neurodegeneration in studies to monitor disease progression 
and potentially as a marker for treatment effects.  
 In the present report, an association between hippocampal atrophy rate 
and two-year change in dementia severity was only detected in the full cohort of 
participants and not in the sub-set of participants with CC at baseline. This 
association appears to be primarily driven by the differences between AD 
patients and all other groups (Figure 20A). Both the full sample and the CC at 
baseline sub-sample showed a significant association between hippocampal 
atrophy rate and two-year change in memory performance. However, patients 
with a CC diagnosis at baseline show a stronger association between 
hippocampal atrophy rate and two-year change in memory performance than 
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seen in the full cohort (Figure 20C and 20D). These results suggest that 
hippocampal atrophy rate is most strongly linked to changes in memory 
performance in the early stages of AD. In later stages of disease, hippocampal 
atrophy rate is more strongly associated with the progression of clinical 
symptoms, including declines in daily functioning and the onset of dementia. 
These results support the AD biomarker models described in previous reports 
[14, 17]. 
 A significant limitation of this study is the small sample size, particularly for 
the AD, MCI-C, and CC-C groups. Future studies in larger cohorts are needed to 
confirm the present findings. In addition, all AD patients, four MCI-C, and 13 MCI 
patients were using AD-indicated medication, such as acetylcholinesterase 
inhibitors and memantine. The presence of medications in a sub-sample of our 
cohort may have affected the results. We also did not evaluate the impact of 
APOE genotype on MRI measures of brain atrophy and atrophy rate in the 
present report because of the small sample size. However, APOE ε4 status is 
likely to be an important variable contributing to the extent of baseline atrophy 
and speed of the longitudinal atrophy rate in all groups, as has been previously 
observed [291, 299, 305]. Interestingly, the percentage of APOE ε4 positive 
healthy older adults was notably high (>40% APOE ε4 positive) relative to what 
would be expected in a normal population of older adults (~25% APOE ε4 
positive). The elevated percentage of APOE ε4 positive HC participants in this 
study is potentially due to the fact that healthy older adults with a family history of 
AD are more likely to participate in AD research in the absence of concerns or 
symptoms. In fact, 10 of the 14 APOE ε4 positive HC participants in this report 
were positive for a family history of dementia and/or AD. Future studies in 
expanded samples are needed to evaluate the role of APOE ε4 genotype in older 
adults with cognitive complaints. Finally, the inclusion of other neuroimaging 
biomarkers (e.g., functional MRI, DTI measures of WM degeneration, positron 
emission tomography (PET)) may have additional benefits for monitoring clinical 
decline in this cohort, especially in CC-C participants. Future studies evaluating 
multiple neuroimaging biomarkers in the prediction and monitoring of patients 
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with AD and MCI and especially CC patients will be important for determining the 
validity of these methods for early detection of AD-related neuropathology.  
 In conclusion, patients who show clinical progression towards AD have 
greater baseline atrophy, as well as faster rates of atrophy over two years. In 
fact, patients who convert from either MCI to probable AD or from CC to MCI 
show greater temporal lobe atrophy and a faster decline in temporal lobe 
measures up to two years before conversion than stable MCI and stable CC 
participants, respectively. Measures of annualized atrophy rate in temporal lobe 
structures appear to be the most sensitive to differences between converting 
patients and stable patients (MCI-C vs. MCI-S and CC-C vs. CC-S). A greater 
hippocampal atrophy rate is associated with an increase in clinical dementia 
severity over two years, as well as a decrease in memory performance. The 
latter association is particularly strong in the earliest clinical stages of disease 
(i.e., CC). In summary, older adults with CC appear to have AD-like 
neurodegeneration up to two years before the emergence of significant cognitive 
impairment. These results support the premise that the presence of CC in older 
adults may represent a pre-MCI stage of AD. MRI biomarkers may be sensitive 
measures to detect and monitor neurodegeneration even in this early stage of 
disease. Future studies to further evaluate the clinical course of individuals with 
CC, as well as studies with other AD biomarkers will help elucidate the role of CC 
in the AD disease continuum.  
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Chapter 3: Visual Contrast Sensitivity as a Novel Biomarker for AD 
The final chapter explores a novel biomarker for AD, visual contrast 
sensitivity. Contrast sensitivity is the ability to distinguish between dark and light 
in a static image, and has been shown to be impaired in patients with AD, likely 
due to degeneration of retinal ganglion cells and/or central neural visual 
pathways. In this chapter, cross-sectional data from participants in the cohort 
utilized in Chapter 2b from Dartmouth Medical School, as well as additional 
participants from the Indiana University School of Medicine, are assessed. 
Participants included patients with a diagnosis of probable AD, patients with a 
diagnosis of MCI, older adults with cognitive complaints (CC) but no significant 
cognitive impairment, and healthy older adults without cognitive complaints (HC). 
Contrast sensitivity was measured using a standardized tool called frequency 
doubling technology (FDT-2; Welch Allyn, Inc.). Measure of brain atrophy from 
MRI scans, as well as clinical and psychometric performance data, were also 
evaluated. MRI scans were analyzed using VBM and automated parcellation 
(Freesurfer version 4), as discussed in Chapters 1 and 2. In this study, we first 
assessed differences in contrast sensitivity performance among groups (AD, 
MCI, CC, HC). Next, we evaluated the distribution of contrast sensitivity deficits 
across the visual field. We also estimated the ability of contrast sensitivity 
measures to accurately classify MCI vs. HC participants. In order to further 
explore contrast sensitivity as an AD biomarker, we assessed the relationship 
between contrast sensitivity performance and known markers of AD. We 
evaluated the relationship between contrast sensitivity measures and 
performance on a test of general cognition (MMSE total score) and a memory 
test (CVLT total score and short delay recall score). We also analyzed the 
relationship between contrast sensitivity measures and grey matter (GM) density 
on a voxel-wise basis across the whole brain. Finally, we assessed the 
relationship between contrast sensitivity performance and selected regional brain 
volumetric and cortical thickness measures.  
The results of this study indicated that patients with MCI and AD have 
significant contrast sensitivity deficits. In addition, patients with CC show 
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intermediate contrast sensitivity performance between patients with MCI and HC. 
The contrast sensitivity impairment in patients with MCI and AD appears to be 
relatively evenly distributed across the visual field (VF) but is most apparent in 
the upper right VF quadrant. Measures of contrast sensitivity also show a 75-
80% overall accuracy in classifying MCI vs. HC participants. Significant 
associations between measures of contrast sensitivity and both global cognition 
and memory performance were observed across the full cohort. Furthermore, 
contrast sensitivity shows a significant association with MRI biomarkers of 
neurodegeneration. Specifically, impaired contrast sensitivity is associated with 
reduced GM density in medial temporal lobe, as well as reduced temporal lobe 
cortical thickness. Overall, the results of this study suggest that visual contrast 
sensitivity may be a useful biomarker for AD, even in early stages such as MCI 
and CC.  
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Introduction 
Alzheimer’s disease (AD) is the most common form of dementia, affecting 
more than five million Americans over the age of 65 years [331]. Characterized 
by memory deficits, cognitive impairment, and dementia, AD is a progressive 
neurodegenerative disease that evolves over many years, possibly over decades 
[331, 355]. In addition to cognitive deficits, patients with AD also show alterations 
in sensory perception, including visual processing [356-358], auditory processing 
[359-360], and olfaction [361-362]. AD patients show deficits in some types of 
visual processing, while others are relatively spared. Specifically, patients with 
AD show deficits in visual contrast sensitivity, color discrimination (lower spectral 
wavelengths), and motion discrimination, as well as other visual field (VF) deficits 
[356, 363-367]. Patients with AD also show degeneration in the visual pathway 
both in the brain and in the retina, including central degeneration of the 
magnocellular pathway in the lateral geniculate nucleus (LGN) and the visual 
cortex [368-372], and loss of retinal ganglion cells (RGC) within the retinal nerve 
fiber layer, respectively [373-380]. 
Frequency doubling technology (FDT) is a automated tool that can detect 
contrast sensitivity and VF defects [381-382] and is often used in glaucoma 
testing [383-384]. This technique utilizes an optical illusion called “frequency 
doubling,” which occurs when an achromatic, low spatial frequency sinusoidal 
grating undergoes counterphased flickering at high temporal frequency, resulting 
in an apparent doubling of the spatial frequency of the grating [381-382, 385-
386]. Processing of the FDT signal is thought to specifically involve activation in 
the magnocellular visual pathway and visual association areas [386-387].  
In an effort to understand the development of AD and assist with early 
identification of at-risk individuals, prodromal stages of AD have been defined 
and extensively studied. Mild cognitive impairment (MCI), a disorder 
characterized by significant deficits in one or more cognitive domains (typically 
memory) in the absence of dementia, is the most commonly studied disorder 
considered to be an early stage of AD [64]. With yearly conversion of 10-15% of 
MCI patients to probable AD, MCI also represents the most widely accepted pre-
118 
 
AD stage [67]. In order to identify patients who may progress to AD even before 
significant cognitive impairments are evident, recent studies have attempted to 
define earlier stages of AD than MCI using genetic background (i.e., 
apolipoprotein E ε4 status) [74, 388], family history of AD [333, 336], the 
presence of extensive Aβ deposition [14], and/or the presence of cognitive 
complaints [73, 77]. For example, Saykin et al. (2006) demonstrated that older 
adults with cognitive complaints have significant atrophy in AD-related regions 
(i.e., hippocampus), supporting this classification as a “pre-MCI” stage [77]. 
The development and evaluation of sensitive and specific biomarkers for 
the detection and monitoring of AD has become an important goal for many 
scientists. Neuroimaging and cerebrospinal fluid (CSF) markers are the most 
commonly used in AD research [17, 82, 86, 88-89, 93]. Structural magnetic 
resonance imaging (MRI) is an AD biomarker that measures brain structure and 
tissue morphology [87, 95]. MRI measures have been shown to sensitively 
measure neurodegeneration associated with AD even in early stages of disease 
(i.e., MCI and pre-MCI) [98, 139, 213, 310, 313], predictive of future disease 
progression [92, 166, 213], and useful for monitoring longitudinal decline [197, 
201, 291, 389]. As such, structural MRI measures are commonly used in AD 
research as biomarkers of disease and associated neurodegeneration, as well as 
in clinical trials for sample enrichment and/or evaluation of treatment efficacy 
[262, 300]. 
Alterations in contrast sensitivity have not previously been evaluated in 
patients with MCI or “pre-MCI” symptoms (e.g., patients with cognitive 
complaints). Additionally, the relationship of contrast sensitivity measures to 
other markers of AD pathology, including cognitive deficits and 
neurodegeneration measured using MRI, has not been established. Therefore, 
the goals of the present study were: (1) to assess whether AD participants 
demonstrate the expected deficits in contrast sensitivity using the FDT-2 24-2 VF 
contrast sensitivity test; (2) to determine the extent to which patients with MCI 
and older adults with cognitive complaints (CC) show contrast sensitivity deficits 
relative to healthy older controls (HC); (3) to evaluate how contrast sensitivity 
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deficits are distributed across the VF; (4) to evaluate the accuracy of contrast 
sensitivity measures to classify MCI versus HC; (5) to assess the association 
between contrast sensitivity and cognition; and, (6) to evaluate the relationship 
between contrast sensitivity measures and a known biomarker of AD, MRI 
measures of neurodegeneration. 
 
Methods 
 
Participants 
107 participants from an ongoing study of aging and cognition at two 
academic medical centers, Dartmouth-Hitchcock Medical Center (DHMC) and 
the Indiana University School of Medicine (IUSM), received a comprehensive 
ophthalmologic examination, including the FDT-2 24-2 VF contrast sensitivity 
test, as well as an extensive protocol of structural and functional neuroimaging 
scans, clinical evaluation, and neuropsychological assessment. Of the 107 
participants who underwent the ophthalmological examination and FDT-2 testing, 
23 participants were excluded, including 10 participants with evidence of 
glaucoma, 10 participants with comorbid visual problems and health disorders 
which would significantly affect visual contrast sensitivity (e.g., significant 
cataracts, poor visual acuity, amblyopia, nystagmus, Graves’ disease, significant 
epiretinal membrane), and three healthy controls who were performance outliers 
on one or more of the FDT-2 summary variables (mean deviation and/or pattern 
standard deviation), scoring significantly below the expected performance for 
their age as determined by an independent sample of healthy participants [390] 
(<0.5% probability that normal participants would show age-adjusted 
performance at that level). Consequently, the sample used for analyses reported 
here includes 84 participants (28 male, 56 female): nine diagnosed with probable 
Alzheimer’s disease (AD; 2 male, 7 female); 27 diagnosed with mild cognitive 
impairment (MCI; 13 male, 14 female); 19 euthymic individuals with significant 
cognitive complaints (CC) but normal cognitive performance on psychometric 
tests (4 male, 15 female); and 29 age-matched healthy controls (HC; 9 male, 20 
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female). All participants provided written informed consent in accordance with the 
Declaration of Helsinki via protocols approved by the appropriate Institutional 
Review Board.  
 
FDT-2 Contrast Sensitivity Threshold Visual Field Test (24-2) 
All participants were tested with the standard FDT-2 24-2 VF contrast 
sensitivity threshold exam protocol which evaluates 55 VF regions in the right 
eye, followed by 55 regions in the left eye [382]. This test provides a single 
measure of contrast sensitivity threshold (in decibels (dB)) at each of the 110 VF 
regions, using a maximum likelihood threshold strategy known as ZEST (Zippy 
Estimate of Sequential Testing) [391-392]. The 24-2 exam features 24-degree 
coverage with a stimulus size of five degrees, a spatial frequency of 0.5 cycles 
per degree, and a temporal frequency of 18Hz [382]. In addition to the threshold 
values for each VF region, two summary measures of general contrast sensitivity 
across the entire VF are reported for each eye, including mean deviation and 
pattern standard deviation. Mean deviation is a measure of the overall contrast 
sensitivity in each eye, while pattern standard deviation indicates how each of the 
55 VF test locations deviates from the expected value from an age-adjusted 
normative database, after adjustment for any general reduction or enhancement 
of contrast sensitivity. In addition to the threshold tests, reliability tests were also 
completed, including assessment of fixation errors, false positive errors, and 
false negative errors. Fixation errors are tested by a stimulus of 50% contrast in 
the location of the blind spot (Heijl-Krakau method), which should not be detected 
if proper fixation is maintained. False positive errors are tested by presenting 
stimuli at 0% contrast, with any responses to these stimuli considered to be false 
positive errors. False negative errors are tested by presenting stimuli at 100% 
contrast, such that no response would be a false negative error [381-382]. In the 
24-2 test, 10 fixation error trials, 10 false positive trials, and six false negative 
trials are included.  
 
  
121 
 
Neuropsychological and Clinical Assessments 
All participants received a detailed clinical exam, as well as a number of 
clinical, psychometric, and neuropsychiatric assessments [77]. Measures 
examined in this study included: the Mini-Mental Status Exam (MMSE) [274-275] 
and Mattis Dementia Rating Scale-2 (DRS) [349] to assess general cognition; the 
California Verbal Learning Test-II (CVLT) [350-351] to evaluate memory 
performance; and the Wisconsin Card Sorting Task (WCST) [393] to determine 
executive functioning. Cognitive complaints were evaluated using ratings from 
both from the participant and an informant with a variety of assessments 
described previously [77]. Clinical diagnoses for all participants were done using 
group consensus of clinicians and clinically trained research scientists, and the 
Clinical Dementia Rating Scale (CDR) [276] was used to quantify the severity of 
clinical symptoms and complaints. 
 
Structural Magnetic Resonance Imaging (MRI) 
1.5 Tesla and 3.0 Tesla MP-RAGE structural MRI scans for all available 
participants were obtained from both sites, as part of a comprehensive 
neuroimaging protocol, which includes both structural and functional MRI scans. 
The scans from the DHMC site came from two scanners including a 1.5T GE 
scanner and a 3.0T GE scanner, due to an upgrade. All structural MRI scans 
from IUSM were done on a 3.0T Siemens MRI scanner. Structural MRI scans 
from all participants were processed using two widely used analysis techniques, 
including voxel-based morphometry (VBM) and automated parcellation 
(Freesurfer version 4), using methods described previously [213] and briefly 
below. Five participants (1 MCI, 3 CC, 1 HC) were excluded from all MRI 
analyses (VBM and automated parcellation) due to a missing MRI scan or failed 
QC. 
VBM: All MP-RAGE scans were converted from DICOM to NIfTI format, 
aligned to a standard T1-weighted template image, and segmented with bias 
correction into grey matter (GM), white matter (WM), and cerebrospinal fluid 
(CSF) compartments using standard templates. The resulting GM images were 
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then normalized to MNI space using parameters from the segmentation step. 
SPM5 (http://www.fil.ion.ucl.ac.uk/spm/) was used for all VBM processing. 
Quality control (QC) was performed on all scans at each processing step by a 
trained research scientist and scans with poor quality segmentation or other 
failures were excluded before further analysis.  
Automated Parcellation: Freesurfer version 4 was utilized to automatically 
generate volumetric and cortical thickness estimates for more than 100 regions 
of interest (ROIs) for each participant with an available MRI scan. Due to the 
known sensitivity of these measures to AD-related neurodegenerative changes, 
volumetric values from the medial temporal lobe, as well as cortical thickness 
values from the temporal, parietal, occipital, and frontal lobes were extracted for 
use in the present analysis.  
 
VBM Statistical Analyses 
 A multiple linear regression model was used to evaluate the relationship 
between selected measures of contrast sensitivity and whole brain GM density 
on a voxel-wise level. Measures of contrast sensitivity evaluated included mean 
deviation, pattern standard deviation, and mean contrast threshold in the upper 
right VF quadrant. An explicit GM mask was applied to limit the statistical 
analysis to GM regions. In addition, a threshold of p<0.005 (uncorrected) and a 
minimum cluster size (k) of 100 voxels was used for displaying the relationships. 
Gender, education, MRI scanner type (1.5 Tesla GE, 3.0 Tesla GE, 3.0 Tesla 
Siemens), and mean intracranial volume (ICV) were used as covariates in all 
analyses. Age at FDT-2 visit was also included as a covariate in only the 
analyses using the mean contrast threshold of the upper right VF quadrant.  
 
Other Statistical Analyses 
All continuous variables, including demographic information, psychometric 
performance, visual acuity, intraocular pressure (IOP), and FDT-2 visual contrast 
sensitivity performance, exam duration, and exam errors were evaluated for the 
effect of diagnostic group (AD, MCI, CC, HC) using one-way analysis of variance 
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(ANOVA) or covariance (ANCOVA). FDT-2 performance values for the left and 
right eye as well as bilateral mean values were evaluated independently. Post-
hoc testing with Bonferroni correction for multiple comparisons was used to 
assess between-group differences. A chi-square test was used to evaluate the 
effect of diagnostic group on categorical variables (e.g., gender, cataract history). 
PASW version 18.0.0 (SPSS Inc., Chicago, IL) was used for all statistical 
analyses. All graphs were created using SigmaPlot (version 10). 
Statistical analyses assessing psychometric performance and FDT-2 
exam duration, exam errors, and all regional VF contrast sensitivity thresholds 
included age at visit, gender, and years of education as covariates. Since FDT-2 
mean deviation and pattern standard deviation are reported as age-adjusted 
values, the analyses for these variables included only gender and years of 
education as covariates. Previous studies have reported an association between 
the presence of cataracts and/or visual acuity with contrast sensitivity 
performance [394-396]; however, other studies have suggested these factors 
may not significantly influence FDT performance [381, 397-398]. We investigated 
the role of a history of cataracts or cataract surgery and visual acuity (raw and/or 
corrected) as covariates and found no significant effects (see results). Therefore, 
the final FDT analyses reported here did not include either cataract history or 
visual acuity as covariates. 
Logistic regression models were used to calculate sensitivity, specificity, 
and overall accuracy of MCI vs. HC classification using visual contrast sensitivity 
measures, which were pre-adjusted for appropriate demographic variables and 
entered individually as independent predictors. Specifically, FDT-2 summary 
measures (mean deviation, pattern standard deviation) were pre-adjusted for 
gender and years of education. Visual contrast sensitivity thresholds (single VF 
regions (1-55) and four VF quadrants for each eye), test duration, and memory 
performance were pre-adjusted for age at visit, gender, and years of education. 
Receiver operating characteristic (ROC) curves were then created for the best 
independent classifiers from the logistic regression model. Finally, the ability of 
FDT-2 contrast sensitivity performance to improve diagnostic classification 
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provided by standard psychometric performance was assessed by entering 
memory performance (CVLT total score, pre-adjusted for age at visit, gender, 
and years of education) into a logistic regression model as an independent 
classifier of MCI vs. HC and in combination with the best FDT-2 visual contrast 
sensitivity classifier. We chose to evaluate only the classification of MCI vs. HC 
because these groups had relatively balanced number of participants, while the 
other clinical groups were smaller in size. 
In addition to comparing FDT-2 contrast sensitivity results among 
diagnostic groups, we evaluated the relationship between contrast sensitivity 
deficits and impairments in global cognition and memory. The relationships 
between FDT-2 performance (mean deviation in contrast sensitivity; mean 
contrast sensitivity threshold in the bilateral upper right VF) and clinical 
performance variables (MMSE total score (general cognition); CVLT total score 
and short delay recall score (memory performance)) were assessed using a 
bivariate Pearson correlation. Mean deviation in contrast sensitivity was adjusted 
for gender and years of education prior to the correlation analysis. Clinical 
performance scores and mean contrast threshold in the bilateral upper right VF 
were adjusted for age at visit, gender and years of education prior to the 
correlation analysis.  
Finally, we assessed the relationship between FDT-2 measures of 
contrast sensitivity with selected MRI biomarkers of neurodegeneration. 
Specifically, the relationships between contrast sensitivity measures (mean 
deviation, pattern standard deviation, and mean contrast threshold of the upper 
right VF quadrant) and mean cortical thickness variables (mean temporal lobe, 
mean medial temporal lobe, mean frontal lobe, and mean parietal lobe) were 
evaluated using a bivariate Pearson correlation. All variables were pre-adjusted 
to remove the effects of nuisance variables, including gender and years of 
education (all variables), MRI type (1.5T, 3.0T GE, 3.0T Siemens) and total ICV 
(MRI variables only), and age at visit (MRI variables and mean contrast threshold 
of the upper right VF quadrant).  
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Results 
 
Demographics, Ophthalmologic Exam Variables, and Psychometric Performance 
Demographic information, selected variables from the ophthalmological 
exam, and mean psychometric performance are presented in Table 6. Age at 
visit and years of education differed among groups (both p<0.05). Post-hoc 
analyses indicated that MCI participants were older than CC and HC participants 
(both p<0.05) and HC participants were more educated than AD and MCI 
participants (both p<0.05).  
Psychometric performance showed the expected pattern of significant 
differences among diagnostic groups. Clinical Dementia Rating Scale (CDR) 
Global score (CDR-GL) and Sum of Boxes score (CDR-SB), Mini-Mental Status 
Exam (MMSE) total score, Wisconsin Card Sorting Task (WCST) number of 
categories completed, Dementia Rating Scale-2 (DRS) total score, and California 
Verbal Learning Test-II (CVLT) total score, short delay recall score (CVLT-SD), 
and long delay recall score (CVLT-LD), were different among groups (all 
p<0.001). Post-hoc analyses showed significant impairment in patient groups 
(AD and MCI) relative to HC (see Table 6; all p<0.05). By definition, CC 
participants showed normal mean performance on all psychometric assessments 
(Table 6). Although AD patients reported more depressive symptoms on the 
Geriatric Depression Scale (GDS) than HC (p<0.05), these scores do not 
represent a clinically significant level of symptomatology. 
Cataract history and visual acuity (raw or corrected) were not different 
among diagnostic groups (see Table 6). The inclusion of these variables as 
additional covariates in the assessment of the effect of diagnostic group on FDT-
2 performance (presented below) did not change the overall pattern of findings. 
Therefore, the reported analyses below did not include cataract history or visual 
acuity as covariates. 
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AD 
(n=9) 
MCI 
(n=27) 
CC 
(n=19) 
HC 
(n=29) 
ANOVA 
p-value 
Significant Post-hoc  
Comparisons (p<0.05) 
Age (years) 76.11 (2.3) 77.19 (1.3) 72.00 (1.6) 71.62 (1.3) 0.011 MCI>CC, HC* 
Education (years) 14.89 (0.9) 15.74 (0.5) 16.84 (0.7) 17.62 (0.5) 0.028 HC>MCI, AD* 
Gender (Male, Female) 2, 7 13, 14 4, 15 9, 20 NS None 
 
IOP (mmHg) – Right 13.8 (1.0) 13.8 (0.6) 13.4 (0.7) 14.7 (0.5) NS None 
IOP (mmHg) – Left 14.4 (0.8) 13.3 (0.5) 13.2 (0.6) 14.4 (0.5) NS None 
Cataracts – Right and/or  
Left (mild, none/removal) 7, 2 8, 19 7, 12 13, 16 NS None 
Cup-to-Disc Ratio - Right1 0.38 (0.05) 0.37 (0.03) 0.34 (0.03) 0.30 (0.02) NS None 
Cup-to-Disc Ratio - Left1 0.36 (0.05) 0.36 (0.03) 0.31 (0.03) 0.30 (0.02) NS None 
Uncorrected Acuity – Right 20/29.4 (2.8) 20/25.6 (1.6) 20/27.1 (1.9) 20/27.4 (1.6) NS None 
Uncorrected Acuity – Left 20/31.7 (3.0) 20/26.5 (1.8) 20/27.6 (2.1) 20/26.6 (1.7) NS None 
Corrected Acuity – Right  20/26.7 (1.8) 20/23.0 (1.0) 20/23.4 (1.2) 20/23.3 (1.0) NS None 
Corrected Acuity – Left 20/28.3 (2.2) 20/23.9 (1.2) 20/24.2 (1.5) 20/24.5 (1.2) NS None 
 
CDR-GL2,7 0.93 (0.08) 0.52 (0.05) 0.44 (0.05) 0.07 (0.05) <0.001 AD>MCI,CC>HC 
CDR-SB2,7 4.41 (0.4) 1.40 (0.3) 0.89 (0.3) 0.27 (0.2) <0.001 AD>MCI>HC; AD>CC 
MMSE3,7 23.95 (0.6) 27.88 (0.3) 28.62 (0.4) 28.85 (0.3) <0.001 HC, CC, MCI>AD 
WCST4,7 1.19 (0.5) 2.75 (0.3) 3.55 (0.3) 3.64 (0.2) <0.001 HC, CC, MCI>AD 
CVLT Total7 24.83 (3.0) 35.58 (1.8) 50.19 (2.1) 52.57 (1.7) <0.001 HC, CC>MCI>AD 
CVLT-SD7 3.03 (0.8) 6.73 (0.5) 11.06 (0.6) 12.17 (0.5) <0.001 HC, CC>MCI>AD 
CVLT-LD7 2.42 (0.9) 6.73 (0.5) 11.14 (0.6) 12.52 (0.5) <0.001 HC, CC>MCI>AD 
DRS Total5,7 126.52 (2.0) 136.48 (1.2) 138.69 (1.3) 140.78 (1.1) <0.001 HC, CC, MCI>AD 
GDS (15-item)6,7 5.62 (1.1) 3.95 (0.7) 2.25 (0.8) 1.50 (0.6) 0.009 AD>HC 
* Bonferroni post-hoc correction not included in these comparisons (but in all other post-hoc comparisons) 
1 Missing 14 participants (2 AD, 9 MCI, 3 HC) 
2 Missing 1 AD participant  
3 Missing 1 HC participant  
4 Missing 1 AD participant and 1 MCI participant  
5 Missing 1 AD participant and 1 CC participant 
6 Missing 1 AD participant, 2 MCI participants, and 3 CC participants 
7 Group means are adjusted for selected covariates (age at visit, gender, and years of education) 
AD = Alzheimer’s disease; MCI = mild cognitive impairment; CC = older adults with cognitive complaints; HC = healthy  
age-matched controls; ANOVA = analysis of variance; IOP = intraocular pressure; CDR-GL = Clinical Dementia Rating 
Scale (CDR) Global score; CDR-SB = CDR Sum of Boxes score; MMSE = Mini-Mental Status Exam total score;  
CVLT = California Verbal Learning Test; CVLT-SD = CVLT short delay recall score; CVLT-LD = CVLT long delay recall 
score; DRS = Mattis Dementia Rating Scale total score; GDS = Geriatric Depression Scale total score 
 
Table 6. Demographics, Ophthalmologic Exam Variables, and Psychometric 
Performance (Adjusted Mean (SE)) 
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FDT-2 Exam Duration and Performance Errors 
The duration of the FDT-2 exam for both the left and right eyes was 
different among diagnostic groups (both p<0.001; Figure 21A). Post-hoc 
comparisons indicated that AD patients took longer to complete the exam on 
average than HC participants for both eyes (both p<0.001). Additionally, AD 
participants had greater mean exam durations than CC participants in both eyes 
(left (L): p<0.05; right (R): p<0.01) and MCI participants in the right eye (p<0.05). 
MCI participants also had longer exam durations than HC in both eyes (both 
p<0.05). 
Fixation errors and false negative errors did not differ among groups 
(Figure 21B and 21D). However, false positive errors were different among 
groups for the left eye only (p<0.05; Figure 21C). Post-hoc comparisons 
indicated more false positive errors in AD patients than in CC and HC 
participants for the left eye (both p<0.05). 
 
FDT-2 Summary Variables 
Mean deviation in FDT-2 contrast sensitivity was different among groups 
in both eyes (both p<0.0001; Figure 22A). Post-hoc comparisons demonstrated 
more impairment in both eyes (lower mean deviation) in AD patients relative to 
CC (L: p<0.001; R: p<0.01) and HC (both p<0.001). MCI patients also showed 
lower mean deviation than HC participants in both eyes (L: p<0.01; R: p<0.05) 
and CC participants in the left eye (p<0.05). CC participants also showed slight 
impairments in mean deviation relative to HC, with intermediate performance 
between MCI and HC groups, although the comparisons did not reach statistical 
significance. 
Mean pattern standard deviation in FDT-2 contrast sensitivity also differed 
among groups in both eyes (both p<0.001; Figure 22B). AD patients had more 
impaired pattern standard deviation in both eyes (larger mean pattern standard 
deviation value) than CC (L: p<0.01; R: p<0.05) and HC participants (both 
p<0.001). MCI participants also had significantly greater mean pattern standard 
deviation than HC in the right eye only (p<0.05). Similar to the results for the 
128 
 
mean deviation comparison, CC participants demonstrated slightly elevated 
mean pattern standard deviation relative to HC in both eyes, but this finding did 
not reach statistical significance. 
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Figure 21. FDT-2 24-2 Exam Duration and Performance Errors 
Measures of FDT-2 24-2 test duration (A) and performance errors, including 
fixation errors (B), false positive errors (C) and false negative errors (D) are shown in 
Figure 21. Differences among groups were observed in test duration (A) in both eyes 
(both p<0.001), with post-hoc comparisons indicating AD participants take longer to 
complete the exam on average than CC (L: p<0.05, R: p<0.01) and HC participants 
(both p<0.001) in both eyes, and MCI in the right eye only (p<0.05). MCI participants 
also took longer to complete the exam than HC participants in both eyes (both p<0.05). 
False positive errors (C) also differed among groups in the left eye only (p<0.05), with 
post-hoc comparisons indicating more false positive errors in AD patients relative to CC 
and HC (both p<0.05). No significant differences across groups in fixation errors (B) and 
false negative errors (C) were observed. See experimental procedures section for a 
description of how FDT-2 performance errors are tested. In panel A, bars represent the 
mean duration (+/- SE) adjusted for age visit, gender, and years of education. In panels 
B-D, bars represent raw (unadjusted) mean performance errors (+/- SE). However, all 
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statistical models (panels A-D) included age at visit, gender, and years of education as 
covariates. 
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Figure 22. Mean Deviation and Pattern Standard Deviation in Visual 
Contrast Sensitivity 
Summary measures of visual contrast sensitivity performance, including mean 
deviation (A), which is a measure of general contrast sensitivity performance, and 
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pattern standard deviation (B), which measures the variability of contrast sensitivity 
across the VF, were significantly different across groups in both eyes (all p<0.001). Post-
hoc comparisons indicate that patients with AD show a more impaired mean deviation in 
both eyes than CC (left (L): p<0.001; right (R): p<0.01) and HC (both p<0.001), as well 
as a greater pattern standard deviation in both eyes than CC (L: p<0.01; R: p<0.05) and 
HC (both p<0.001). In addition, MCI patients show a more impaired mean deviation than 
CC in the left eye only (p<0.05) and HC in both eyes (L: p<0.01; R: p<0.05), as well as a 
greater pattern standard deviation than HC in the right eye only (p<0.05). Bars represent 
group mean values (+/- SE) adjusted for gender and education. 
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Regional Contrast Sensitivity Performance across the Visual Field 
Contrast sensitivity thresholds in 49 of the 55 VF regions in the left eye 
(Figure 23A) and 44 of the 55 VF regions in the right eye (Figure 23B) were 
different among diagnostic groups (see significance values in Figure 23). Post-
hoc comparisons indicated that 88 of the 110 VF regions were impaired in AD 
patients relative to HC, while MCI patients showed significant impairment in 37 of 
the 110 VF regions relative to HC (p<0.05). 
Differences among diagnostic groups in mean contrast sensitivity were 
also detected in the four VF quadrants bilaterally (significance shown in Figure 
23C and 23D), with the upper right VF quadrant showing the largest difference 
among groups in both eyes. Post-hoc comparisons demonstrated impaired mean 
contrast sensitivity in all VF quadrants of both eyes in AD patients relative to CC 
(all p<0.05) and HC participants (all p<0.01), and relative to MCI patients in the 
upper right VF quadrants of both eyes (both p<0.05). MCI patients also 
demonstrated a reduced mean contrast sensitivity relative to HC in all quadrants 
of the VF of the left eye (all p<0.05) and the upper and lower right VF quadrants 
of the right eye (both p<0.05), as well as an impaired mean contrast sensitivity 
relative to CC participants in the upper right VF quadrant of the left eye (p<0.05). 
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Figure 23. Distribution of Group Differences in FDT-2 Contrast Sensitivity 
Thresholds across the Visual Field 
Significant differences among groups (n=84; 9 AD, 27 MCI, 19 CC, 29 HC) were 
observed in contrast sensitivity thresholds in 93 of 110 regions across the visual field 
(VF) in the left (A) and right (B) eyes. In addition to evaluating single regions, mean 
contrast thresholds for the four VF quadrants within each eye were assessed. All VF 
quadrants of the left (C) and right (D) eyes were significantly different among diagnostic 
groups. See text for discussion of between-group differences. All statistical models 
represented in this figure included age at visit, gender, and years of education as 
covariates.  
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Logistic Regression and ROC Curves for Diagnostic Classification of MCI vs. HC 
Univariate and multivariate classification capabilities of the FDT-2 
variables were examined in a preliminary manner considering the available 
sample sizes and non-independence of some variables. Logistic regression 
models demonstrated significant predictive ability of summary and threshold 
contrast sensitivity variables for classification of MCI patients versus HC. Mean 
contrast sensitivity threshold in the bilateral lower left VF quadrant was the best 
MCI vs. HC classifier with 80.4% overall accuracy (specificity=86.2%, 
sensitivity=74.1%; Figure 24A, area under the curve (AUC)=0.842), while 
bilateral mean deviation had 75% accuracy (specificity=82.8%, 
sensitivity=66.7%; Figure 24B, AUC=0.808). Finally, the classification accuracy 
for MCI vs. HC using a measure of memory performance (CVLT total score) was 
improved by adding bilateral mean deviation as a second classifier, with CVLT 
total score alone showing an overall accuracy of 87.5% (specificity=89.7%, 
sensitivity=85.2%) and CVLT total score and bilateral mean deviation showing an 
overall accuracy of 94.2% (specificity=93.1%, sensitivity=96.3%). 
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Figure 24. ROC Curves of MCI vs. HC Classification for Selected FDT-2 
Measures of Visual Contrast Sensitivity 
Visual contrast sensitivity measures effectively classified patients with MCI and 
HC by diagnostic group (n=56; 27 MCI, 29 HC). The bilateral mean lower left visual field 
(VF) quadrant contrast threshold (A) was the best classifier of MCI vs. HC. Bilateral 
mean deviation (B) also successfully classified patients with MCI and HC by diagnostic 
group. Prior to evaluation for classification accuracy, the bilateral mean lower left VF 
quadrant contrast threshold was adjusted for age at visit, gender, and years of 
education, while bilateral mean deviation was adjusted for gender and years of 
education. 
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Relationship between Contrast Sensitivity Performance and Cognitive 
Performance 
FDT-2 contrast sensitivity performance was associated with performance 
on cognitive screening and memory measures. Impaired performance on the 
MMSE was significantly associated with a reduced mean contrast sensitivity 
threshold in the bilateral upper right VF quadrant (Figure 25A; r=0.527, p<0.001). 
In this association one AD participant appeared to be a significant outlier with a 
MMSE total score of 15. After excluding this participant the association remained, 
with mild attenuation (Figure 25B; r=0.383, p<0.001). Poorer memory 
performance on the CVLT was also significantly associated with impaired FDT-2 
contrast sensitivity performance, including associations between CVLT total 
score and bilateral mean deviation in contrast sensitivity (Figure 25C; r=0.471, 
p<0.001), as well as between CVLT-SD and the mean contrast sensitivity 
threshold in the bilateral upper right VF quadrant (Figure 25D; r=0.567, p<0.001). 
The associations between memory performance and contrast sensitivity were 
nearly unchanged when the AD participant discussed above was excluded, so all 
participants were included in Figures 25C and 25D.  
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Figure 25. Relationship between Visual Contrast Sensitivity and Cognition 
Significant associations between FDT-2 measures of visual contrast sensitivity 
and cognitive performance were observed. (A) Impaired general cognition (MMSE total 
score) was significantly associated with reduced mean bilateral contrast threshold of the 
upper right visual field (VF) quadrant. Upon visual inspection, one AD participant 
appeared to be a significant outlier, with an MMSE total score well below all other 
participants. However, when this participant was excluded (B), MMSE total score was 
still significantly associated with contrast sensitivity as measured by the mean bilateral 
contrast threshold of the upper right VF quadrant. Impaired memory performance was 
also significantly associated with reduced contrast sensitivity performance, including a 
significant association between CVLT total score and bilateral mean deviation in contrast 
sensitivity (C) and between CVLT short delay recall score and the mean bilateral 
contrast threshold of the upper right VF quadrant (D). All participants (n=84; 9 AD, 27 
MCI, 19 CC, 29 HC) were included in panels A, C, and D, while 1 AD participant was 
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excluded (due to low MMSE total score) from panel B (n=83; 8 AD, 27 MCI, 19 CC, 29 
HC). Exclusion of the AD outlier did not significantly affect the results in panels C and D. 
All psychometric and contrast sensitivity performance variables were pre-adjusted for 
age at visit (all variables except for mean deviation), gender (all variables), and years of 
education (all variables). 
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Relationship between Contrast Sensitivity Performance and Grey Matter Density 
 Significant associations between mean deviation and GM density (Figure 
26A), between pattern standard deviation and GM density (Figure 26C), and 
between the mean contrast threshold in the upper right VF quadrant and GM 
density (Figure 26E) were found in the medial temporal lobe, including significant 
clusters in the left and right hippocampi. Other significant clusters were observed 
in the left and right striatum for all associations (Figures 26B, 26D, and 26F). For 
these comparisons, only 79 participants were included (9 AD, 26 MCI, 16 CC, 
and 28 HC) due to failed MRI acquisition or processing. 
 
Relationship between Contrast Sensitivity Performance and Selected MRI 
Measures 
 Significant associations were observed between mean deviation in 
contrast sensitivity and bilateral mean medial temporal lobe cortical thickness 
(Figure 27A; r=0.327, p=0.003) and mean temporal lobe cortical thickness 
(Figure 27B; r=0.331, p=0.003). Mean temporal lobe cortical thickness was also 
associated with mean pattern standard deviation (Figure 27C; r=-0.380, p<0.001) 
and mean contrast threshold of the upper right VF quadrant (Figure 27D; 
r=0.382, p<0.001). Only 79 participants were included (9 AD, 26 MCI, 16 CC, 
and 28 HC) in these comparisons due to failed MRI acquisition or processing. 
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Figure 26. Relationship between Visual Contrast Sensitivity and Grey 
Matter Density 
 Significant associations between impaired contrast sensitivity (reduced mean 
deviation) and decreased GM density were observed in the (A) medial temporal lobe and 
(B) striatum. Significant associations between increased pattern standard deviation in 
contrast sensitivity and reduced GM density were also observed in the (C) medial 
temporal lobe and (D) striatum. Reductions in the mean contrast threshold in the upper 
right visual field quadrant were significantly associated with reduced GM density in the 
(E) medial temporal lobe and (F) striatum, as well as a small cluster in the (F) medial 
parietal lobe. Age at visit, gender, years of education, MRI type and total ICV were 
included as covariates as appropriate. All images displayed at p<0.005 (uncorrected for 
multiple comparisons), minimum cluster size (k) = 100 voxels. (Note: n=79, 9 AD, 26 
MCI, 16 CC, 28 HC due to failed MRI acquisition or processing; GMD=grey matter 
density, URVF=upper right visual field) 
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Figure 27. Relationship between Visual Contrast Sensitivity and Temporal 
Lobe Atrophy 
 Significant relationships were observed between mean medial temporal lobe 
cortical thickness and mean deviation in contrast sensitivity (A; r=0.327, p=0.003), as 
well as between mean temporal lobe cortical thickness and mean deviation in contrast 
sensitivity (B; r=0.331, p=0.003), pattern standard deviation in contrast sensitivity (C; r=      
-0.380, p<0.001), and the mean contrast threshold in the upper right visual field quadrant 
(D; r=0.382, p<0.001). All variables were pre-adjusted for age at visit, gender, and years 
of education as appropriate. (Note: n=79, 9 AD, 26 MCI, 16 CC, and 28 HC due to failed 
MRI acquisition or processing; VF=visual field) 
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Discussion 
The present study was designed to evaluate visual contrast sensitivity in 
patients with MCI and AD, as well as in older adults with cognitive complaints. 
The results demonstrated that patients with both AD and MCI show marked 
deficits in contrast sensitivity with reduced general sensitivity (lower mean 
deviation) and abnormal variability (higher pattern standard deviation). Significant 
differences were detected in the majority of the 110 regions tested in the FDT-2 
24-2 exam, with the most notable differences in the upper right VF quadrant. In a 
preliminary assessment using the available data set, measures of contrast 
sensitivity demonstrated significant capability to classify MCI and HC by 
diagnostic group. In addition to detected differences among diagnostic groups, 
contrast sensitivity deficits were associated with impaired cognitive performance, 
including in global functioning (MMSE total score) and memory performance 
(CVLT total score and short delay recall score). Finally, significant associations 
between contrast sensitivity deficits and reduced GM density and cortical 
thickness in the medial and lateral temporal lobes were observed.  
These results suggest that contrast sensitivity deficits are a feature of AD 
and AD-related changes, even in early prodromal stages of the disease (i.e., CC 
and MCI). However, the biological and/or neuropathological basis of this deficit in 
contrast sensitivity is currently unknown. These deficits could result from a 
number of pathological changes in the visual system of AD patients, including 
(but not limited to): (1) sub-threshold glaucomatous damage; (2) performance 
deficits due to cognitive inability to complete the task; (3) degeneration and/or 
dysfunction of retinal ganglion cells (RGC); and/or, (4) degeneration and/or 
dysfunction of visual pathways within the brain. However, our findings are 
unlikely to result from either of the first two explanations. Although previous 
reports have shown a high co-occurrence of glaucoma and AD [399-401], as well 
as an association between the primary genetic predictor of late-onset AD 
(apolipoprotein E ε4 genotype) and glaucoma [402-404], participants in our 
cohort who showed even mild glaucoma symptoms were excluded. Additionally, 
no significant differences among diagnostic groups in cup-to-disc ratio or 
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intraocular pressure (IOP) were observed (Table 6), suggesting that 
glaucomatous symptoms do not likely underlie the differences among groups. In 
addition, it is unlikely that impaired contrast sensitivity was due solely to impaired 
cognition, as participants in the present study show relatively mild cognitive 
deficits and showed minimal errors on the FDT-2 24-2 exam (Table 6 and Figure 
21). 
Therefore, the observed deficits in contrast sensitivity are most likely 
reflecting changes associated with neuropathological and/or functional changes 
in the retina and/or central visual processing pathways. Patients with AD have 
previously been shown to have extensive retinal and optic nerve degeneration 
with loss of RGC, measured as thinning of the retinal nerve fiber layer using 
optical coherence tomography (OCT) and other techniques [376-377, 380, 405-
406], as well as RGC loss noted in post-mortem retinal tissues [373-374, 378, 
407-409], changes in retinal vasculature [410], and functional changes in retinal 
activation [366, 377, 411-412]. In addition, MCI patients have also been shown to 
have intermediate thinning of the nerve fiber layer using OCT [376].  
RGC loss in AD and MCI may result from amyloid pathology in the eye 
and/or retina. Both amyloid-beta (Aβ) plaques and oligomers have been reported 
in post-mortem retinal tissue from patients with AD and a mouse model of AD 
[413], as well as in vivo human retinal tissue (vitreous humor) from patients with 
glaucoma [414-416]. In addition, amyloid has been shown to be associated with 
degeneration of RGC in a mouse model of glaucoma [417]. Amyloid-beta has 
also been shown to be present in the lenses of patients with AD, at levels 
comparable to the brain [418]. Therefore, in AD patients, amyloid accumulation in 
the eye and/or retina may result in degeneration of RGC in parallel to amyloid 
accumulation and Aβ-related neurodegeneration in the brain. In fact, in a mouse 
model of AD, plaque accumulation in the retina was not only significantly 
associated with amyloid plaques in the brain, but actually preceded extensive 
brain amyloid deposition [413]. 
Degeneration of RGC and/or impairment in contrast sensitivity may also 
result from AD pathology in the central visual pathways. AD patients show 
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degeneration of the primary and secondary visual cortex [366, 368-369, 371-
372], as well as degeneration of subcortical regions comprising parts of the visual 
pathway (e.g., LGN) [370]. Previous studies have also reported that 
magnocellular visual pathways appear to be particularly vulnerable to 
degeneration in AD, with magnocellular cortical layers showing more 
degeneration than neighboring regions [369-370]. Interestingly, FDT contrast 
sensitivity performance has been shown to heavily involve the magnocellular 
visual pathway [381-382]. Thus, degeneration of RGC and/or visual pathways in 
the brain may individually affect or combine to underlie the functional deficits in 
contrast sensitivity seen in patients with AD and MCI, as well as CC, in this 
study. 
The potential importance of neurodegeneration in the brain underlying the 
observed contrast sensitivity deficits is also supported by the observed 
associations with MRI measures of neurodegeneration, particularly in the 
reduced GM density and cortical thickness in the medial temporal lobe. These 
associations suggest that neurodegeneration near or in magnocellular pathways 
in the MTL and thalamus may partially explain the observed deficits. 
Furthermore, associations between impaired visual contrast sensitivity 
performance and reduced GM density in the striatum were also observed. The 
striatum is known to be important in visual processing and perception, particularly 
in sensory gating, attention, and visual discrimination [419]. Degeneration and 
dysfunction of striatal dopaminergic pathways are thought to contribute to the 
visual perceptual deficits associated with Huntington’s and Parkinson’s diseases, 
as well as visual hallucinations in schizophrenia [419]. Furthermore, the striatum 
is thought to be involved with sensory-motor tasks [420-421]. The FDT exam 
involves responding to a visual signal by clicking a button and therefore, FDT 
responses may be partially coordinated through the striatum. Thus, 
neurodegeneration in striatal regions may also affect the contrast sensitivity 
performance as measured using FDT in the present study.  
The observation that the upper right visual field quadrant shows the 
greatest differences between groups may also support the role of central 
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degeneration in the observed deficits. The right visual field is processed by the 
left hemisphere of the brain and signals are sent along the optic tract through the 
left thalamus (i.e., LGN) and near the left MTL. Although neurodegeneration 
associated with AD occurs bilaterally, the left hippocampus has been reported to 
show slightly more degeneration than the right hippocampus [213]. Furthermore, 
in the present study, GM density changes in left MTL showed a greater 
association with contrast sensitivity performance than changes in the right MTL. 
Future studies utilizing advanced neuroimaging techniques, including amyloid 
PET imaging, diffusion tensor imaging of white matter tracts, and potentially 
functional neuroimaging of contrast sensitivity paradigms, may also help to 
identify the neurobiological basis for the observed deficits. 
Despite the strong effects and novel observations, the present study has 
several limitations. We did not assess RGC loss or nerve fiber layer changes 
directly using OCT or other techniques. The association of RGC loss to contrast 
sensitivity performance would be beneficial in elucidating the neurobiological 
substrates of the observed contrast sensitivity deficits (i.e., retinal and/or central 
basis). Future studies utilizing both FDT-2 measures of retinal function and OCT 
measures of retinal morphology would be ideal. Second, in the present report our 
group of patients with AD was small relative to the other groups. This 
shortcoming is not surprising and somewhat unavoidable due to our exclusion of 
patients with glaucoma and the high co-occurrence of glaucoma and AD [399-
401]. In addition, the focus of our study was to evaluate contrast sensitivity in 
prodromal stages of AD. Finally, the cross-sectional nature of the study design 
precludes assessment of the ability of FDT-2 contrast sensitivity deficits to 
predict and/or monitor disease progression. Future studies designed to 
determine the sensitivity of FDT-2 to longitudinal change and clinical outcome, as 
well as those including larger AD cohorts, will be informative.  
The presence of contrast sensitivity deficits in patients with MCI and even 
some individuals who show normal cognitive function but have complaints about 
their cognition is noteworthy and warrants additional investigation. The results of 
this cross-sectional design study suggest that visual contrast sensitivity 
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performance, as measured by FDT-2, may represent a novel biomarker for early 
detection of AD and AD-related changes. However, the ability of impaired 
contrast sensitivity to predict future progression to AD in patients in early stages 
of disease or even in cognitively normal elders at-risk for progression to AD due 
to genetics or high amyloid accumulation is presently unknown. Future studies to 
determine whether contrast sensitivity can be used effectively as a biomarker for 
differential diagnosis and prediction of disease progression are needed. In 
particular, studies evaluating longitudinal contrast sensitivity performance 
monitoring as a screening tool or outcome variable would be particularly 
beneficial. FDT-2 measures of contrast sensitivity performance have previously 
been shown to be relatively stable, despite a learning effect, in healthy adults 
[422]. If proven to be dynamically sensitive to changes associated to disease 
progression, contrast sensitivity and/or other ocular biomarkers of AD would be 
particularly useful in early detection and disease monitoring due to the fact that 
they are relatively non-invasive, inexpensive, and widely available [423].  
In conclusion, patients with MCI and AD show deficits in contrast 
sensitivity measured using FDT-2. Older adults with cognitive complaints but no 
clinically significant cognitive impairments also show some mild alterations in 
contrast sensitivity performance. The deficits in contrast sensitivity are generally 
distributed across the entire retina, although the greatest difference between 
patients with MCI and AD and HC is observed in the upper right VF quadrant. 
Measures of contrast sensitivity can also effectively categorize MCI patients 
versus HC. Impairments in contrast sensitivity are significantly associated with 
cognitive deficits, including general cognition and memory impairments, as well 
as neurodegeneration in the medial and lateral temporal lobe as measured using 
structural MRI. These results suggest that visual contrast sensitivity measured 
using FDT-2 may be a useful biomarker for AD, even in early clinical stages. 
Future studies are needed to help elucidate the biological basis of the observed 
contrast sensitivity deficits, as well as to examine their utility in detecting AD 
precursors and predicting disease progression to AD. 
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Summary 
The results of this report indicate that structural MRI measures of 
neurodegeneration are sensitive biomarkers for AD, even in early clinical stages 
such as MCI and older adults with cognitive complaints. The first chapter 
explores the use of cross-sectional MRI measures of brain atrophy to detect 
differences between patients with MCI and AD and healthy older adults in the 
largest sample to date, the Alzheimer’s Disease Neuroimaging Initiative (ADNI). 
The results support previous findings in smaller samples, showing significant 
atrophy in patients with MCI and AD throughout the brain and most significantly 
in the medial temporal lobe (MTL). Furthermore, patients who converted from 
MCI to probable AD within one year after the MRI scan (MCI-Converters (MCI-C) 
showed significantly more MTL atrophy at baseline than participants who were 
stable for the subsequent year (MCI-Stables (MCI-S)). In fact, MCI-C had nearly 
equivalent atrophy in the hippocampus and MTL to patients already diagnosed 
with AD up to one year before clinical conversion. These results suggest that the 
neurodegeneration observed with MRI measures of atrophy is an antecedent 
marker of future clinical decline to dementia. Finally, the results of the effect size 
calculation for selected MRI regions of interest (ROIs) indicate that hippocampal 
and other MTL atrophy measures are the most sensitive biomarkers for detecting 
differences between patients who convert from MCI to probable AD during the 
subsequent year and those who have a stable MCI diagnosis. In sum, Chapter 1 
confirms the sensitivity of cross-sectional MRI measures as biomarkers for 
detecting neurodegeneration associated with AD and for predicting future 
progression of patients with MCI to probable AD. 
The second chapter of this report explores the use of dynamic MRI 
measures of brain atrophy rate as biomarkers for AD. In particular, the change in 
brain volume, cortical thickness, and grey matter (GM) density and GM volume 
between two MRI scans spaced 1-2 years apart was assessed either as an 
absolute change (Figure 8, Table 4) or as an annualized percent change (APC) 
in a target ROI (Figures 9-14 and Figures 16-20). In Chapter 2a, the change in 
whole brain GM density over one year on a voxel-wise level and APC in target 
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ROIs were assessed for differences among patients with AD and MCI and HC in 
the ADNI cohort. Similar to the analyses in Chapter 1, the differences in 
longitudinal atrophy and target region atrophy rates between patients who 
converted from MCI to probable AD over the first year of the study (MCI-C) and 
patients with a stable MCI diagnosis (MCI-S) were evaluated. We observed a 
significantly greater decline in GM density across the whole brain, as well as a 
faster rate of atrophy in the medial and lateral temporal, frontal, and parietal 
lobes, in patients with AD relative to HC. In addition, MCI-C showed greater GM 
atrophy and a faster rate of atrophy in all evaluated ROIs than MCI-S 
participants. In fact, MCI-C participants showed nearly equivalent atrophy rates in 
many target ROIs to AD participants, suggesting that MCI-C patients show AD-
like rates of neurodegeneration during, at minimum, the year preceding clinical 
conversion.  
The effect sizes for baseline and APC MRI measures were also calculated 
for all group comparisons (AD vs. HC, MCI-C vs. MCI-S, MCI-C vs. HC, MCI-S 
vs. HC, AD vs. MCI-S, AD vs. MCI-C). Interestingly, the effect sizes of baseline 
measures were greater than those of atrophy rate measures for the comparison 
of AD vs. HC participants. The greater sensitivity of baseline measures relative to 
APC measures in the comparison of AD vs. HC may be due to the fact that 
baseline differences developed over multiple years while the APC metrics are 
calculated from changes occurring over a single year. However, the effect sizes 
of atrophy rate measures were greater than those of baseline measures for the 
comparison of MCI-C vs. MCI-S. This result suggests that dynamic measures of 
brain atrophy rate are most sensitive to detecting neurodegeneration in 
participants undergoing significant clinical decline relative to those who are more 
clinically stable. Finally, the relationship between apolipoprotein E (APOE) ε4 
genotype (presence or absence of 1 or 2 ε4 alleles), the most commonly reported 
genetic factor associated with late-onset AD, and APC in target MTL ROIs was 
evaluated. The results showed that APOE ε4 positive participants showed a 
higher rate of atrophy relative to APOE ε4 negative participants within each 
diagnostic group. These results support a relationship between the presence of 
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an APOE ε4 allele and AD-related neurodegeneration. Furthermore, these 
findings suggest that APOE ε4 positive AD and MCI patients show more severe 
disease-related neurodegeneration and that APOE ε4 positive HC participants 
may be at higher risk for cognitive decline.  
Chapter 2b examines the role of longitudinal MRI measures of brain 
atrophy rate as biomarkers in a pre-MCI stage of disease, specifically, older 
adults with cognitive complaints (CC) but no significant cognitive impairment. 
Baseline atrophy and APC in temporal lobe ROIs over two years were evaluated 
for differences among patients with a stable AD diagnosis, MCI to probable AD 
converters, stable MCI patients, older adults with CC at baseline who progressed 
to a diagnosis of MCI over the two-year follow-up period, older adults with a 
stable CC diagnosis, and stable HC without cognitive complaints. Similar to 
results from previous studies and Chapters 1 and 2a, patients with AD and MCI 
showed greater atrophy at baseline and faster annualized atrophy rate in the 
temporal lobe relative to HC participants. In addition, MCI-C had greater atrophy 
at baseline and a faster annualized atrophy rate than MCI-S participants. 
However, the novel finding in this chapter concerns the CC participants. 
Participants who converted from CC to MCI over the course of the two-year 
follow-up period had slightly more atrophy at baseline and faster rates of atrophy 
in the temporal lobe than participants with a stable CC diagnosis. This result 
suggests that MRI measures of neurodegeneration are sensitive to AD-like 
pathological changes in older adults who are progressing towards MCI and AD in 
preclinical stages without significant cognitive deficits. Similar to previous 
chapters (Chapters 1 and 2a), effect sizes of baseline atrophy measures and 
APC in target ROIs for the comparison between converters and stable 
participants were calculated. Measures of APC in medial and lateral temporal 
lobe ROIs were most sensitive to the differences between MCI-C and MCI-S 
participants, as well as between CC-C and CC-S participants. These results 
support the previous finding (Chapter 2a) that dynamic measures of atrophy rate 
are most sensitive to the differences between patients who are declining clinically 
relative to those who are clinically stable. Furthermore, these results suggest that 
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measures of temporal lobe atrophy rate effectively detect neurodegeneration 
associated with clinical decline even before patients show marked cognitive 
impairment. Finally, the relationship between hippocampal atrophy rate and two-
year change in clinical dementia severity and memory performance was 
evaluated for the full cohort and in the sub-group of patients who had a CC 
diagnosis at baseline (CC-C and CC-S). The results demonstrated that 
hippocampal atrophy rate was significantly associated with two-year change in 
clinical dementia severity across the full sample only, likely due to the differences 
between diagnostic groups (particularly between AD patients and all other 
groups). Hippocampal atrophy rate was also significantly associated with two-
year change in memory performance in both the full sample and the CC at 
baseline only sub-group. In fact, the relationship between hippocampal atrophy 
rate and two-year change in memory performance was more significant in the CC 
at baseline sub-group (p=0.004) than in the full sample (p=0.014). These results 
suggest that a higher rate of hippocampal atrophy is more closely linked to 
memory decline in the earliest stages of disease (i.e., CC participants) and more 
closely linked to clinical dementia severity and impaired activities of daily living in 
the later stages of disease (AD and MCI). Overall, the results of this chapter 
support the role of MRI as a biomarker for AD and suggest that MRI measures 
can detect and monitor AD-related neurodegeneration even in very early pre-
clinical stages (i.e., CC). 
The final chapter of this report explores a novel biomarker for AD, visual 
contrast sensitivity. In addition, the relationships between MRI biomarkers of 
neurodegeneration and measures of visual contrast sensitivity were assessed. In 
order to establish the ability of this novel marker to detect changes associated 
with AD, visual contrast sensitivity, as measured by frequency doubling 
technology (FDT-2, Welch Allyn Inc.), was compared among a cohort of 
participants that included older adults with AD, MCI, and CC, as well as HC. 
Patients with MCI and AD showed significant impairments in contrast sensitivity, 
with general deficits and abnormal variability across the visual field (VF). In 
addition, CC participants showed notable contrast sensitivity impairments, with a 
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performance level intermediate between MCI and HC participants. Although 
general deficits were observed across the entire VF, the most severe contrast 
sensitivity impairment in patients with AD and MCI relative to HC was in the 
upper right VF quadrant. Measures of contrast sensitivity also showed accurate 
classification of MCI vs. HC, with an overall accuracy of 75-80%. Next, the 
relationship between contrast sensitivity and cognition was assessed, including 
relationships between contrast sensitivity and general cognition (MMSE total 
score) and between contrast sensitivity and memory performance (CVLT total 
score, short delay recall score). The results demonstrated significant 
associations between contrast sensitivity and both general cognition and memory 
performance. Finally, the relationship between contrast sensitivity and MRI 
markers of neurodegeneration was evaluated. First, the relationship between 
contrast sensitivity and GM density across the entire brain was assessed on a 
voxel-wise basis. The results indicated that contrast sensitivity impairment is 
associated with reduced GM density in the MTL, including the hippocampus, the 
striatum, as well as temporal and parietal lobar cortical regions. The relationship 
between contrast sensitivity and regional cortical thickness estimates was also 
examined. Similar to the whole brain analyses, impaired contrast sensitivity was 
associated with reductions in medial and lateral temporal lobe cortical thickness. 
These results suggest that impairments in contrast sensitivity observed in 
patients with MCI and AD may be partially mediated by neurodegeneration in the 
brain, particularly in the medial and lateral temporal lobes. Overall, the results in 
Chapter 3 indicated that visual contrast sensitivity may be a useful biomarker for 
detecting changes associated with AD, even in early stages of disease. Future 
studies designed to evaluate the ability of these measures to predict and monitor 
clinical progression will further elucidate the potential utility of visual contrast 
sensitivity as a biomarker for AD. 
In summary, this report highlights the important role that MRI measures of 
neurodegeneration can play in studies of patients with AD, as well as in patients 
at earlier stages of disease (i.e., MCI, CC). The ability of MRI to detect AD-
related neurodegeneration in preclinical stages, as well as to predict future 
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disease progression, suggests that these markers would be particularly useful in 
therapeutic intervention studies. For example, enriching the treatment group with 
patients showing significant atrophy at baseline may lead to a cleaner cohort 
which would be more amenable to effective intervention. Additionally, MRI 
measures of atrophy rate could also be used as outcome measures in a 
pharmaceutical trial to assess the mechanisms of a treatment (i.e., whether the 
treatment promotes neuronal viability and/or prevents AD-related 
neurodegeneration) and evaluate treatment efficacy. As discussed in Chapter 2a, 
the use of MRI as an outcome measure in clinical trials would require a smaller 
sample size to detect a reduction in neurodegeneration than changes in 
psychometric test performance or clinical dementia severity. Finally, MRI 
measures of neurodegeneration could also be utilized in the clinical diagnosis 
and treatment of AD to effectively detect and diagnose patients likely to progress 
to AD in early preclinical stages. Many scientists and clinicians now believe that 
an effective treatment for AD will likely involve disease prevention rather than 
amelioration of symptoms once a patient is already diagnosed with AD. Thus, 
sensitive biomarkers to detect patients most likely to degenerate will be essential 
for any interventional treatment to be effective. Given the sensitivity 
demonstrated in this report, MRI measures of neurodegeneration may be one of 
the biomarkers utilized in the future once an effective interventional treatment is 
developed to prevent AD. Furthermore, the development of new biomarkers for 
AD (i.e., visual contrast sensitivity) may also assist in future clinical diagnosis and 
therapeutic trials. The use of established biomarkers to measure known changes 
associated with AD will help identify the underlying pathology associated with 
new markers, as well as help confirm the utility of newly developed techniques. 
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Future Directions 
The results of this report, as well as those of other researchers, present a 
number of future directions for continued exploration of the role of MRI and other 
biomarkers in diagnosis, monitoring, and predicting progression of AD. With the 
availability of increasing amounts of long-term longitudinal cohorts with advanced 
neuroimaging and protein biomarker data, a more comprehensive analysis of 
multiple biomarkers together (i.e., not just MRI measures) and a longer follow-up 
of patients with MCI, as well as CC and even HC participants, will provide 
important information. In particular, I would like to pursue the following future 
directions: (1) an extension of the longitudinal studies with a 3-5 year follow-up 
time to evaluate the ability of MRI markers to detect and monitor ongoing 
neurodegeneration, as well as to predict future progression; (2) longitudinal 
follow-up and monitoring with MRI biomarkers of HC participants, in particular 
those who show progression towards dementia (i.e., to CC, MCI and/or AD); (3) 
evaluation of other imaging measures as biomarkers of AD, specifically amyloid 
PET imaging and functional MRI of task-related brain activation; and, (4) further 
investigate visual contrast sensitivity as a biomarker for AD, especially for utility 
in monitoring disease progression in a longitudinal study with multiple contrast 
sensitivity tests over a 1-2 year period. I believe these additional research 
directions will further elucidate the role of MRI and other neuroimaging measures 
as biomarkers of AD and the ability of these measures to function as an 
important part of AD research, clinical diagnosis, and treatment. 
Briefly, the first extension of the current work would be a longer-term 
follow-up (3-5 years) of the cohorts studied in Chapters 2a and 2b to evaluate 
cross-sectional atrophy and longitudinal rates of atrophy. Assessing the role of 
MRI measures over a more extensive follow-up period would establish the 
sensitivity of these markers to detecting changes more than two years before 
MCI to probable AD conversion, as well as CC to MCI conversion. Furthermore, 
a longer study period would likely allow for more participants who were classified 
as stable in the current study (Chapters 2a and 2b) to convert. Finally, a longer 
follow-up window may also allow for more HC participants to begin to progress 
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towards dementia. An assessment of MRI biomarkers in these participants (HC 
progressors) would help clarify the sensitivity of these markers to detect 
neurodegeneration in stages before CC and MCI, as well as to elucidate the 
pathological processes that initiate clinical decline. 
Next, the role of other selected imaging measures as biomarkers for AD 
would be evaluated. Specifically, studies to evaluate amyloid deposition 
measured using [11C]PiB or [18F]florbetapir PET [100, 120, 122, 424-425] and 
functional MRI measures of brain activity [229, 241] in early clinical and 
preclinical stages of AD (e.g., MCI, CC) would provide evidence as to the utility of 
these measures as biomarkers of AD. In addition, a study to evaluate the 
relationship between measures of amyloid deposition, functional MRI measures 
of brain activation, and neurodegeneration measured using structural MRI at 
different stages of disease would provide interesting information about the 
associations between these neurobiological processes. In fact, studies have 
suggested that some of these measures are only minimally related, and thus 
provide independent information about disease pathology (i.e., amyloid PET and 
MRI measures) [17, 90]. Assessment of the independent and combined ability of 
measures of amyloid deposition, brain activation, and neurodegeneration to 
monitor and predict clinical course would also be informative. Previous studies 
have already shown an added benefit of combining multiple imaging biomarkers 
for the detection and monitoring of AD relative to a single measure [314, 426]. To 
date, the use of multiple combined biomarkers for disease detection, monitoring, 
and prediction of clinical progression has not been evaluated in older adults with 
cognitive complaints. Therefore, future studies assessing multiple imaging 
biomarkers in pre-MCI stages of disease and even in longitudinal studies of 
declining HC participants would provide valuable insight into the underlying 
mechanisms at these early stages of disease, as well as an estimate of the 
added benefit of multiple measures of AD-related pathology. 
Finally, the analyses in Chapter 3 showed that visual contrast sensitivity is 
impaired in patients with AD and MCI and demonstrated a significant association 
of these measures with known clinical and biological markers of AD. However, 
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additional studies of visual contrast sensitivity measures are needed to fully 
characterize its utility as a biomarker for AD. In particular, longitudinal studies to 
assess change in visual contrast sensitivity over time (1-2 years) from 2 or more 
visits would provide needed information about the longitudinal stability of the 
measure, as well as the sensitivity of these measures to monitoring disease 
progression. Furthermore, these studies would be essential for determining 
whether visual contrast sensitivity would be a useful outcome measures for 
clinical therapeutic trials. In addition, the ability of visual contrast sensitivity 
measures to predict future decline to AD in patients with MCI as well as in earlier 
stages of disease should be assessed. Similar to the studies in Chapters 1 and 
2, visual contrast sensitivity at baseline and/or change in visual contrast 
sensitivity would be compared between patients who are known to subsequently 
progress clinically and those who are clinically stable. The predictive ability of 
contrast sensitivity measures for future conversion to AD from MCI and/or CC 
would also be assessed. Finally, future studies in an expanded sample of 
participants and eventually a second independent cohort would be necessary to 
confirm visual contrast sensitivity as a valid biomarker for AD. 
In summary, the findings of the present report support the role of MRI 
measures of neurodegeneration as a biomarker for AD.  
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Conclusions 
 In conclusion, the present report explored the role of MRI measures of 
neurodegeneration as biomarkers for AD. The results confirmed that both cross-
sectional and longitudinal MRI measures are sensitive to detection of AD-related 
neurodegenerative changes, able to monitor disease progression, and predictive 
of future clinical decline. In addition, MRI measures appear to be useful for 
measuring neurodegeneration in not only AD patients, but also patients in earlier 
clinical stages, such as MCI and CC. MRI measures are also useful for 
evaluating novel biomarkers for AD, including visual contrast sensitivity. Thus, 
MRI measures of neurodegeneration are likely to be useful in therapeutic trials of 
potential disease-modifying treatments and potentially in the clinical diagnosis of 
AD. 
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